EXTENDED TO FEBRUARY 17, 2026

Form **990-PF**

Department of the Treasury
Internal Revenue Service

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as Private Foundation

Do not enter social security numbers on this form as it may be made public.

Go to www.irs.gov/Form990PF for instructions and the latest information.

OMB No. 1545-0047

2024

Open to Public Inspection

For calendar year 2024 or tax year beginning APR 1, 2024 **, and ending** MAR 31, 2025

Name of foundation
THE LEONA M. AND HARRY B. HELMSLEY
CHARITABLE TRUST

A Employer identification number
13-7184401

Number and street (or P.O. box number if mail is not delivered to street address) | Room/suite
230 PARK AVENUE | 659

B Telephone number
212-679-3600

City or town, state or province, country, and ZIP or foreign postal code
NEW YORK, NY 10169

C If exemption application is pending, check here ... ☐

G Check all that apply: ☐ Initial return ☐ Initial return of a former public charity ☐ Final return ☐ Amended return ☐ Address change ☐ Name change

D 1. Foreign organizations, check here ..... ☐

2. Foreign organizations meeting the 85% test, check here and attach computation ..... ☐

H Check type of organization: ☒ Section 501(c)(3) exempt private foundation ☐ Section 4947(a)(1) nonexempt charitable trust ☐ Other taxable private foundation

E If private foundation status was terminated under section 507(b)(1)(A), check here ... ☐

I Fair market value of all assets at end of year (from Part II, col. (c), line 16) $ 7,108,379,897.

J Accounting method: ☐ Cash ☒ Accrual ☐ Other (specify) _____ (Part I, column (d), must be on cash basis.)

F If the foundation is in a 60-month termination under section 507(b)(1)(B), check here ... ☐

Part I **Analysis of Revenue and Expenses** (The total of amounts in columns (b), (c), and (d) may not necessarily equal the amounts in column (a).)

		(a) Revenue and expenses per books	(b) Net investment income	(c) Adjusted net income	(d) Disbursements for charitable purposes (cash basis only)
Revenue	1 Contributions, gifts, grants, etc., received			N/A	
	2 Check ☒ if the foundation is not required to attach Sch. B				
	3 Interest on savings and temporary cash investments	3,123,289.	3,123,289.		STATEMENT 1
	4 Dividends and interest from securities	69,499,667.	141,050,038.		STATEMENT 2
	5a Gross rents				
	b Net rental income or (loss)				
	6a Net gain or (loss) from sale of assets not on line 10	388,637,842.			
	b Gross sales price for all assets on line 6a 669,040,022.				
	7 Capital gain net income (from Part IV, line 2)		270,254,392.		
	8 Net short-term capital gain				
	9 Income modifications				
	10a Gross sales less returns and allowances				
	b Less: Cost of goods sold				
	c Gross profit or (loss)				
	11 Other income	35,998,860.	24,476,876.		STATEMENT 3
	12 **Total.** Add lines 1 through 11	497,259,658.	438,904,595.		
Operating and Administrative Expenses	13 Compensation of officers, directors, trustees, etc.	3,489,555.	1,116,119.		2,340,081.
	14 Other employee salaries and wages	20,708,479.	4,393,931.		16,117,382.
	15 Pension plans, employee benefits	10,117,682.	2,130,594.		8,160,451.
	16a Legal fees STMT 4	555,243.	184,836.		434,251.
	b Accounting fees STMT 5	303,925.	6,023.		228,750.
	c Other professional fees STMT 6	17,084,502.	14,847,388.		2,538,508.
	17 Interest		3,396,683.		
	18 Taxes STMT 7	1,302,511.	3,875,590.		0.
	19 Depreciation and depletion	883,605.	96,753.		
	20 Occupancy	1,733,287.	7,513.		1,998,276.
	21 Travel, conferences, and meetings	2,631,178.	247,403.		2,325,918.
	22 Printing and publications				
	23 Other expenses STMT 8	16,592,645.	56,278,149.		2,489,275.
	24 **Total operating and administrative expenses.** Add lines 13 through 23	75,402,612.	86,580,982.		36,632,892.
	25 Contributions, gifts, grants paid	346,765,830.			440,927,206.
	26 **Total expenses and disbursements.** Add lines 24 and 25	422,168,442.	86,580,982.		477,560,098.
	27 Subtract line 26 from line 12:				
	a Excess of revenue over expenses and disbursements	75,091,216.			
	b **Net investment income** (if negative, enter -0-)		352,323,613.		
	c **Adjusted net income** (if negative, enter -0-)			N/A	

Form **8868**
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Application for Extension of Time To File an Exempt Organization Return or Excise Taxes Related to Employee Benefit Plans

File a separate application for each return.
Go to www.irs.gov/Form8868 for the latest information.

OMB No. 1545-0047

Electronic filing (e-file). You can electronically file Form 8868 to request up to a 6-month extension of time to file any of the forms listed below except for Form 8870, Information Return for Transfers Associated With Certain Personal Benefit Contracts. An extension request for Form 8870 must be sent to the IRS in a paper format (see instructions). For more details on the electronic filing of Form 8868, visit www.irs.gov/e-file-providers/e-file-for-charities-and-non-profits.

Caution: If you are going to make an electronic funds withdrawal (direct debit) with this Form 8868, see Form 8453-TE and Form 8879-TE for payment instructions.

All corporations required to file an income tax return other than Form 990-T (including 1120-C filers), partnerships, REMICs, and trusts must use Form 7004 to request an extension of time to file income tax returns.

Part I - Identification

Type or Print

File by the due date for filing your return. See instructions.

Name of exempt organization, employer, or other filer, see instructions.
THE LEONA M. AND HARRY B. HELMSLEY
CHARITABLE TRUST

Taxpayer identification number (TIN)
13-7184401

Number, street, and room or suite no. If a P.O. box, see instructions.
230 PARK AVENUE, 659

City, town or post office, state, and ZIP code. For a foreign address, see instructions.
NEW YORK, NY 10169

Enter the Return Code for the return that this application is for (file a separate application for each return) 04

Application Is For	Return Code	Application Is For	Return Code
Form 990 or Form 990-EZ	01	Form 4720 (other than individual)	09
Form 4720 (individual)	03	Form 5227	10
Form 990-PF	04	Form 6069	11
Form 990-T (sec. 401(a) or 408(a) trust)	05	Form 8870	12
Form 990-T (trust other than above)	06	Form 5330 (individual)	13
Form 990-T (corporation)	07	Form 5330 (other than individual)	14
Form 1041-A	08	Form 990-T (governmental entities)	15

- After you enter your Return Code, complete either Part II or Part III. Part III, including signature, is applicable only for an extension of time to file Form 5330.
- If this application is for an extension of time to file Form 5330, you must enter the following information.

Plan Name _____
Plan Number _____
Plan Year Ending (MM/DD/YYYY)

Part II - Automatic Extension of Time To File for Exempt Organizations (see instructions)

The books are in the care of NICHOLAS J. SCHIAVO, CFO
230 PARK AVENUE, SUITE 659 - NEW YORK, NY 10169

Telephone No. 212-679-3600 Fax No. _____

- If the organization does not have an office or place of business in the United States, check this box ..... ☐
- If this is for a Group Return, enter the organization's four-digit Group Exemption Number (GEN) _____. If this is for the whole group, check this box ..... ☐. If it is for part of the group, check this box ... ☐ and attach a list with the names and TINs of all members the extension is for.

1 I request an automatic 6-month extension of time until FEBRUARY 15, 20 26, to file the exempt organization return for the organization named above. The extension is for the organization's return for:

☐ calendar year 20 _____ or
☒ tax year beginning APR 1, 20 24, and ending MAR 31, 20 25

2 If the tax year entered in line 1 is for less than 12 months, check reason: ☐ Initial return ☐ Final return ☐ Change in accounting period

3a	If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions.	**3a**	$	8,900,234.
b	If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit.	**3b**	$	7,900,234.
c	**Balance due.** Subtract line 3b from line 3a. Include your payment with this form, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions.	**3c**	$	1,000,000.

For Privacy Act and Paperwork Reduction Act Notice, see instructions. Form **8868** (Rev. 1-2025)

LHA 423841 01-02-25

Part II Balance Sheets Attached schedules and amounts in the description column should be for end-of-year amounts only.

		Beginning of year	End of year	
		(a) Book Value	(b) Book Value	(c) Fair Market Value
Assets	1 Cash - non-interest-bearing	89,496,038.	58,011,746.	58,011,746.
	2 Savings and temporary cash investments	55,980,540.	71,184,590.	71,184,590.
	3 Accounts receivable 285,890.			
	Less: allowance for doubtful accounts	604,736.	285,890.	285,890.
	4 Pledges receivable			
	Less: allowance for doubtful accounts			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons			
	7 Other notes and loans receivable			
	Less: allowance for doubtful accounts			
	8 Inventories for sale or use			
	9 Prepaid expenses and deferred charges	1,033,231.	1,117,294.	1,117,294.
	10a Investments - U.S. and state government obligations			
	b Investments - corporate stock STMT 10	643,618,129.	797,048,528.	797,048,528.
	c Investments - corporate bonds			
	11 Investments - land, buildings, and equipment: basis			
	Less: accumulated depreciation			
	12 Investments - mortgage loans			
	13 Investments - other STMT 11	6,446,813,297.	6,125,814,330.	6,125,814,330.
	14 Land, buildings, and equipment: basis 10,602,402.			
	Less: accumulated depreciation STMT 12 4,745,371.	6,670,262.	5,857,031.	5,857,031.
	15 Other assets (describe STATEMENT 13)	55,861,389.	49,060,488.	49,060,488.
	16 **Total assets** (to be completed by all filers - see the instructions. Also, see page 1, item I)	7,300,077,622.	7,108,379,897.	7,108,379,897.
Liabilities	17 Accounts payable and accrued expenses	11,499,434.	3,968,491.	
	18 Grants payable	564,121,729.	469,960,352.	
	19 Deferred revenue			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable			
	22 Other liabilities (describe STATEMENT 14)	45,857,428.	40,418,243.	
	23 **Total liabilities** (add lines 17 through 22)	621,478,591.	514,347,086.	
Net Assets or Fund Balances	**Foundations that follow FASB ASC 958, check here** [X] **and complete lines 24, 25, 29, and 30.**			
	24 Net assets without donor restrictions	6,678,599,031.	6,594,032,811.	
	25 Net assets with donor restrictions			
	Foundations that do not follow FASB ASC 958, check here [ ] **and complete lines 26 through 30.**			
	26 Capital stock, trust principal, or current funds			
	27 Paid-in or capital surplus, or land, bldg., and equipment fund			
	28 Retained earnings, accumulated income, endowment, or other funds			
	29 **Total net assets or fund balances**	6,678,599,031.	6,594,032,811.	
	30 **Total liabilities and net assets/fund balances**	7,300,077,622.	7,108,379,897.	

Part III Analysis of Changes in Net Assets or Fund Balances

1	Total net assets or fund balances at beginning of year - Part II, column (a), line 29 (must agree with end-of-year figure reported on prior year's return)	1	6,678,599,031.
2	Enter amount from Part I, line 27a	2	75,091,216.
3	Other increases not included in line 2 (itemize) DEFERRED FEDERAL EXCISE TAX BENEFIT	3	2,181,205.
4	Add lines 1, 2, and 3	4	6,755,871,452.
5	Decreases not included in line 2 (itemize) SEE STATEMENT 9	5	161,838,641.
6	Total net assets or fund balances at end of year (line 4 minus line 5) - Part II, column (b), line 29	6	6,594,032,811.

Part IV Capital Gains and Losses for Tax on Investment Income SEE ATTACHED STATEMENTS

	(a) List and describe the kind(s) of property sold (for example, real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.)	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a				
b				
c				
d				
e				

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) ((e) plus (f) minus (g))
a				
b				
c				
d				
e	669,040,022.		172,857,597.	270,254,392.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69.

	(i) FMV as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Gains (Col. (h) gain minus col. (k), but not less than -0-) **or** Losses (from col. (h))
a				
b				
c				
d				
e				270,254,392.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter -0- in Part I, line 7 }	2	270,254,392.
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). See instructions. If (loss), enter -0- in Part I, line 8	3	N/A

Part V Excise Tax Based on Investment Income (Section 4940(a), 4940(b), or 4948 - see instructions)

1a	Exempt operating foundations described in section 4940(d)(2), check here ☐ and enter "N/A" on line 1. Date of ruling or determination letter: _____ **(attach copy of letter if necessary - see instructions)**		1	4,897,298.
b	All other domestic foundations enter 1.39% (0.0139) of line 27b. Exempt foreign organizations, enter 4% (0.04) of Part I, line 12, col. (b)			
2	Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)		2	0.
3	Add lines 1 and 2		3	4,897,298.
4	Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)		4	0.
5	**Tax based on investment income.** Subtract line 4 from line 3. If zero or less, enter -0-		5	4,897,298.
6	Credits/Payments:			
a	2024 estimated tax payments and 2023 overpayment credited to 2024	6a 7,900,234.		
b	Exempt foreign organizations - tax withheld at source	6b 0.		
c	Tax paid with application for extension of time to file (Form 8868)	6c 1,000,000.		
d	Backup withholding erroneously withheld	6d 0.		
7	Total credits and payments. Add lines 6a through 6d		7	8,900,234.
8	Enter any **penalty** for underpayment of estimated tax. Check here [X] if Form 2220 is attached		8	0.
9	**Tax due.** If the total of lines 5 and 8 is more than line 7, enter **amount owed**		9	
10	**Overpayment.** If line 7 is more than the total of lines 5 and 8, enter the **amount overpaid**		10	4,002,936.
11	Enter the amount of line 10 to be: **Credited to 2025 estimated tax** 4,002,936. **Refunded**		11	0.

Form **990-PF** (2024)

423521 12-06-24

Part VI-A Statements Regarding Activities

			Yes	No
1a	During the tax year, did the foundation attempt to influence any national, state, or local legislation or did it participate or intervene in any political campaign?	1a		X
b	Did it spend more than $100 during the year (either directly or indirectly) for political purposes? See the instructions for the definition	1b		X
	If the answer is "Yes" to **1a** or **1b**, attach a detailed description of the activities and copies of any materials published or distributed by the foundation in connection with the activities.			
c	Did the foundation file **Form 1120-POL** for this year?	1c		X
d	Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year: **(1)** On the foundation. $ 0. **(2)** On foundation managers. $ 0.			
e	Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax imposed on foundation managers. $ 0.			
2	Has the foundation engaged in any activities that have not previously been reported to the IRS? If "Yes," attach a detailed description of the activities.	2		X
3	Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes	3		X
4a	Did the foundation have unrelated business gross income of $1,000 or more during the year?	4a	X	
b	If "Yes," has it filed a tax return on **Form 990-T** for this year?	4b	X	
5	Was there a liquidation, termination, dissolution, or substantial contraction during the year? If "Yes," attach the statement required by *General Instruction T.*	5		X
6	Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either: • By language in the governing instrument, or • By state legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the state law remain in the governing instrument?	6	X	
7	Did the foundation have at least $5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part XIV	7	X	
8a	Enter the states to which the foundation reports or with which it is registered. See instructions. NY			
b	If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney General (or designate) of each state as required by *General Instruction G?* If "No," attach explanation	8b	X	
9	Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 2024 or the tax year beginning in 2024? See the instructions for Part XIII. If "Yes," complete Part XIII	9		X
10	Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing their names and addresses	10		X
11	At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the meaning of section 512(b)(13)? If "Yes," attach schedule. See instructions STATEMENT 16 STATEMENT 17 STMT 18	11	X	
12	Did the foundation make a distribution to a donor advised fund over which the foundation or a disqualified person had advisory privileges? If "Yes," attach statement. See instructions	12		X
13	Did the foundation comply with the public inspection requirements for its annual returns and exemption application?	13	X	

Website address HELMSLEYTRUST.ORG

14 The books are in care of NICHOLAS J. SCHIAVO, CFO Telephone no. 212-679-3600

Located at 230 PARK AVENUE, SUITE 659, NEW YORK, NY ZIP+4 10169

15 Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of **Form 1041** - check here ☐

and enter the amount of tax-exempt interest received or accrued during the year 15 N/A

			Yes	No
16	At any time during calendar year 2024, did the foundation have an interest in or a signature or other authority over a bank, securities, or other financial account in a foreign country? See the instructions for exceptions and filing requirements for FinCEN Form 114. If "Yes," enter the name of the foreign country SEE STATEMENT 15	16	X	

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required

File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.		Yes	No
1a During the year, did the foundation (either directly or indirectly):			
(1) Engage in the sale or exchange, or leasing of property with a disqualified person?	1a(1)	X	
(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person?	1a(2)		X
(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?	1a(3)	X	
(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person?	1a(4)	X	
(5) Transfer any income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)?	1a(5)		X
(6) Agree to pay money or property to a government official? (**Exception.** Check "No" if the foundation agreed to make a grant to or to employ the official for a period after termination of government service, if terminating within 90 days.)	1a(6)		X
b If any answer is "Yes" to 1a(1)-(6), did **any** of the acts fail to qualify under the exceptions described in Regulations section 53.4941(d)-3 or in a current notice regarding disaster assistance? See instructions	1b		X
c Organizations relying on a current notice regarding disaster assistance, check here ☐			
d Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that were not corrected before the first day of the tax year beginning in 2024?	1d		X
2 Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)):			
a At the end of tax year 2024, did the foundation have any undistributed income (Part XII, lines 6d and 6e) for tax year(s) beginning before 2024?	2a		X
If "Yes," list the years _____, _____, _____, _____			
b Are there any years listed in 2a for which the foundation is **not** applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to **all** years listed, answer "No" and attach statement - see instructions.) N/A	2b		
c If the provisions of section 4942(a)(2) are being applied to **any** of the years listed in 2a, list the years here. _____, _____, _____, _____			
3a Did the foundation hold more than a 2% direct or indirect interest in any business enterprise at any time during the year?	3a	X	
b If "Yes," did it have excess business holdings in 2024 as a result of **(1)** any purchase by the foundation or disqualified persons after May 26, 1969; **(2)** the lapse of the 5-year period (or longer period approved by the Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or **(3)** the lapse of the 10-, 15-, or 20-year first phase holding period? (Use Form 4720, Schedule C, to determine if the foundation had excess business holdings in 2024.)	3b		X
4a Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?	4a		X
b Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2024?	4b		X

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required *(continued)*

		Yes	No
5a During the year, did the foundation pay or incur any amount to:			
(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?	5a(1)		X
(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?	5a(2)		X
(3) Provide a grant to an individual for travel, study, or other similar purposes?	5a(3)		X
(4) Provide a grant to an organization other than a charitable, etc., organization described in section 4945(d)(4)(A)? See instructions	5a(4)	X	
(5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?	5a(5)		X
b If any answer is "Yes" to 5a(1)-(5), did **any** of the transactions fail to qualify under the exceptions described in Regulations section 53.4945 or in a current notice regarding disaster assistance? See instructions	5b		X
c Organizations relying on a current notice regarding disaster assistance, check here ☐			
d If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? SEE STATEMENT 20	5d	X	
If "Yes," attach the statement required by Regulations section 53.4945-5(d).			
6a Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?	6a		X
b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract?	6b		X
If "Yes" to 6b, file Form 8870.			
7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?	7a		X
b If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? N/A	7b		
8 Is the foundation subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year?	8		X

Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors

1 List all officers, directors, trustees, and foundation managers and their compensation.

(a) Name and address	(b) Title, and average hours per week devoted to position	(c) Compensation (If not paid, enter -0-)	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 19		3637224	702117.	0.

2 Compensation of five highest-paid employees (other than those included on line 1). If none, enter "NONE."

(a) Name and address of each employee paid more than $50,000	(b) Title, and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
AL Y. KIM - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	769,227.	177,456.	0.
MEENAKSHI C. LAKSHMAN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIR. OF STRATEGY & RESEARCH 40.00	764,742.	177,456.	0.
CHRISTOPHER J. RAPCEWICZ - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY	DIR. OF RISK MNGMT. & OPERATIONS 40.00	760,560.	156,747.	0.
BRIAN B. CHUN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	550,358.	110,848.	0.
MAUREEN E. RAYHILL - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF HUMAN RESOURCES 40.00	505,841.	102,226.	0.

Total number of other employees paid over $50,000 109

Part VII **Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors** *(continued)*

3 Five highest-paid independent contractors for professional services. If none, enter "NONE."

(a) Name and address of each person paid more than $50,000	(b) Type of service	(c) Compensation
NEWMARKET IIFC - 1325 NORTH BEACH STREET, SUITE 201, PHILADELPHIA, PA 19125	INVESTMENT MANAGEMENT	8,414,015.
HIG GROWTH II 600 5TH AVE., 24TH FL., NEW YORK, NY 10020	INVESTMENT MANAGEMENT	2,620,945.
IFP GLOBAL FRANCHISE - LEVEL 1, 10 PORTMAN SQUARE, LONDON, UNITED KINGDOM W1H 6AZ	INVESTMENT MANAGEMENT	1,828,023.
COLLER VII - 116 PARK STREET, LONDON, UNITED KINGDOM W1K 6AZ	INVESTMENT MANAGEMENT	1,618,408.
HIGHCLERE INTERNATIONAL INVESTORS 2 MANCHESTER SQUARE, LONDON, UNITED KINGDOM	INVESTMENT MANAGEMENT	1,530,277.
Total number of others receiving over $50,000 for professional services		38

Part VIII-A **Summary of Direct Charitable Activities**

List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.	Expenses
1 SEE STATEMENT 21	1,390,656.
2 FOR TECHNICAL SUPPORT TO GRANTEES, INCLUDING PROVIDING RESEARCH DATA, TO HELP MEET THEIR CHARITABLE GOALS.	93,051.
3 SEE STATEMENT 22	312,168.
4	

Part VIII-B **Summary of Program-Related Investments**

Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2.	Amount
1 THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHN'S DISEASE	4,400,000.
2 TIXIMED, INC. - DEVELOPING A DRUG TO PROTECT BETA CELLS DURING TYPE 1 DIABETES DEVELOPMENT	2,650,000.
All other program-related investments. See instructions.	
3 SEE STATEMENT 23	1,520,000.
Total. Add lines 1 through 3	8,570,000.

Part IX Minimum Investment Return (All domestic foundations must complete this part. Foreign foundations, see instructions.)

1	Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:			
a	Average monthly fair market value of securities		1a	6,991,393,403.
b	Average of monthly cash balances		1b	160,961,317.
c	Fair market value of all other assets (see instructions)		1c	769,022.
d	**Total** (add lines 1a, b, and c)		1d	7,153,123,742.
e	Reduction claimed for blockage or other factors reported on lines 1a and 1c (attach detailed explanation)	1e 0.		
2	Acquisition indebtedness applicable to line 1 assets		2	0.
3	Subtract line 2 from line 1d		3	7,153,123,742.
4	Cash deemed held for charitable activities. Enter 1.5% (0.015) of line 3 (for greater amount, see instructions)		4	107,296,856.
5	**Net value of noncharitable-use assets.** Subtract line 4 from line 3		5	7,045,826,886.
6	**Minimum investment return.** Enter 5% (0.05) of line 5		6	352,291,344.

Part X Distributable Amount (see instructions) (Section 4942(j)(3) and (j)(5) private operating foundations and certain foreign organizations, check here ☐ and do not complete this part.)

1	Minimum investment return from Part IX, line 6			1	352,291,344.
2a	Tax on investment income for 2024 from Part V, line 5	2a	4,897,298.		
b	Income tax for 2024. (This does not include the tax from Part V.)	2b	471,679.		
c	Add lines 2a and 2b			2c	5,368,977.
3	Distributable amount before adjustments. Subtract line 2c from line 1			3	346,922,367.
4	Recoveries of amounts treated as qualifying distributions			4	7,276,276.
5	Add lines 3 and 4			5	354,198,643.
6	Deduction from distributable amount (see instructions)			6	0.
7	**Distributable amount** as adjusted. Subtract line 6 from line 5. Enter here and on Part XII, line 1			7	354,198,643.

Part XI Qualifying Distributions (see instructions)

1	Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:		
a	Expenses, contributions, gifts, etc. - total from Part I, column (d), line 26	1a	477,560,098.
b	Program-related investments - total from Part VIII-B	1b	8,570,000.
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	2	70,375.
3	Amounts set aside for specific charitable projects that satisfy the:		
a	Suitability test (prior IRS approval required)	3a	
b	Cash distribution test (attach the required schedule)	3b	
4	**Qualifying distributions.** Add lines 1a through 3b. Enter here and on Part XII, line 4	4	486,200,473.

Part XII Undistributed Income (see instructions)

	(a) Corpus	(b) Years prior to 2023	(c) 2023	(d) 2024
1 Distributable amount for 2024 from Part X, line 7				354,198,643.
2 Undistributed income, if any, as of the end of 2024:				
a Enter amount for 2023 only			0.	
b Total for prior years: _____, _____, _____		0.		
3 Excess distributions carryover, if any, to 2024:				
a From 2019				
b From 2020				
c From 2021				
d From 2022				
e From 2023 129,248,898.				
f **Total** of lines 3a through e	129,248,898.			
4 Qualifying distributions for 2024 from Part XI, line 4: $ 486,200,473.				
a Applied to 2023, but not more than line 2a			0.	
b Applied to undistributed income of prior years (Election required - see instructions)		0.		
c Treated as distributions out of corpus (Election required - see instructions)	0.			
d Applied to 2024 distributable amount				354,198,643.
e Remaining amount distributed out of corpus	132,001,830.			
5 Excess distributions carryover applied to 2024 (If an amount appears in column (d), the same amount must be shown in column (a).)	0.			0.
6 **Enter the net total of each column as indicated below:**				
a Corpus. Add lines 3f, 4c, and 4e. Subtract line 5	261,250,728.			
b Prior years' undistributed income. Subtract line 4b from line 2b		0.		
c Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed		0.		
d Subtract line 6c from line 6b. Taxable amount - see instructions		0.		
e Undistributed income for 2023. Subtract line 4a from line 2a. Taxable amount - see instr.			0.	
f Undistributed income for 2024. Subtract lines 4d and 5 from line 1. This amount must be distributed in 2025				0.
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3) (Election may be required - see instructions)	0.			
8 Excess distributions carryover from 2019 not applied on line 5 or line 7	0.			
9 **Excess distributions carryover to 2025.** Subtract lines 7 and 8 from line 6a	261,250,728.			
10 Analysis of line 9:				
a Excess from 2020				
b Excess from 2021				
c Excess from 2022				
d Excess from 2023 129,248,898.				
e Excess from 2024 132,001,830.				

Part XIII Private Operating Foundations (see instructions and Part VI-A, question 9) N/A

1 a If the foundation has received a ruling or determination letter that it is a private operating foundation, and the ruling is effective for 2024, enter the date of the ruling .....

b Check box to indicate whether the foundation is a private operating foundation described in section ..... ☐ 4942(j)(3) or ☐ 4942(j)(5)

	Tax year	Prior 3 years			
	(a) 2024	(b) 2023	(c) 2022	(d) 2021	(e) Total
2 a Enter the lesser of the adjusted net income from Part I or the minimum investment return from Part IX for each year listed					
b 85% (0.85) of line 2a					
c Qualifying distributions from Part XI, line 4, for each year listed					
d Amounts included in line 2c not used directly for active conduct of exempt activities					
e Qualifying distributions made directly for active conduct of exempt activities. Subtract line 2d from line 2c					
3 Complete 3a, b, or c for the alternative test relied upon: a "Assets" alternative test - enter: (1) Value of all assets					
(2) Value of assets qualifying under section 4942(j)(3)(B)(i) ...					
b "Endowment" alternative test - enter 2/3 of minimum investment return shown in Part IX, line 6, for each year listed					
c "Support" alternative test - enter: (1) Total support other than gross investment income (interest, dividends, rents, payments on securities loans (section 512(a)(5)), or royalties)					
(2) Support from general public and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii)					
(3) Largest amount of support from an exempt organization					
(4) Gross investment income					

Part XIV Supplementary Information (Complete this part only if the foundation had $5,000 or more in assets at any time during the year-see instructions.)

1 **Information Regarding Foundation Managers:**

a List any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than $5,000). (See section 507(d)(2).)

NONE

b List any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.

NONE

2 **Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs:**

Check here ☒ if the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds. If the foundation makes gifts, grants, etc., to individuals or organizations under other conditions, complete items 2a, b, c, and d.

a The name, address, and telephone number or email address of the person to whom applications should be addressed:

b The form in which applications should be submitted and information and materials they should include:

c Any submission deadlines:

d Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

Part XIV Supplementary Information *(continued)*

3 Grants and Contributions Paid During the Year or Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution **	Amount
a *Paid during the year*				
A GLIMMER OF HOPE FOUNDATION 11101 LOS COMANCHEROS RD AUSTIN, TX 78717	N/A	PF	EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY	1,446,574.
ACTION4DIABETES 9 PARKFIELD ROAD TAUNTON, UNITED KINGDOM	N/A	PC	PHILIPPINES T1D TASK FORCE	222,500.
ACUMEN AMERICA, LLC 40 WORTH STREET NEW YORK, NY 10013	N/A	PC	SEE STATEMENT	50,000.
ADI NEGEV-NAHALAT ERAN, R.A. POB 331 OFAKIM, ISRAEL	N/A	PC	REHABILITATION EQUIPMENT	244,998.
AFRICAN MISSION HEALTHCARE FOUNDATION 101 NORTH WOODLAND BOULEVARD DELAND, FL 32720	N/A	PC	ST. FRANCIS HOSPITAL MATERNITY CENTER	191,802.
Total SEE CONTINUATION SHEET(S)			**3a**	440,927,206.
b *Approved for future payment*				
ACADEMISCH ZIEKENHUIS LEIDEN 2 ALBINUSDREEF LEIDEN, NETHERLANDS	N/A	GOV	SEE STATEMENT	238,910.
ACADEMISCH ZIEKENHUIS LEIDEN 2 ALBINUSDREEF LEIDEN, NETHERLANDS	N/A	GOV	SEE STATEMENT	93,238.
ACTION4DIABETES 9 PARKFIELD ROAD TAUNTON, UNITED KINGDOM	N/A	PC	PHILIPPINES T1D TASK FORCE	284,390.
Total SEE CONTINUATION SHEET(S)			**3b**	482,120,897.

423611 12-06-24 ** SEE PURPOSE OF GRANT CONTINUATIONS

Part XV-A Analysis of Income-Producing Activities

Enter gross amounts unless otherwise indicated.	Unrelated business income		Excluded by section 512, 513, or 514		(e)
	(a) Business code	(b) Amount	(c) Exclusion code	(d) Amount	Related or exempt function income
1 Program service revenue:					
a					
b					
c					
d					
e					
f					
g Fees and contracts from government agencies					
2 Membership dues and assessments					
3 Interest on savings and temporary cash investments			14	3,123,289.	
4 Dividends and interest from securities	901101	3,051,525.	14	66,448,142.	
5 Net rental income or (loss) from real estate:					
a Debt-financed property					
b Not debt-financed property					
6 Net rental income or (loss) from personal property					
7 Other investment income	901101	14,231,233.	14	11,117,546.	
8 Gain or (loss) from sales of assets other than inventory	901101	3,193,622.	18	385,444,220.	
9 Net income or (loss) from special events					
10 Gross profit or (loss) from sales of inventory					
11 Other revenue:					
a GRANT RECOVERIES			01	7,276,276.	
b OTHER NON-TAXABLE INCOME			01	27,454.	
c FEDERAL EXCISE TAX BENEFIT			01	3,842,567.	
d FX TRANSACTION NET LOSS - BOOK			14	-496,216.	
e					
12 Subtotal. Add columns (b), (d), and (e)		20,476,380.		476,783,278.	0.
13 **Total.** Add line 12, columns (b), (d), and (e)				13	497,259,658.

(See worksheet in line 13 instructions to verify calculations.)

Part XV-B Relationship of Activities to the Accomplishment of Exempt Purposes

Line No.	Explain below how each activity for which income is reported in column (e) of Part XV-A contributed importantly to the accomplishment of the foundation's exempt purposes (other than by providing funds for such purposes).

Part XVI Information Regarding Transfers to and Transactions and Relationships With Noncharitable Exempt Organizations

			Yes	No
1	Did the organization directly or indirectly engage in any of the following with any other organization described in section 501(c) (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?			
a	Transfers from the reporting foundation to a noncharitable exempt organization of:			
	(1) Cash	1a(1)	X	
	(2) Other assets	1a(2)		X
b	Other transactions:			
	(1) Sales of assets to a noncharitable exempt organization	1b(1)		X
	(2) Purchases of assets from a noncharitable exempt organization	1b(2)		X
	(3) Rental of facilities, equipment, or other assets	1b(3)		X
	(4) Reimbursement arrangements	1b(4)		X
	(5) Loans or loan guarantees	1b(5)		X
	(6) Performance of services or membership or fundraising solicitations	1b(6)		X
c	Sharing of facilities, equipment, mailing lists, other assets, or paid employees	1c		X

d If the answer to any of the above is "Yes," complete the following schedule. Column **(b)** should always show the fair market value of the goods, other assets, or services given by the reporting foundation. If the foundation received less than fair market value in any transaction or sharing arrangement, show in column **(d)** the value of the goods, other assets, or services received.

(a) Line no.	(b) Amount involved	(c) Name of noncharitable exempt organization	(d) Description of transfers, transactions, and sharing arrangements
		ASSOCIATION OF DIABETES CARE & EDUCATION	SEE STATEMENT 24
A1	1,885,608.	SPECIALISTS	

2a Is the foundation directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) (other than section 501(c)(3)) or in section 527? ☐ Yes ☒ No

b If "Yes," complete the following schedule.

(a) Name of organization	(b) Type of organization	(c) Description of relationship
N/A		

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than taxpayer) is based on all information of which preparer has any knowledge.

Nicholas Schiano — 02/04/2026 — CFO

Signature of officer or trustee — Date — Title

May the IRS discuss this return with the preparer shown below? See instr. ☒ Yes ☐ No

Paid Preparer Use Only

Preparer's name	Preparer's signature	Date	Check ☐ if self-employed	PTIN
THOMAS BLANEY	THOMAS BLANEY	02/03/26		P00234022

Firm's name PKF O'CONNOR DAVIES ADVISORY, LLC — Firm's EIN 33-1374517

Firm's address 245 PARK AVENUE, 12TH FLOOR NEW YORK, NY 10167 — Phone no. 212-286-2600

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SALE OF PUBLICLY TRADED SECURITIES	P		
b	ACADIAN FRONTIER	P		02/21/25
c	ACADIAN FRONTIER	P		04/12/24
d	ACCEL GROWTH FUND IV	P		05/28/24
e	ACCEL GROWTH FUND IV	P		10/09/24
f	ACCEL GROWTH II	P		08/06/24
g	ACCEL GROWTH II	P		02/20/25
h	ACCEL GROWTH II	P		12/20/24
i	ACCEL GROWTH II	P		08/27/24
j	ACCEL GROWTH II	P		09/04/24
k	ACCEL GROWTH II	P		09/09/24
l	ACCEL GROWTH II	P		09/19/24
m	ACCEL GROWTH II	P		11/07/24
n	ACCEL GROWTH II	P		11/21/24
o	ACCEL GROWTH V	P		11/12/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	100,776,909.		49,067.	100,727,842.
b	8,137.			8,137.
c	170,334.			170,334.
d	60,891.			60,891.
e	194,429.			194,429.
f	95,530.			95,530.
g	285,950.			285,950.
h	790,579.			790,579.
i	93,382.			93,382.
j	110,121.			110,121.
k	110,121.			110,121.
l	110,346.			110,346.
m	267,610.			267,610.
n	260,384.			260,384.
o	56,579.			56,579.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				100,727,842.
b				8,137.
c				170,334.
d				60,891.
e				194,429.
f				95,530.
g				285,950.
h				790,579.
i				93,382.
j				110,121.
k				110,121.
l				110,346.
m				267,610.
n				260,384.
o				56,579.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	ACCEL GROWTH V	P		08/12/24
b	ACCEL LEADERS FUND	P		07/08/24
c	ACCEL LEADERS II	P		11/12/24
d	ACCEL LEADERS II	P		08/12/24
e	ACCEL XII	P		07/01/24
f	ACCEL XII	P		01/14/25
g	ACCEL XII	P		05/28/24
h	AH IV	P		05/10/24
i	AH IV	P		04/17/24
j	AH IV	P		02/06/25
k	AH IV	P		12/09/24
l	AH IV	P		11/13/24
m	AH IV	P		09/10/24
n	AH IV	P		08/08/24
o	AH IV	P		08/05/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	44,712.			44,712.
b	339,577.			339,577.
c	169,631.			169,631.
d	134,020.			134,020.
e	310,941.			310,941.
f	223,664.			223,664.
g	66,765.			66,765.
h	554,375.			554,375.
i	135,239.			135,239.
j	581,363.			581,363.
k	5,422,148.			5,422,148.
l	506,086.			506,086.
m	5,475,799.			5,475,799.
n	1,007,639.			1,007,639.
o	488,086.			488,086.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				44,712.
b				339,577.
c				169,631.
d				134,020.
e				310,941.
f				223,664.
g				66,765.
h				554,375.
i				135,239.
j				581,363.
k				5,422,148.
l				506,086.
m				5,475,799.
n				1,007,639.
o				488,086.

2	Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	AH IV	P		07/16/24
b	AH IV	P		04/17/24
c	AH IV	P		06/13/24
d	AH IV PARALLEL	P		04/17/24
e	AH IV PARALLEL	P		05/10/24
f	AH IV PARALLEL	P		06/13/24
g	AH IV PARALLEL	P		07/16/24
h	AH IV PARALLEL	P		08/05/24
i	AH IV PARALLEL	P		08/08/24
j	AH IV PARALLEL	P		09/10/24
k	AH IV PARALLEL	P		11/13/24
l	AH IV PARALLEL	P		12/09/24
m	AH IV PARALLEL	P		02/06/25
n	AH LSV I	P		09/10/24
o	AH LSV I	P		12/11/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	445,055.			445,055.
b	37,200.			37,200.
c	408,164.			408,164.
d	307,142.			307,142.
e	401,912.			401,912.
f	727,034.			727,034.
g	792,745.			792,745.
h	337,469.			337,469.
i	247,006.			247,006.
j	433,039.			433,039.
k	342,430.			342,430.
l	461,124.			461,124.
m	1,035,544.			1,035,544.
n	439,031.			439,031.
o	543,327.			543,327.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				445,055.
b				37,200.
c				408,164.
d				307,142.
e				401,912.
f				727,034.
g				792,745.
h				337,469.
i				247,006.
j				433,039.
k				342,430.
l				461,124.
m				1,035,544.
n				439,031.
o				543,327.

2	Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	AH LSV I	P		02/06/25
b	AH LSV I	P		11/06/24
c	AH LSV I	P		12/09/24
d	BAYVIEW	P		08/08/24
e	BAYVIEW	P		01/10/25
f	BAYVIEW	P		12/31/24
g	BLACKROCK US DEBT	P		06/04/24
h	BLACKROCK US DEBT	P		08/27/24
i	BLACKROCK US DEBT	P		04/24/24
j	BLACKROCK US DEBT	P		09/03/24
k	BLACKROCK US DEBT	P		10/22/24
l	BLACKROCK US DEBT	P		07/22/24
m	BLACKROCK US DEBT	P		01/24/25
n	CAMBER	P		12/31/24
o	CHATHAM	P		10/17/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	484,717.			484,717.
b	412,821.			412,821.
c	475,224.			475,224.
d	676,375.			676,375.
e	124,950.			124,950.
f	50,495.			50,495.
g	20,000,000.		18,609,900.	1,390,100.
h	15,000,000.		13,391,867.	1,608,133.
i	14,245.		13,611.	634.
j	15,000,000.		13,384,573.	1,615,427.
k	12,127.		10,961.	1,166.
l	13,647.		12,559.	1,088.
m	10,756.		9,826.	930.
n	15,000,000.		9,232,493.	5,767,507.
o			516.	-516.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				484,717.
b				412,821.
c				475,224.
d				676,375.
e				124,950.
f				50,495.
g				1,390,100.
h				1,608,133.
i				634.
j				1,615,427.
k				1,166.
l				1,088.
m				930.
n				5,767,507.
o				-516.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	CHATHAM	P		09/30/24
b	CHATHAM	P		03/31/25
c	CHATHAM OFFSHORE	P		03/31/25
d	CHATHAM OFFSHORE	P		09/30/24
e	COLLER VI	P		09/20/24
f	COLLER VI	P		03/28/25
g	COLLER VI	P		12/16/24
h	COLLER VI	P		02/12/25
i	COLLER VI	P		07/03/24
j	COLLER VI	P		05/10/24
k	COLLER VII	P		09/30/24
l	COLLER VII	P		10/21/24
m	COLLER VII	P		07/26/24
n	COLLER VII	P		01/07/25
o	COLLER VII	P		06/27/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	10,000,516.		4,632,028.	5,368,488.
b	5,000,000.		2,228,298.	2,771,702.
c	5,000,000.		2,261,774.	2,738,226.
d	10,000,000.		4,738,543.	5,261,457.
e	581,635.			581,635.
f	114,941.			114,941.
g	86,683.			86,683.
h	96,318.			96,318.
i	178,332.			178,332.
j	298,045.			298,045.
k	2,733,736.			2,733,736.
l	1,439,065.			1,439,065.
m	940,500.			940,500.
n	3,196,572.			3,196,572.
o	1,182,116.			1,182,116.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				5,368,488.
b				2,771,702.
c				2,738,226.
d				5,261,457.
e				581,635.
f				114,941.
g				86,683.
h				96,318.
i				178,332.
j				298,045.
k				2,733,736.
l				1,439,065.
m				940,500.
n				3,196,572.
o				1,182,116.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	CRESTVIEW III	P		12/23/24
b	CRESTVIEW III	P		06/18/24
c	CRESTVIEW IV	P		06/18/24
d	EIG ENERGY FUND XVI	P		04/16/24
e	EIG ENERGY FUND XVI	P		06/28/24
f	EIG ENERGY XV	P		03/25/25
g	EIG ENERGY XVII	P		03/31/25
h	EIG ENERGY XVII	P		06/28/24
i	EIG ENERGY XVII	P		08/06/24
j	EIG ENERGY XVII	P		10/30/24
k	EIG ENERGY XVII	P		12/31/24
l	EIG ENERGY XVII	P		04/10/24
m	EMERGENCE III	P		12/03/24
n	EMERGENCE OPP I	P		02/12/25
o	EMERGENCE OPP I	P		11/12/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	716,723.			716,723.
b	350,515.			350,515.
c	217,828.			217,828.
d	96,495.			96,495.
e	345,347.			345,347.
f	351,294.			351,294.
g	57,950.			57,950.
h	23,663.			23,663.
i	431,455.			431,455.
j	406,437.			406,437.
k	3,056.			3,056.
l	218,737.			218,737.
m	5,086,839.			5,086,839.
n	342,981.			342,981.
o	223,517.			223,517.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				716,723.
b				350,515.
c				217,828.
d				96,495.
e				345,347.
f				351,294.
g				57,950.
h				23,663.
i				431,455.
j				406,437.
k				3,056.
l				218,737.
m				5,086,839.
n				342,981.
o				223,517.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	EPIRIS ELEC CO INV	P		01/21/25
b	EPIRIS ELEC CO INV	P		09/26/24
c	EPIRIS II	P		09/26/24
d	EPIRIS II	P		08/28/24
e	EPIRIS III	P		01/21/25
f	EPIRIS III	P		08/20/24
g	EPIRIS III	P		10/30/24
h	FORTISSIMO V	P		08/14/24
i	FRAZIER IX	P		03/14/25
j	FRAZIER IX	P		05/14/24
k	FRAZIER IX	P		01/07/25
l	FRAZIER OVERAGE	P		03/20/25
m	FRAZIER PUBLIC FUND	P		03/20/25
n	FRAZIER PUBLIC FUND	P		05/23/24
o	FRAZIER X	P		02/07/25

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	616,412.			616,412.
b	505,163.			505,163.
c	55,373.			55,373.
d	58,548.			58,548.
e	251,128.			251,128.
f	18,351.			18,351.
g	1,163,419.			1,163,419.
h	3,256,380.			3,256,380.
i	68,206.			68,206.
j	90,172.			90,172.
k	422,015.			422,015.
l	416,477.			416,477.
m	544,640.			544,640.
n	3,316,055.			3,316,055.
o	164,995.			164,995.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				616,412.
b				505,163.
c				55,373.
d				58,548.
e				251,128.
f				18,351.
g				1,163,419.
h				3,256,380.
i				68,206.
j				90,172.
k				422,015.
l				416,477.
m				544,640.
n				3,316,055.
o				164,995.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	FRAZIER X	P		04/19/24
b	FRAZIER XI	P		02/07/25
c	FRAZIER XI	P		03/26/25
d	FRAZIER XI	P		09/18/24
e	GAVEA V	P		02/14/25
f	GAVEA V	P		11/21/24
g	GAVEA V PLUS	P		08/20/24
h	GENERL ATLANTIC 2013	P		05/23/24
i	GENERL ATLANTIC 2013	P		12/09/24
j	GENERL ATLANTIC 2013	P		11/15/24
k	GENERL ATLANTIC 2013	P		11/01/24
l	GENERL ATLANTIC 2013	P		09/17/24
m	GENERL ATLANTIC 2013	P		06/18/24
n	GENERL ATLANTIC 2013	P		06/27/24
o	GENERL ATLANTIC 2013	P		07/29/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	91,483.			91,483.
b	415,117.			415,117.
c	153,232.			153,232.
d	134,642.			134,642.
e	125,558.			125,558.
f	28,701.			28,701.
g	296,683.		1,820,727.	-1,524,044.
h	262,194.			262,194.
i	778,044.			778,044.
j	687,815.			687,815.
k	2,448,001.			2,448,001.
l			1,203,436.	-1,203,436.
m			251,741.	-251,741.
n			318,109.	-318,109.
o	214,699.			214,699.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				91,483.
b				415,117.
c				153,232.
d				134,642.
e				125,558.
f				28,701.
g				-1,524,044.
h				262,194.
i				778,044.
j				687,815.
k				2,448,001.
l				-1,203,436.
m				-251,741.
n				-318,109.
o				214,699.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	GENERL ATLANTIC 2013	P		08/20/24
b	GENERL ATLANTIC 2013	P		09/10/24
c	GENERL ATLANTIC 2013	P		10/22/24
d	GENERL ATLANTIC 2018	P		01/23/25
e	GENERL ATLANTIC 2018	P		12/19/24
f	GENERL ATLANTIC 2018	P		12/09/24
g	GENERL ATLANTIC 2018	P		09/23/24
h	GENERL ATLANTIC 2018	P		09/10/24
i	GENERL ATLANTIC 2018	P		08/08/24
j	GENERL ATLANTIC 2018	P		06/21/24
k	GENERL ATLANTIC 2018	P		04/18/24
l	GENERL ATLANTIC 2018	P		08/13/24
m	HIG BRAZIL LATAM B	P		01/28/25
n	HIG BRAZIL LATAM B	P		04/09/24
o	HIG BRAZIL LATAM C	P		01/28/25

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	352,356.			352,356.
b			300,519.	-300,519.
c	602,031.			602,031.
d	248,139.			248,139.
e			62,458.	-62,458.
f	7,824.			7,824.
g			150,412.	-150,412.
h			300,340.	-300,340.
i	4,965.			4,965.
j	253,065.			253,065.
k	24,276.			24,276.
l			20,669.	-20,669.
m	1,923,570.			1,923,570.
n	1,271.			1,271.
o	1,923,570.			1,923,570.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				352,356.
b				-300,519.
c				602,031.
d				248,139.
e				-62,458.
f				7,824.
g				-150,412.
h				-300,340.
i				4,965.
j				253,065.
k				24,276.
l				-20,669.
m				1,923,570.
n				1,271.
o				1,923,570.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	HIG BRAZIL LATAM C	P		04/09/24
b	HIG CAPITAL V	P		10/10/24
c	HIG CAPITAL V	P		09/27/24
d	HIG GROWTH II	P		06/18/24
e	HIG GROWTH II	P		10/30/24
f	HIG GROWTH II	P		07/18/24
g	HIG GROWTH III	P		06/24/24
h	HIG MID MARKET II	P		10/10/24
i	HIG MID MARKET III	P		02/28/25
j	HIG MID MARKET III	P		01/23/25
k	HIG MID MARKET III	P		11/07/24
l	HIG MID MARKET III	P		01/23/25
m	HIG MID MARKET III	P		11/27/24
n	HIGHCLERE INTL SC	P		04/30/24
o	HIGHCLERE INTL SC	P		05/31/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	1,271.			1,271.
b	2,238,351.			2,238,351.
c	108,903.			108,903.
d	6,589,895.			6,589,895.
e	428,825.			428,825.
f	2,981,167.			2,981,167.
g	15,245.			15,245.
h	4,540,155.			4,540,155.
i	2,730,340.			2,730,340.
j			80,215.	-80,215.
k	983,432.			983,432.
l	643,259.			643,259.
m	495,998.			495,998.
n	98,500.			98,500.
o	101,636.			101,636.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				1,271.
b				2,238,351.
c				108,903.
d				6,589,895.
e				428,825.
f				2,981,167.
g				15,245.
h				4,540,155.
i				2,730,340.
j				-80,215.
k				983,432.
l				643,259.
m				495,998.
n				98,500.
o				101,636.

2 Capital gain net income or (net capital loss) ..... { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 } 2

3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6):
If gain, also enter in Part I, line 8, column (c).
If (loss), enter "-0-" in Part I, line 8 3

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	HIGHCLERE INTL SC	P		06/30/24
b	HIGHCLERE INTL SC	P		07/31/24
c	HIGHCLERE INTL SC	P		08/31/24
d	HIGHCLERE INTL SC	P		09/30/24
e	HIGHCLERE INTL SC	P		10/31/24
f	HIGHCLERE INTL SC	P		11/30/24
g	HIGHCLERE INTL SC	P		12/31/24
h	HIGHCLERE INTL SC	P		01/31/25
i	HIGHCLERE INTL SC	P		02/28/25
j	HIGHCLERE INTL SC	P		03/31/25
k	HIGHCLERE INTL SMID	P		07/08/24
l	HIGHCLERE INTL SMID	P		07/31/24
m	HIGHCLERE INTL SMID	P		08/31/24
n	HIGHCLERE INTL SMID	P		09/30/24
o	HIGHCLERE INTL SMID	P		10/31/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	99,653.			99,653.
b	104,842.			104,842.
c	105,581.			105,581.
d	108,549.			108,549.
e	101,394.			101,394.
f	100,737.			100,737.
g	98,786.			98,786.
h	100,783.			100,783.
i	100,535.			100,535.
j	101,235.			101,235.
k	10,000,000.			10,000,000.
l	41,808.			41,808.
m	42,158.			42,158.
n	43,332.			43,332.
o	28,085.			28,085.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				99,653.
b				104,842.
c				105,581.
d				108,549.
e				101,394.
f				100,737.
g				98,786.
h				100,783.
i				100,535.
j				101,235.
k				10,000,000.
l				41,808.
m				42,158.
n				43,332.
o				28,085.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	HIGHCLERE INTL SMID	P		10/07/24
b	HIGHCLERE INTL SMID	P		11/07/24
c	HIGHCLERE INTL SMID	P		11/30/24
d	HIGHCLERE INTL SMID	P		12/06/24
e	HIGHCLERE INTL SMID	P		12/06/24
f	HIGHCLERE INTL SMID	P		06/30/24
g	HIGHCLERE INTL SMID	P		05/31/24
h	HIGHCLERE INTL SMID	P		04/30/24
i	HONGSHAN GROWTH III	P		01/28/25
j	HONGSHAN GROWTH III	P		01/16/25
k	HONGSHAN GROWTH IV	P		04/05/24
l	HONGSHAN GROWTH IV	P		02/11/25
m	HONGSHAN GROWTH IV	P		09/27/24
n	HONGSHAN GROWTH IV	P		10/03/24
o	HONGSHAN GROWTH V	P		06/06/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	20,000,000.			20,000,000.
b	20,000,000.			20,000,000.
c	13,000.			13,000.
d	16,366,469.			16,366,469.
e	40,967.			40,967.
f	45,862.			45,862.
g	47,403.			47,403.
h	46,398.			46,398.
i	2,324,829.			2,324,829.
j	158,779.			158,779.
k	356,150.			356,150.
l	267,294.			267,294.
m	469,601.			469,601.
n	1,462,758.			1,462,758.
o	886,290.			886,290.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a				20,000,000.
b				20,000,000.
c				13,000.
d				16,366,469.
e				40,967.
f				45,862.
g				47,403.
h				46,398.
i				2,324,829.
j				158,779.
k				356,150.
l				267,294.
m				469,601.
n				1,462,758.
o				886,290.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	HONGSHAN GROWTH V	P		02/20/25
b	HONGSHAN GROWTH V	P		10/03/24
c	HONGSHAN VTR IV	P		01/07/25
d	HONGSHAN VTR V	P		06/27/24
e	HONGSHAN VTR V	P		12/06/24
f	HONGSHAN VTR VI	P		02/04/25
g	HONGSHAN VTR VII	P		01/23/25
h	IDG CHINA CAP III	P		06/26/24
i	IDG CHINA CAP III	P		12/23/24
j	IDG CHINA VTR IV	P		12/27/24
k	IDG CHINA VTR IV	P		06/26/24
l	IDG CHINA VTR IV	P		03/26/25
m	IDG-ACCEL CHINA CAP	P		03/28/25
n	IDG-ACCEL CHINA CAP	P		12/27/24
o	IDG-ACCEL CHINA GWTH	P		12/27/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	387,389.			387,389.
b	120,258.			120,258.
c	1,724,725.			1,724,725.
d	1,572,764.			1,572,764.
e	976,372.			976,372.
f	272,166.			272,166.
g	226,056.			226,056.
h	356,085.			356,085.
i	692,441.			692,441.
j	1,431,875.			1,431,875.
k	1,540,318.			1,540,318.
l	629,533.			629,533.
m	153,499.			153,499.
n	347,979.			347,979.
o	342,633.			342,633.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				387,389.
b				120,258.
c				1,724,725.
d				1,572,764.
e				976,372.
f				272,166.
g				226,056.
h				356,085.
i				692,441.
j				1,431,875.
k				1,540,318.
l				629,533.
m				153,499.
n				347,979.
o				342,633.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	IRON POINT IV	P		11/26/24
b	IRON POINT IV	P		01/31/25
c	IRON POINT IV	P		05/31/24
d	JPM PEG SECONDRY III	P		06/11/24
e	JPM PEG SECONDRY III	P		02/20/25
f	LA CAPITAL GLOBAL	P		08/31/24
g	LA CAPITAL GLOBAL	P		07/31/24
h	LA CAPITAL GLOBAL	P		06/30/24
i	LA CAPITAL GLOBAL	P		05/31/24
j	LA CAPITAL GLOBAL	P		09/30/24
k	LA CAPITAL GLOBAL	P		09/03/24
l	LA CAPITAL GLOBAL	P		09/04/24
m	LA CAPITAL GLOBAL	P		09/10/24
n	LA CAPITAL GLOBAL	P		04/30/24
o	LACM WORLD SMALL CAP	P		02/28/25

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	98,074.			98,074.
b	116,088.			116,088.
c	589,300.			589,300.
d	832,831.			832,831.
e	260,094.			260,094.
f	16,782.			16,782.
g	16,269.			16,269.
h	16,198.			16,198.
i	15,942.			15,942.
j	42,967.			42,967.
k	85,991,115.			85,991,115.
l	11,000,000.			11,000,000.
m	3,420,000.			3,420,000.
n	15,402.			15,402.
o	20,503.		33,936.	-13,433.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				98,074.
b				116,088.
c				589,300.
d				832,831.
e				260,094.
f				16,782.
g				16,269.
h				16,198.
i				15,942.
j				42,967.
k				85,991,115.
l				11,000,000.
m				3,420,000.
n				15,402.
o				-13,433.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	LACM WORLD SMALL CAP	P		03/31/25
b	LACM WORLD SMALL CAP	P		04/30/24
c	LACM WORLD SMALL CAP	P		05/31/24
d	LACM WORLD SMALL CAP	P		06/28/24
e	LACM WORLD SMALL CAP	P		07/31/24
f	LACM WORLD SMALL CAP	P		08/31/24
g	LACM WORLD SMALL CAP	P		09/30/24
h	LACM WORLD SMALL CAP	P		10/31/24
i	LACM WORLD SMALL CAP	P		11/30/24
j	LACM WORLD SMALL CAP	P		01/31/25
k	MARATHON GLOBAL	P		03/31/25
l	MARATHON GLOBAL	P		01/31/25
m	MARATHON GLOBAL	P		02/28/25
n	MARATHON GLOBAL	P		12/31/24
o	MARATHON GLOBAL	P		11/30/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	19,904.		47,400.	-27,496.
b	15,602.			15,602.
c	16,197.			16,197.
d	15,997.			15,997.
e	17,165.			17,165.
f	17,262.			17,262.
g	17,624.			17,624.
h	17,198.			17,198.
i	18,342.			18,342.
j	21,118.		34,954.	-13,836.
k	113,216.		120,019.	-6,803.
l	121,799.		117,793.	4,006.
m	117,910.		118,743.	-833.
n	106,095.		98,764.	7,331.
o	106,715.		98,641.	8,074.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				-27,496.
b				15,602.
c				16,197.
d				15,997.
e				17,165.
f				17,262.
g				17,624.
h				17,198.
i				18,342.
j				-13,836.
k				-6,803.
l				4,006.
m				-833.
n				7,331.
o				8,074.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	MARATHON GLOBAL	P		10/31/24
b	MARATHON GLOBAL	P		09/30/24
c	MARATHON GLOBAL	P		08/31/24
d	MARATHON GLOBAL	P		05/31/24
e	MARATHON GLOBAL	P		07/31/24
f	MARATHON GLOBAL	P		04/30/24
g	MARATHON GLOBAL	P		06/28/24
h	MHR AXIOM	P		04/10/24
i	MHR AXIOM	P		01/23/24
j	MHR AXIOM	P		02/25/25
k	MHR AXIOM	P		05/15/24
l	MHR AXIOM	P		09/30/24
m	MHR AXIOM	P		03/26/25
n	MHR INST PARTNERS IV	P		09/26/24
o	NEWMARKET IIFC	P		04/05/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	104,541.		99,327.	5,214.
b	107,477.		98,535.	8,942.
c	105,618.		99,118.	6,500.
d	99,672.		101,153.	-1,481.
e	103,314.		99,863.	3,451.
f	98,157.		101,736.	-3,579.
g	101,595.		100,460.	1,135.
h	8,756,041.		7,122,665.	1,633,376.
i	6,549,708.		5,404,893.	1,144,815.
j	4,200,693.		3,346,112.	854,581.
k	7,449,691.		6,060,005.	1,389,686.
l	13,146,060.		10,728,930.	2,417,130.
m	10,799,601.		8,610,687.	2,188,914.
n	70,584.			70,584.
o	2,534,924.			2,534,924.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				5,214.
b				8,942.
c				6,500.
d				-1,481.
e				3,451.
f				-3,579.
g				1,135.
h				1,633,376.
i				1,144,815.
j				854,581.
k				1,389,686.
l				2,417,130.
m				2,188,914.
n				70,584.
o				2,534,924.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	ORBIMED ASIA III	P		04/08/24
b	ORBIMED ASIA III	P		12/12/24
c	ORBIMED ASIA IV	P		06/27/24
d	ORBIMED ASIA IV	P		04/09/24
e	ORBIMED ISRAEL II	P		07/18/24
f	ORBIMED PI IX	P		12/17/24
g	ORBIMED PI VI	P		11/13/24
h	ORBIMED PI VI	P		03/20/25
i	ORBIMED PI VI	P		05/23/24
j	ORBIMED PI VI	P		07/30/24
k	ORBIMED PI VI	P		08/22/24
l	ORBIMED PI VI	P		04/24/24
m	ORBIMED ROYALTY II	P		12/06/24
n	ORBIMED ROYALTY II	P		06/06/24
o	PEAK XV V	P		11/04/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	981,047.			981,047.
b	1,568,863.			1,568,863.
c	6,453,395.			6,453,395.
d			134,561.	-134,561.
e	1,675,630.			1,675,630.
f	3,560,122.			3,560,122.
g	414,196.			414,196.
h	198,429.			198,429.
i	1,541,464.			1,541,464.
j			163,168.	-163,168.
k	398,545.			398,545.
l	23,202.			23,202.
m			1,141,698.	-1,141,698.
n	293.			293.
o	192,662.			192,662.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				981,047.
b				1,568,863.
c				6,453,395.
d				-134,561.
e				1,675,630.
f				3,560,122.
g				414,196.
h				198,429.
i				1,541,464.
j				-163,168.
k				398,545.
l				23,202.
m				-1,141,698.
n				293.
o				192,662.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	PEAK XV V	P		10/16/24
b	PEAK XV V	P		06/26/24
c	PEAK XV V	P		02/14/25
d	PEAK XV V	P		12/30/24
e	PEAK XV V	P		12/12/24
f	PEAK XV V	P		09/20/24
g	PEAK XV VI	P		05/07/24
h	PEAK XV VI	P		09/24/24
i	PEAK XV VI	P		12/11/24
j	PITANGO VTR VI	P		10/08/24
k	RIDGEWOOD III	P		06/21/24
l	RIDGEWOOD III	P		12/26/24
m	RIDGEWOOD III	P		09/25/24
n	RIDGEWOOD IV	P		12/26/24
o	RIDGEWOOD IV	P		06/21/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	354,728.			354,728.
b	192,266.			192,266.
c	120,937.			120,937.
d	200,242.			200,242.
e	481,436.			481,436.
f	375,158.			375,158.
g	45,646.			45,646.
h	292,130.			292,130.
i	42,054.			42,054.
j	2,748,514.			2,748,514.
k	3,738,082.			3,738,082.
l	2,224,439.			2,224,439.
m	3,696,054.			3,696,054.
n	700,091.			700,091.
o	1,383,990.			1,383,990.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				354,728.
b				192,266.
c				120,937.
d				200,242.
e				481,436.
f				375,158.
g				45,646.
h				292,130.
i				42,054.
j				2,748,514.
k				3,738,082.
l				2,224,439.
m				3,696,054.
n				700,091.
o				1,383,990.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	RIDGEWOOD IV	P		09/25/24
b	S CAPITAL	P		01/23/25
c	S CAPITAL	P		01/23/25
d	SCF LIQUID PORTFOLIO	P		10/25/24
e	SCF LIQUID PORTFOLIO	P		10/25/24
f	SCF LIQUID PORTFOLIO	P		10/25/24
g	SCF LIQUID PORTFOLIO	P		10/31/24
h	SCF LIQUID PORTFOLIO	P		10/31/24
i	SCF LIQUID PORTFOLIO	P		02/28/25
j	SCF LIQUID PORTFOLIO	P		11/30/24
k	SCF LIQUID PORTFOLIO	P		11/30/24
l	SCF LIQUID PORTFOLIO	P		11/30/24
m	SCF LIQUID PORTFOLIO	P		12/04/24
n	SCF LIQUID PORTFOLIO	P		12/31/24
o	SCF LIQUID PORTFOLIO	P		12/31/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	1,471,699.			1,471,699.
b	4,737.			4,737.
c	7,385,395.			7,385,395.
d	349,840.		289,035.	60,805.
e	427,320.		353,048.	74,272.
f	35,600.		29,412.	6,188.
g	43,950.		36,311.	7,639.
h	63,079.		52,115.	10,964.
i	286,232.		220,713.	65,519.
j	43,950.		36,163.	7,787.
k	249,200.		205,050.	44,150.
l	142,440.		117,204.	25,236.
m	569,760.		468,817.	100,943.
n	63,607.		52,189.	11,418.
o	35,600.		29,210.	6,390.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a				1,471,699.
b				4,737.
c				7,385,395.
d				60,805.
e				74,272.
f				6,188.
g				7,639.
h				10,964.
i				65,519.
j				7,787.
k				44,150.
l				25,236.
m				100,943.
n				11,418.
o				6,390.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SCF LIQUID PORTFOLIO	P		01/16/25
b	SCF LIQUID PORTFOLIO	P		01/16/25
c	SCF LIQUID PORTFOLIO	P		01/27/25
d	SCF LIQUID PORTFOLIO	P		01/31/25
e	SCF LIQUID PORTFOLIO	P		01/31/25
f	SCF LIQUID PORTFOLIO	P		02/28/25
g	SCF LIQUID PORTFOLIO	P		03/31/25
h	SCF LIQUID PORTFOLIO	P		03/31/25
i	SCF LIQUID PORTFOLIO	P		03/31/25
j	SCF LIQUID PORTFOLIO	P		04/30/24
k	SCF LIQUID PORTFOLIO	P		04/30/24
l	SCF LIQUID PORTFOLIO	P		04/19/24
m	SCF LIQUID PORTFOLIO	P		04/30/24
n	SCF LIQUID PORTFOLIO	P		04/30/24
o	SCF LIQUID PORTFOLIO	P		05/31/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	43,950.		35,880.	8,070.
b	71,200.		58,126.	13,074.
c	922,304.		752,943.	169,361.
d	284,880.		232,568.	52,312.
e	84,105.		68,661.	15,444.
f	712,200.		549,176.	163,024.
g	462,931.		343,809.	119,122.
h	35,600.		26,439.	9,161.
i	63,079.		46,847.	16,232.
j	43,950.		40,512.	3,438.
k	63,079.		58,145.	4,934.
l	249,270.		229,771.	19,499.
m	106,800.		98,446.	8,354.
n	63,607.		58,631.	4,976.
o	142,400.		112,834.	29,566.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				8,070.
b				13,074.
c				169,361.
d				52,312.
e				15,444.
f				163,024.
g				119,122.
h				9,161.
i				16,232.
j				3,438.
k				4,934.
l				19,499.
m				8,354.
n				4,976.
o				29,566.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SCF LIQUID PORTFOLIO	P		05/31/24
b	SCF LIQUID PORTFOLIO	P		05/31/24
c	SCF LIQUID PORTFOLIO	P		06/20/24
d	SCF LIQUID PORTFOLIO	P		06/30/24
e	SCF LIQUID PORTFOLIO	P		06/30/24
f	SCF LIQUID PORTFOLIO	P		07/12/24
g	SCF LIQUID PORTFOLIO	P		07/12/24
h	SCF LIQUID PORTFOLIO	P		07/31/24
i	SCF LIQUID PORTFOLIO	P		07/31/24
j	SCF LIQUID PORTFOLIO	P		07/31/24
k	SCF LIQUID PORTFOLIO	P		07/31/24
l	SCF LIQUID PORTFOLIO	P		08/06/24
m	SCF LIQUID PORTFOLIO	P		08/12/24
n	SCF LIQUID PORTFOLIO	P		08/31/24
o	SCF LIQUID PORTFOLIO	P		08/31/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	397,545.		315,003.	82,542.
b	142,440.		112,866.	29,574.
c	178,049.		141,082.	36,967.
d	159,018.		126,002.	33,016.
e	71,200.		56,417.	14,783.
f	43,950.		34,825.	9,125.
g	178,049.		141,082.	36,967.
h	231,400.		183,356.	48,044.
i	63,079.		49,982.	13,097.
j	43,950.		34,825.	9,125.
k	106,829.		84,649.	22,180.
l	95,411.		75,601.	19,810.
m	127,214.		100,801.	26,413.
n	556,563.		441,007.	115,556.
o	149,561.		118,508.	31,053.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				82,542.
b				29,574.
c				36,967.
d				33,016.
e				14,783.
f				9,125.
g				36,967.
h				48,044.
i				13,097.
j				9,125.
k				22,180.
l				19,810.
m				26,413.
n				115,556.
o				31,053.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SCF LIQUID PORTFOLIO	P		09/30/24
b	SCF LIQUID PORTFOLIO	P		09/30/24
c	SEQUOIA GBL GRTH III	P		11/22/24
d	SEQUOIA GBL GRTH III	P		10/22/24
e	SEQUOIA GBL GRTH III	P		02/12/25
f	SEQUOIA GBL GRTH III	P		07/01/24
g	SEQUOIA GBL GRTH III	P		07/01/24
h	SEQUOIA GBL GRTH III	P		05/14/24
i	SEQUOIA GBL GRTH III	P		12/16/24
j	SEQUOIA GBL GRTH III	P		12/06/24
k	SEQUOIA GBL GRTH III	P		12/04/24
l	SEQUOIA GBL GRTH III	P		11/25/24
m	SEQUOIA GBL GRTH III	P		10/03/24
n	SEQUOIA GBL GRTH III	P		11/11/24
o	SEQUOIA GBL GRTH III	P		11/18/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	249,271.		217,871.	31,400.
b	35,600.		31,116.	4,484.
c	225,234.			225,234.
d	145,975.			145,975.
e	241,753.			241,753.
f	106,342.			106,342.
g	16,718.			16,718.
h	47,923.			47,923.
i	816,743.			816,743.
j	582,029.			582,029.
k	548,708.			548,708.
l	505,809.			505,809.
m	353,024.			353,024.
n	675,056.			675,056.
o	299,295.			299,295.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				31,400.
b				4,484.
c				225,234.
d				145,975.
e				241,753.
f				106,342.
g				16,718.
h				47,923.
i				816,743.
j				582,029.
k				548,708.
l				505,809.
m				353,024.
n				675,056.
o				299,295.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SEQUOIA GLB GROWTH	P		02/18/25
b	SEQUOIA GLB GROWTH	P		07/31/24
c	SEQUOIA GLB GROWTH	P		05/14/24
d	SEQUOIA GLB GRWTH II	P		10/09/24
e	SEQUOIA GLB GRWTH II	P		04/02/24
f	SEQUOIA GLB GRWTH II	P		07/31/24
g	SEQUOIA GLB GRWTH II	P		02/11/25
h	SEQUOIA GLB GRWTH II	P		10/03/24
i	SEQUOIA GLB GRWTH II	P		11/19/24
j	SEQUOIA SCOUT III	P		11/29/24
k	SEQUOIA US GROWTH V	P		11/11/24
l	SEQUOIA US GROWTH V	P		11/18/24
m	SEQUOIA US GROWTH V	P		11/25/24
n	SEQUOIA US GROWTH V	P		12/04/24
o	SEQUOIA US GROWTH V	P		12/06/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	313,584.			313,584.
b	319,901.			319,901.
c	922,194.			922,194.
d	298,310.			298,310.
e	154,892.			154,892.
f	121,872.			121,872.
g	581,737.			581,737.
h	1,027,919.			1,027,919.
i	881,711.			881,711.
j	58,909.			58,909.
k	126,528.			126,528.
l	55,501.			55,501.
m	92,839.			92,839.
n	100,044.			100,044.
o	105,609.			105,609.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				313,584.
b				319,901.
c				922,194.
d				298,310.
e				154,892.
f				121,872.
g				581,737.
h				1,027,919.
i				881,711.
j				58,909.
k				126,528.
l				55,501.
m				92,839.
n				100,044.
o				105,609.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SEQUOIA US GROWTH V	P		12/16/24
b	SEQUOIA US GRWTH VII	P		10/31/24
c	SEQUOIA US GRWTH VII	P		11/19/24
d	SEQUOIA US GWTH VI	P		08/30/24
e	SEQUOIA US GWTH VI	P		09/05/24
f	SEQUOIA US GWTH VI	P		08/26/24
g	SEQUOIA US GWTH VI	P		08/09/24
h	SEQUOIA US GWTH VI	P		05/14/24
i	SEQUOIA US VTR XIV	P		08/30/24
j	SEQUOIA US VTR XIV	P		08/26/24
k	SEQUOIA US VTR XIV	P		09/05/24
l	SEQUOIA US VTR XV	P		12/31/24
m	SEQUOIA US VTR XV	P		07/15/24
n	SILCHESTER INTL	P		04/30/24
o	SILCHESTER INTL	P		06/28/24

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	147,690.			147,690.
b	102,785.			102,785.
c	261,085.			261,085.
d	264,174.			264,174.
e	88,705.			88,705.
f	325,459.			325,459.
g	590,261.			590,261.
h	144,996.			144,996.
i	1,785,910.			1,785,910.
j	1,808,952.			1,808,952.
k	849,984.			849,984.
l	34,863.			34,863.
m	59,055.			59,055.
n	76,619.		59,146.	17,473.
o	76,804.		59,052.	17,752.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				147,690.
b				102,785.
c				261,085.
d				264,174.
e				88,705.
f				325,459.
g				590,261.
h				144,996.
i				1,785,910.
j				1,808,952.
k				849,984.
l				34,863.
m				59,055.
n				17,473.
o				17,752.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

423591
04-01-24

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	SILCHESTER INTL	P		07/05/24
b	SILCHESTER INTL	P		05/31/24
c	SILCHESTER INTL	P		07/31/24
d	SILCHESTER INTL	P		08/31/24
e	SILCHESTER INTL	P		02/28/25
f	SILCHESTER INTL	P		01/31/25
g	SILCHESTER INTL	P		03/31/25
h	SILCHESTER INTL	P		10/31/24
i	SILCHESTER INTL	P		11/30/24
j	SILCHESTER INTL	P		12/31/24
k	SILCHESTER INTL	P		09/30/24
l	SPDR TRUST SERIES I	P		05/30/24
m	SQUOIA GG 3 US IN AX	P		12/20/24
n	SQUOIA GG 3 US IN AX	P		12/31/24
o	SQUOIA GG 3 US IN AX	P		02/19/25

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	10,000,000.		7,613,469.	2,386,531.
b	79,271.		58,654.	20,617.
c	75,772.		55,236.	20,536.
d	77,190.		52,756.	24,434.
e	74,929.		52,965.	21,964.
f	74,532.		53,061.	21,471.
g	75,928.		52,770.	23,158.
h	75,014.		53,060.	21,954.
i	73,288.		53,336.	19,952.
j	72,652.		53,425.	19,227.
k	78,402.		52,540.	25,862.
l	9,950,569.		8,832,019.	1,118,550.
m	69,881.			69,881.
n	368,722.			368,722.
o	1,040,506.			1,040,506.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a				2,386,531.
b				20,617.
c				20,536.
d				24,434.
e				21,964.
f				21,471.
g				23,158.
h				21,954.
i				19,952.
j				19,227.
k				25,862.
l				1,118,550.
m				69,881.
n				368,722.
o				1,040,506.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	STARWOOD XI	P		09/30/24
b	STARWOOD XI	P		09/30/24
c	ACADIAN FRONTIER	P		
d	ACADIAN FRONTIER	P		
e	ACADIAN FRONTIER	P		
f	ACADIAN FRONTIER	P		
g	ACADIAN FRONTIER	P		
h	ACADIAN FRONTIER	P		
i	ACADIAN FRONTIER	P		
j	ACADIAN FRONTIER	P		
k	ACADIAN FRONTIER	P		
l	ACADIAN FRONTIER	P		
m	ACADIAN FRONTIER	P		
n	ACADIAN FRONTIER	P		
o	ACADIAN FRONTIER	P		

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a	221,679.			221,679.
b	686,978.			686,978.
c	136.			136.
d	2,120.			2,120.
e	134.			134.
f	4.			4.
g			123,269.	-123,269.
h			2,680.	-2,680.
i			448.	-448.
j			25.	-25.
k			77.	-77.
l			7.	-7.
m			51.	-51.
n			8,114.	-8,114.
o			3.	-3.

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				221,679.
b				686,978.
c				136.
d				2,120.
e				134.
f				4.
g				-123,269.
h				-2,680.
i				-448.
j				-25.
k				-77.
l				-7.
m				-51.
n				-8,114.
o				-3.

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

	(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	ACADIAN FRONTIER	P		
b	HIG GROWTH III	P		
c	SCF LIQUID PORTFOLIO	P		
d	SCF LIQUID PORTFOLIO	P		
e	HIGHCLERE SMID	P		
f	ACADIAN FRONTIER	P		
g	TAURUS RESOURCES	P		
h	BITCOIN	P		
i	K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE	P		
j				
k				
l				
m				
n				
o				

	(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a			44,294.	-44,294.
b	210,548.			210,548.
c	2,040,335.			2,040,335.
d			1,783,318.	-1,783,318.
e			192,969.	-192,969.
f	245,581.		343,630.	-98,049.
g	40,318,331.		24,689,818.	15,628,513.
h	7,282,986.		4,532,554.	2,750,432.
i				-225,928,033.
j				
k				
l				
m				
n				
o				

	Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
	(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a				-44,294.
b				210,548.
c				2,040,335.
d				-1,783,318.
e				-192,969.
f				-98,049.
g				15,628,513.
h				2,750,432.
i				-225,928,033.
j				
k				
l				
m				
n				
o				

2	Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 / If (loss), enter "-0-" in Part I, line 7 }	2	270,254,392.
3	Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	N/A

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D	173,613.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	259,951.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE	469,915.
ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC 1825 EYE STREET NW, 401 WASHINGTON, DC 20006	N/A	SOI	COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION	500,000.
ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC 1825 EYE STREET NW, 401 WASHINGTON, DC 20006	N/A	SOI	COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION	539,349.
ALTRU HEALTH SYSTEM PO BOX 6002 GRAND FORKS, ND 58206	N/A	PC	ALTRU HEALTH SYSTEM ULTRASOUND INITIATIVE	4,214,824.
ALVIN AILEY DANCE FOUNDATION, INC. 405 W 55TH ST NEW YORK, NY 10019	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
Total from continuation sheets				438,771,332.

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN CAMPING ASSOCIATION, INC. 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2024-2027	55,330.
AMERICAN COLLEGE OF DIABETOLOGY INC PO BOX 87633 FAYETTEVILLE, NC 28304	N/A	PC	IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS	1,200,436.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2025-2027 TYPE 1 DIABETES CAMP INITIATIVE	480,260.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	350,108.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	455,274.
AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE 4930 DEL RAY AVE BETHESDA, MD 20814	N/A	PC	AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION	64,189.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	POST-ACUTE STROKE CARE IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA	379,458.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	871,217.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH	6,966,024.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA	908,680.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE SOUTH DAKOTA	957,913.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE HAWAII	1,606,124.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE IOWA	2,521,277.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	PROJECT IMPACT CGM EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES	1,335,393.
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	PROJECT IMPACT CGM EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES	167,500.
AMERICAN SAMOA DEPT OF HEALTH FOR AMERICAN SAMOA COMMUNITY HEALTH CTR ONE FAGAALU ROAD PAGO PAGO, AS 96799	N/A	GOV	IMAGING EQUIPMENT AT AMERICAN SAMOA COMMUNITY HEALTH CENTERS	1,335,622.
AMERICAN TELEMEDICINE ASSOCIATION 601 13TH ST NW WASHINGTON, DC 20005	N/A	PC	GENERAL OPERATING SUPPORT	25,500.
AMERICAN TELEMEDICINE ASSOCIATION 601 13TH ST NW WASHINGTON, DC 20005	N/A	PC	LEVEL 5 MEMBERSHIP	25,500.
AMERICANS FOR BEN-GURION UNIVERSITY 1001 AVENUE OF THE AMERICAS, 19TH FLOOR NEW YORK CITY, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	20,000.
AMICI DI ADWA ENTE DEL TERZO SETTORE VIA GIACOMO MATTEOTTI, 8 CENTO, ITALY	N/A	PC	A HOSPITAL FOR ADWA, ETHIOPIA IN THE TIGRAY REGION	1,398,329.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMSTERDAM UMC RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE OMICROHN	1,532,103.
AMSTERDAM UMC RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	225,500.
AMSTERDAM UMC RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE	306,900.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	2,325,006.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	500,000.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	1,000,000.
ASHLEY MEDICAL CENTER 612 CENTER AVE N ASHLEY, ND 58413-0450	N/A	PC	ASHLEY MEDICAL CENTER (ND) ULTRASOUND INITIATIVE	76,961.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION & MAINTENANCE	1,030,062.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM	432,057.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF THE DANATECH PLATFORM	423,489.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	587,221.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. 55 VICTORIA PARADE FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.	315,421.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. 55 VICTORIA PARADE FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.	209,377.
BALLAD RESEARCH INSTITUTE 3525 JOHN HOPKINS COURT SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN	315,380.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAPTIST MEDICAL CENTRE BAPTIST MEDICAL CENTRE ROAD NALERIGU, GHANA	N/A	PC	ELEVATING MATERNAL AND PEDIATRIC HEALTHCARE	4,505,896.
BAPTIST MEDICAL CENTRE BAPTIST MEDICAL CENTRE ROAD NALERIGU, GHANA	N/A	PC	CT SCANNER FOR BAPTIST MEDICAL CENTRE	848,730.
BAR ILAN UNIVERSITY IN ISRAEL MAX VE-ANNA WEBB ST. RAMAT GAN, ISRAEL	N/A	PC	THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY	3,348,125.
BARBARA'S HOUSE 100 MELROSE AVENUE GREENWICH, CT 06830	N/A	PC	GENERAL OPERATING SUPPORT	45,000.
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	265,400.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS	379,135.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CD.	765,436.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	5,785,714.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	555,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	600,000.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	600,000.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT	2,000,000.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT	5,000,000.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	EXPANDING ECMO SERVICES AT BILLINGS CLINIC	449,629.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC TRANSFER CENTER	2,215,173.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW, #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES	658,783.
BLUE CIRCLE HEALTH, INC. 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	DEVELOPMENT OF BLUE CIRCLE HEALTH	3,975,887.
BLUE CIRCLE HEALTH, INC. 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,843.
BLUE CIRCLE HEALTH, INC. 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	DEVELOPMENT OF BLUE CIRCLE HEALTH	4,470,844.
BNAI ZION MEDICAL CENTER 47 GOLOMB ST. HAIFA, ISRAEL	N/A	GOV	DEVELOPMENT OF THE HELMSLEY CARDIOVASCULAR CARE UNIT	2,764,483.
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM	137,345.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION 2601 ENTERPRISE ROAD RENO, NV 89512	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN NEVADA	197,208.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D	758,218.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE	667,666.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR	1,306,247.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABDOCS NATIONAL K12 SUPPLEMENT	201,490.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABETESWISE FOR EXERCISE	835,639.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL CENTER PLACE BOSTON, MA 02118	N/A	PC	SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D	128,527.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOSTON SYMPHONY ORCHESTRA, INC. 301 MASSACHUSETTS AVENUE BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT	12,500.
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	567,155.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A 3-B-HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR	200,000.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,332.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	93,442.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA	2,306,101.
CANDID 32 OLD SLIP, 24TH FLOOR NEW YORK, NY 10005	N/A	PC	GENERAL OPERATING SUPPORT	28,749.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CARDIFF UNIVERSITY 30-36 NEWPORT RD WALES, UNITED KINGDOM	N/A	PC	T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	211,718.
CARE-FOR-RARE FOUNDATION LINDWURMSTRASSE 4 MUNICH, GERMANY	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES MUNICH STUDIES	667,252.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,337,724.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	EXPANDING COMMUNITY RECOVERY AND RESILIENCE	1,808,630.
CAVALIER COUNTY MEMORIAL HOSPITAL ASSOCIATION 909 2ND SREET LANGDON, ND 58249	N/A	PC	NORTH DAKOTA ULTRASOUND INITIATIVE	408,100.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	211,815.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY	219,514.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION	519,768.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION	733,694.
CENTER FOR HEALTH CARE STRATEGIES, INC. 300 AMERICAN METRO BOULEVARD, SUITE 125 HAMILTON, NJ 08619	N/A	PC	IDENTIFYING OPPORTUNITIES TO SUPPORT T1D AUTOANTIBODY SCREENING IN MEDICAID PROGRAMS AND HEALTH CARE SYSTEMS THAT SERVE MEDICAID BENEFICIARIES	149,672.
CENTER FOR HEALTH CARE STRATEGIES, INC. 300 AMERICAN METRO BOULEVARD, SUITE 125 HAMILTON, NJ 08619	N/A	PC	CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	1,002,514.
CENTER FOR HEALTH CARE STRATEGIES, INC. 300 AMERICAN METRO BOULEVARD, SUITE 125 HAMILTON, NJ 08619	N/A	PC	EXPANDING ACCESS TO AID DEVICES IN MEDICAID	141,530.
CENTER FOR URBAN COMMUNITY SERVICES, INC. 198 EAST 121ST STREET NEW YORK, NY 10035	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATTRE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE THE NEMO PROJECT	94,386.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.	612,471.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD	244,860.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	359,722.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	458,920.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	CHI HEALTH ND ULTRASOUND INITIATIVE	903,993.
CHILDREN'S HOSPITAL CORPORATION PO BOX 414413 BOSTON, MA 02241-4413	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES BOSTON STUDIES	1,470,081.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION PO BOX 414413 BOSTON, MA 02241-4413	N/A	PC	ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,296,628.
CHILDREN'S HOSPITAL CORPORATION PO BOX 414413 BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)	732,284.
CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BOULEVARD LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1 EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	153,056.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)	583,113.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE	1,093,319.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	963,282.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES	439,601.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	725,157.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D	107,168.
CHRISTIAN UNITY HOSPITAL CORPORATION 164 WEST 13TH STREET GRAFTON, ND 58237	N/A	PC	NORTH DAKOTA ULTRASOUND INITIATIVE	646,571.
CITY FUTURES, INC. 80 8TH AVE NEW YORK, NY 10011	N/A	PC	NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE	150,000.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	CATALYST SUSTAINABILITY THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN PARKS	161,100.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	STRENGTHENING NYCS URBAN FOREST PLAN PUBLIC PARK LANDS	466,100.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN FUND	750,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES	463,512.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	700,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	2,658,835.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER	2,541,165.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	1,472,591.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT	145,605.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CT LINEAR ACCELERATOR FOR RABIN CANCER CENTER	2,050,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)	1,652,598.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION	2,811,261.
COMMUNITY HEALTH SERVICE INC. 2310 4TH AVE N MOORHEAD, MN 56560	N/A	PC	COMMUNITY HEALTH SERVICE INC ULTRASOUND INITIATIVE	132,287.
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	500,000.
CORNELL UNIVERSITY FOR THE JOAN & SANFORD I. WEILL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	863,618.
CORPORATION FOR SUPPORTIVE HOUSING 55 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	500,000.
COUNCIL FOR ECONOMIC EDUCATION 122 EAST 42ND STREET NEW YORK CITY, NY 10168	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT FOR ONE YEAR MEMBERSHIP	34,000.
COUNCIL ON THE ENVIRONMENT, INC. 100 GOLD ST., SUITE 3300 NEW YORK, NY 10038	N/A	PC	GENERAL OPERATING SUPPORT	15,000.
COZAD HOSPITAL DISTRICT NO. 2 300 EAST 12TH STREET COZAD, NE 69130	N/A	GOV	TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM	35,283.
CRITICAL PATH INSTITUTE 1840 EAST RIVER ROAD TUCSON, AZ 85718	N/A	PC	TRANSLATIONAL THERAPEUTICS ACCELERATOR DEVELOPING KINASE INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE TO TREAT T1D	500,000.
CRITICAL PATH INSTITUTE 1840 EAST RIVER ROAD TUCSON, AZ 85718	N/A	PC	T1D CONSORTIUM 2.0	266,741.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SPONSORSHIP FOR THE 2025 CROHNS & COLITIS CONGRESS PRESENTED BY THE CROHNS & COLITIS FOUNDATION AND THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION	235,000.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE	1,632,470.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE	342,493.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	INTERNATIONAL CONSORTIUM ON MEDICAL NUTRITION IN IBD	310,748.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS	744,245.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	IBD VENTURES ACADEMIC INCUBATOR	1,180,400.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA	374,912.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE	297,612.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	IMPLEMENTATION OF A LOWER GI DIAGNOSTIC PATHWAY IN PRIMARY HEALTHCARE AND DEVELOPMENT AND DISSEMINATION OF A LOWER GI PATIENT TOOLKIT	467,726.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S COLITIS CURE 100 HARRIS STREET PYRMONT NSW, AUSTRALIA	N/A	PC	ENHANCING INFLAMMATORY BOWEL DISEASE CARE CONSUMER-CENTRIC PORTAL FOR BETTER COMMUNICATION & REDUCED NAVIGATION STRESS	871,250.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	706,219.
DEUTSCHE WELTHUNGERHILFE E.V. FRIEDRICH-EBERT-STRABE 1 BONN BAD GODESBERG, GERMANY	N/A	PC	HOLISTICALLY ADDRESSING AGROBUSINESS	1,898,076.
DIABETES AUSTRALIA 19-23 MOORE STREET, GROUND FLOOR TURNER, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES THROUGH GEOGRAPHIC EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES	1,855,504.
DUKE UNIVERSITY 2200 WEST MAIN STREET, SUITE 1000 DURHAM, NC 27705	N/A	PC	NOVEL ASSAYS FOR PROGLUCAGON PEPTIDES TO UNDERSTAND ALPHA CELL FUNCTION IN HEALTH AND DIABETES	275,861.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	11,725.
EMERGING PRACTITIONERS IN PHILANTHROPY INC 201 N UNION ST, STE 110 ALEXANDRIA, VA 22314	N/A	PC	GENERAL OPERATING SUPPORT FOR 2024 MEMBERSHIP	11,250.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	302,430.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	EVALUATING RURAL HEALTH CARE FACILITIES	89,417.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	MINGA MISSION HOSPITAL DEVELOPMENT	1,433,145.
ESSENTIA HEALTH 502 E 2ND ST DULUTH, MN 55805	N/A	SOIII FI	ESSENTIA HEALTH ULTRASOUND INITIATIVE	2,065,413.
FAIRVIEW HEALTH SERVICES 2450 RIVERSIDE AVE MINNEAPOLIS, MN 55454	N/A	PC	IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE	3,176,500.
FAMILY HEALTHCARE CENTER 301 NP AVE N FARGO, ND 58102	N/A	PC	FAMILY HEALTHCARE CENTER ULTRASOUND INITIATIVE	172,160.
FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ RAMISTRASSE 101 ZURICH, SWITZERLAND	N/A	PC	SPATIAL BIOLOGY OF CROHNS COLITIS	421,278.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS	1,000,000.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST) 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND CHEMIN DU POMMIER 40 LE GRAND-SACONNEX, SWITZERLAND	N/A	PC	ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT	1,118,735.
FOUNTAIN HOUSE, INC. 425 WEST 47TH STREET NEW YORK, NY 10036	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
FRIENDS OF RYE TOWN PARK INC PO BOX 345 RYE, NY 10580	N/A	PC	GENERAL OPERATING SUPPORT	7,000.
FUNDACIO DE RECERCA CLINIC BARCELONA INSTITUT D'INVESTIGACIONS BIOMED ROSSELLO 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE-PATHOPHYSIOLOGY AND IMAGING	576,960.
GALILEE MEDICAL CENTER BEN ZVI BLVD. POB 21 NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	2,200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GALILEE MEDICAL CENTER BEN ZVI BLVD. POB 21 NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF ONE FLOOR OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	750,000.
GATES PHILANTHROPY PARTNERS PO BOX 60555 CITY OF INDUSTRY, CA 91716	N/A	PC	POLIO ERADICATION FUND SUPPORT	1,000,000.
GAY AND LESBIAN COMMUNITY CENTER OF SOUTHERN NEVADA, INC. 401 S. MARYLAND PARKWAY LAS VEGAS, NV 89101	N/A	PC	CAPITAL SUPPORT FOR THE CENTER	2,267,929.
GENETIC ALLIANCE, INC. 25904 WOODFIELD ROAD DAMASCUS, MD 20872	N/A	PC	IHOPE GENETIC HEALTH	250,000.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	187,672.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	402,672.
GEORGETOWN UNIVERSITY 37TH & O STREET NW WASHINGTON, DC 20057	N/A	PC	ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION	432,998.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET NW ATLANTA, GA 30332-0420	N/A	SOIII FI	LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE	485,616.
GEOSCIENCE AUSTRALIA 101 JERRABOMBERRA AVE SYMONSTON, AUSTRALIA	N/A	GOV	DIGITAL EARTH AFRICA - SUSTAINABLE UPTAKE AND IMPACT	1,195,336.
GOOD SAMARITAN HOSPITAL ASSOCIATION 800 S MAIN AVE RUGBY, ND 58368	N/A	PC	HEART OF AMERICA MEDICAL CENTER ULTRASOUND INITIATIVE	468,841.
GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS 1310 L. STREET NW WASHINGTON, DC 20005	N/A	PC	GENERAL OPERATING SUPPORT	18,920.
GRANTMAKERS IN HEALTH 1100 CONNECTICUT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GENERAL OPERATING SUPPORT FOR 2024	24,640.
HADASSAH MEDICAL ORGANIZATION P.O.B. 12000 JERUSALEM, ISRAEL	N/A	PC	RECRUITMENT OF TOP MEDICAL TALENT FOR THE NEW HADASSAH-HELMSLEY MEDICAL CENTER, NETIVOT	950,450.
HADASSAH MEDICAL ORGANIZATION P.O.B. 12000 JERUSALEM, ISRAEL	N/A	PC	EQUIPPING THE NEW HADASSAH - HELMSLEY MEDICAL CENTER, NETIVOT	5,265,160.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HAWAI'I HEALTH SYSTEMS CORP KAUA'I REGION FOR VETERANS MEMORIAL HOSP 4643 WAIMEA CANYON DRIVE WAIMEA, HI 96796	N/A	GOV	MEDICAL SIMULATION AT KAUA'I VETERANS MEMORIAL HOSPITAL	381,278.
HAZEN MEMORIAL HOSPITAL ASSOCIATION 510 8TH AVE NE HAZEN, ND 58545	N/A	PC	SAKAKAWEA MEDICAL CENTER (ND) ULTRASOUND INITIATIVE	88,179.
HEALING HANDS OF JOY 4747 HEDGEMORE DR CHARLOTTE, NC 28209	N/A	PC	ELIMINATION OF OBSTETRIC FISTULA	500,000.
HEALTH RESEARCH ALLIANCE, INC. PO BOX 146 RALEIGH, NC 27612	N/A	PC	GENERAL OPERATING SUPPORT	22,150.
HEBREW UNIVERSITY OF JERUSALEM BOYAR BUILDING, 5TH FLOOR JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE	221,500.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	1,184,939.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	1,310,183.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	1,927,629.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,282,899.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	794,714.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN	162,877.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,913,981.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL	800,000.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL	1,833,580.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	3,157.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	46,760.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	988,211.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	920,486.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	EUROPEAN PRE-T1D REGISTRY	158,504.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	229,162.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET, NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KFF HEALTH NEWS RURAL HEALTH DESK	1,521,095.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HERLEV OG GENTOFTE HOSPITAL HERLEV RINGVEJ 75, OPG.115 HERLEV, DENMARK	N/A	GOV	INTERACTION BETWEEN AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS	135,722.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS	1,384,586.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	2,112,639.
HILLEL THE FOUNDATION FOR JEWISH CAMPUS LIFE 180 S. GARNER STREET STATE COLLEGE, PA 16804	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	EYE INSTITUTE AND AMBULATORY SURGERY CENTER	3,158,400.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	CONSTRUCTION OF PET-CT INSTITUTE	3,536,258.
HOLON INSTITUTE OF TECHNOLOGY - HIT 52 GOLOMB ST HOLON, ISRAEL	N/A	PC	MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)	681,350.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HUMAN CELL ATLAS, INCORPORATED 415 MAIN ST CAMBRIDGE, MA 02142	N/A	PC	2024 HUMAN CELL ATLAS GENERAL MEETING	50,000.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	39,438.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD	574,537.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.	779,716.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]	523,716.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE FROM GENETIC TO SENESCENT SIGNALS	920,802.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	EARLY LIFE EXPOSOME BIOMARKERS AND CROHN'S DISEASE RISK THE EARLY-CD PROJECT	618,257.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE	993,497.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE PREDICT AND PREVENT	2,303,337.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEVELOPMENT OF NOVEL LRRK2 INHIBITORS TO TREAT CROHNS DISEASE	583,881.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL	44,685.
IMPACT-SE INST FOR MONITORING PEACE & CULTURAL TOLERANCE IN SCHOOL ED 2 JABOTINSKY ST. RAMAT GAN, ISRAEL	N/A	PC	TRANSFORMING EDUCATION FOR PEACE A NATIONWIDE AWARENESS CAMPAIGN ON INCITEMENT IN PALESTINIAN/UNRWA TEXTBOOKS.	150,000.
IMPROVECARENOW, INC. 4 CARMICHAEL ST., UNIT 111 ESSEX JUNCTION, VT 05452	N/A	PC	IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK	931,101.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INNODIA HERESTRAAT 49 LEUVEN, BELGIUM	N/A	PC	INNODIA NONPROFIT LAUNCH	7,905.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	79,723.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	95,213.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION	362,460.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT	749,790.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY	60,700.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC 75 STATE STREET BOSTON, MA 02109	N/A	PC	SEED FUNDING SUPPORT	893,663.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)	645,000.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.	1,168,344.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY	169,420.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)	488,553.
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA	2,449,440.
INT'L BANK FOR RECONSTRUCTION & DEV AND INT'L DEVELOPMENT ASSOC. 1818 H STREET NW WASHINGTON, DC 20433	N/A	PC	HEALTH SYSTEM TRANSFORMATION AND RESILIENCE MULTI-DONOR TRUST FUND - NONCOMMUNICABLE DISEASE PARTNERSHIP GENERAL OPERATING SUPPORT	2,500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ISRAEL ANTIQUITIES AUTHORITY 27 SULTAN SULEIMAN STREET JERUSALEM, ISRAEL	N/A	GOV	REVIVAL EXHIBITION AT BEN GURION AIRPORT	350,000.
ISRAEL CENTER ON ADDICTION R.A. 2 HATZORAN ST NETANYA, ISRAEL	N/A	PC	ICA'S EMERGENCY MENTAL HEALTH SUPPORT	55,000.
JACOBSON MEMORIAL HOSPITAL CARE CENTER 601 EAST ST. N. ELGIN, ND 58533	N/A	PC	JACOBSON MEMORIAL HOSPITAL ULTRASOUND INITIATIVE	77,620.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	TECHNOSPHERE INSULIN VERSUS RAPID ACTING ANALOGUE INSULIN ON EXERCISE-INDUCED HYPOGLYCEMIA IN ADULTS WITH T1D USING AUTOMATED INSULIN DELIVERY	1,025,846.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	194,126.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	180,800.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	47,712.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)	1,337,806.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA	929,309.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA	816,628.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.	100,000.
JERUSALEM FOUNDATION, INC. 420 LEXINGTON AVENUE NEW YORK, NY 10170	N/A	PC	BUILDING A NEW HOME FOR TSAD KADIMA	500,000.
JEWISH BOARD OF FAMILY & CHILDREN'S SERVICES, INC. 463 7TH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING	742,901.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE	750,000.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	569,990.
K9S FOR WARRIORS 114 CAMP K9 ROAD PONTE VEDRA, FL 32081	N/A	PC	GENERAL OPERATING SUPPORT/WARRIOR SERVICE DOG PAIRING PROGRAM	7,500.
KAISER FOUNDATION HEALTH PLAN OF GEORGIA, INC. 1375 PEACHTREE STREET NE ATLANTA, GA 30309	N/A	PC	EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL	41,911.
KAPIOLANI HEALTH FOUNDATION 55 MERCHANT ST HONOLULU, HI 96813	N/A	PC	MARTHA B. SMITH CANCER & INFUSION CENTER AT KAPIOLANI MEDICAL CENTER FOR WOMEN & CHILDREN	5,000,000.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	TARGETING CHRONIC INFLAMMATION AND TISSUE REMODELLING IN CROHN'S DISEASE WITH ENGINEERED T CELLS	426,571.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	221,407.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	FAT AS A VILLAIN IN CROHN'S DISEASE.	1,456,556.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	IDS 2024 BRUGES	50,000.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	1,644,973.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.	384,292.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS	8,567.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	221,552.
KYLER CARES FOUNDATION 8070 CROWDER BOULEVARD, SUITE B NEW ORLEANS, LA 70126	N/A	PC	CAPACITY BUILDING SUPPORT	339,900.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KYLER CARES FOUNDATION 8070 CROWDER BOULEVARD, SUITE B NEW ORLEANS, LA 70126	N/A	PC	CAPACITY BUILDING SUPPORT	339,900.
LANDER COUNTY HOSPITAL DISTRICT 535 SOUTH HUMBOLDT STREET BATTLE MOUNTAIN, NV 89820-1988	N/A	GOV	BATTLE MOUNTAIN GENERAL HOSPITAL HOSPITAL EQUIPMENT REVITALIZATION	1,035,000.
LINTON HOSPITAL 111 ELM AVE WEST LINTON, ND 58552	N/A	PC	LINTON HOSPITAL (ND) ULTRASOUND INITIATIVE	76,961.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, TX 77477	N/A	PC	SCALING INTEGRATED WASH SERVICES	2,574,349.
LUTHERAN CHARITY ASSOCIATION 2422 20TH STREET SW JAMESTOWN, ND 58401	N/A	PC	JAMESTOWN REGIONAL MEDICAL CENTER ULTRASOUND INITIATIVE	693,723.
MARY C. WHEELER SCHOOL, INC. 216 HOPE STREET PROVIDENCE, RI 02906	N/A	PC	GENERAL OPERATING SUPPORT	12,500.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP	6,753,638.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL	2,905,515.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	U.S. PREVENTIVE TYPE 1 DIABETES COALITION	543,037.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE	1,352,242.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	MICROBES, MOLECULES, AND CHEMISTRY DYSBIOSIS IN CROHNS DISEASE	1,722,621.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS	348,553.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	151,705.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	157,469.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MILITARY SCIENCES MEDICAL TRAINING 2024-2026	160,940.
MCKENZIE COUNTY HEALTHCARE SYSTEMS, INC 709 4TH AVE NE WATFORD CITY, ND 58854	N/A	PC	MCKENZIE HEALTH ULTRASOUND INITIATIVE	46,052.
MCKENZIE COUNTY HEALTHCARE SYSTEMS, INC 709 4TH AVE NE WATFORD CITY, ND 58854	N/A	PC	MCKENZIE HEALTH ULTRASOUND INITIATIVE	757,493.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SC 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	28,108.
MEDICINES FOR HUMANITY, INC. 800 HINGHAM STREET ROCKLAND, MA 02370	N/A	PC	MAI MBELEKI II EXPANSION	322,909.
MERCY HOSPITAL OF DEVILS LAKE 1031 7TH STREET NE DEVILS LAKE, ND 58301	N/A	PC	CHI ST. ALEXIUS HEALTH DEVILS LAKE ULTRASOUND INITIATIVE	743,309.
MERCY MEDICAL CENTER 1301 15TH AVENUE WEST WILLISTON, ND 58801	N/A	PC	CHI ST. ALEXIUS HEALTH WILLISTON ULTRASOUND INITIATIVE	619,183.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MICHIGAN STATE UNIVERSITY 426 AUDITORIUM ROAD, ROOM 2 EAST LANSING, MI 48824-2601	N/A	PC	A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH TYPE 1 DIABETES	1,215,611.
MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC. PO BOX 27837 WASHINGTON, DC 20038	N/A	PC	THE INTERCONNECTED IRAN -RUSSIA-CHINA AXIS	300,000.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	17,020.
MINERAL COUNTY HOSPITAL DISTRICT 200 SOUTH A STREET HAWTHORNE, NV 89415	N/A	GOV	USDA COMMUNITY FACILITY DIRECT LOAN PROGRAM APPLICATION	364,679.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	318,700.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	217,428.
MOUNTRAIL COUNTY MEDICAL CENTER INC 615 6TH ST SE STANLEY, ND 58784	N/A	PC	NORTH DAKOTA ULTRASOUND INITIATIVE	238,556.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NATIONAL ASSOCIATION OF SCHOOL NURSES INC 1100 WAYNE AVE. SILVER SPRING, MD 20910	N/A	PC	PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT	763,279.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	753,478.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT	621,487.
NATIONAL MULTIPLE SCLEROSIS SOCIETY 733 THIRD AVENUE NEW YORK CITY, NY 10017	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)	363,328.
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	STRENGTHENING NYC'S URBAN FOREST PLAN NATURAL AREAS	193,132.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	GENERAL OPERATING SUPPORT - NCD ALLIANCE SUPPORTERS GROUP	42,500.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NELSON COUNTY HEALTH SYSTEM 200 NORTH MAIN STREET MCVILLE, ND 58254	N/A	PC	NELSON COUNTY HEALTH SYSTEM ULTRASOUND INITIATIVE	153,546.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,239,092.
NEVADA HEALTH CENTERS, INC. 3325 RESEARCH WAY CARSON CITY, NV 89706	N/A	PC	QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM	14,249.
NEVADA RURAL HOSPITAL PARTNERS FOUNDATION, INC. 4600 KIETZKE LANE RENO, NV 89502	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS	27,500.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS	183,350.
NEW VENTURE FUND 1828 L STREET, NW, SUITE 300-A WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2025-2028)	1,889,319.
NEW VENTURE FUND 1828 L STREET, NW, SUITE 300-A WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2025-2028)	374,930.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK CITY BALLET, INC. 20 LINCOLN CENTER PLAZA NEW YORK, NY 10023	N/A	PC	GENERAL OPERATING SUPPORT	15,000.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 50 WATER STREET NEW YORK, NY 10004	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC	614,668.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 50 WATER STREET NEW YORK, NY 10004	N/A	PC	PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS	777,607.
NEW YORK JUNIOR TENNIS LEAGUE, INC. 36-36 33RD STREET ASTORIA, NY 11106	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
NEW YORK RESTORATION PROJECT 254 WEST 31ST STREET NEW YORK, NY 10001	N/A	PC	NYC URBAN REFORESTATION & EXPANSION	193,536.
NEW YORK UNIVERSITY 665 BROADWAY, SUITE 801 NEW YORK, NY 10012	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	2,756,847.
NORTH DAKOTA STATE UNIVERSITY 1301 12TH AVENUE N FARGO, ND 58102	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA	99,500.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NORTHERN WESTCHESTER HOSPITAL ASSOCIATION 400 EAST MAIN STREET MOUNT KISCO, NY 10549	N/A	PC	EMERGENCY DEPARTMENT RAPID ACCESS EXPANSION	400,000.
NORTHWOOD DEACONESS HEALTH CENTER 4 N PARK ST NORTHWOOD, ND 58267	N/A	PC	NORTHWOOD DEACONESS HEALTH CENTER (ND) ULTRASOUND INITIATIVE	95,182.
NURU INTERNATIONAL 2020 PENNSYLVANIA AVE NW WASHINGTON, CA 20006	N/A	PC	EXPANSION OF AGRIBUSINESS	500,000.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,129,765.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	DISSEMINATION PILOT THE IMPLEMENTATION OF NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH) IN ANOTHER HEALTHCARE SYSTEM	41,318.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,795,816.
P R HEALTH CORPORATION 115 VIVIAN ST PARK RIVER, ND 58270	N/A	PC	FIRST CARE HEALTH CENTER ULTRASOUND INITIATIVE	93,347.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE	318,978.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	T1D COMMUNITY FUND STAGE II	1,469,142.
PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT, INC. 905 KALANIANAOLE HWY KAILUA, HI 96734	N/A	PC	PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING	256,540.
PATH 437 N. 34TH STREET SEATTLE, WA 98103	N/A	PC	THE DIABETES CAREPAK PROJECT ENABLING HIGH-QUALITY DIABETES SELF-CARE	871,123.
PEMBINA COUNTY MEMORIAL HOSPITAL ASSOCIATION 301 MOUNTAIN STREET EAST CAVALIER, ND 58220	N/A	PC	NORTH DAKOTA ULTRASOUND INITIATIVE	312,733.
PENNINGTON COUNTY HEALTH AND HUMAN SERVICES 321 KANSAS CITY STREET RAPID CITY, SD 57701	N/A	GOV	PENNINGTON COUNTY CRISIS STABILIZATION UNIT	1,000,000.
PETALS 4 PAWS LLC PO BOX 112360 STAMFORD, CT 06911	N/A	PC	GENERAL OPERATING SUPPORT	7,500.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PHILANTHROPY NEW YORK, INC. 320 EAST 43RD STREET NEW YORK, NY 10017	N/A	PC	GENERAL OPERATING SUPPORT FOR 2025 MEMBERSHIP	63,750.
PHILANTHROPY NEW YORK, INC. 320 EAST 43RD STREET NEW YORK, NY 10017	N/A	PC	GENERAL OPERATING SUPPORT	39,250.
PHILLIPS COUNTY HOSPITAL ASSOCIATION 311 S. 8TH AVENUE EAST MALTA, MT 59538	N/A	PC	TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY	25,448.
PIONEER MEDICAL CENTER 301 WEST 7TH AVE BIG TIMBER, MT 59011	N/A	PC	TELE-PHARMACY AT PIONEER MEDICAL CENTER	9,988.
PRESENTATION MEDICAL CENTER 213 2ND AVE NE ROLLA, ND 58367	N/A	PC	ST. KATERI ULTRASOUND INITIATIVE	68,957.
PROJECT CONCERN ZAMBIA LIMITED PLOT 37/1P LUSAKA, ZAMBIA	N/A	PC	EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS	1,004,026.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION	393,053.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	ANGIOGRAPHY SYSTEM FOR THE INTERVENTIONAL RADIOLOGY UNIT OF RAMBAM MEDICAL CENTER	1,365,000.
REACH LITERACY 2101 W 41ST ST SIOUX FALLS, SD 57105	N/A	PC	GENERAL OPERATING SUPPORT FOR SIOUX FALLS VOLUNTEER DAY	15,000.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	346,974.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	952,406.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES	1,441,299.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE	92,033.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	226,169.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	CONTINUING DEVELOPMENT OF OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES	273,689.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)	502,750.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	1,296,918.
REGENTS OF UNIVERSITY OF CALIFORNIA, BERKELEY 190 DOE BERKELEY, CA 94720	N/A	PC	DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE	1,054,179.
REGION HOVEDSTADEN KONGENS VAENGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	375,228.
RENOWN HEALTH FOUNDATION 1155 MILL ST RENO, NV 89502	N/A	PC	RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA	1,091,987.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD DURHAM, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS A STATEWIDE IMPLEMENTATION STUDY	1,110,288.
RIVER'S EDGE HOSPITAL AND CLINIC 1900 N. SUNRISE DRIVE ST. PETER, MN 56082	N/A	GOV	TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL	17,567.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING SUSTAINABLE SAFE WATER ACCESS	2,064,000.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES	75,165.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103	N/A	PC	IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES	608,523.
SANFORD RESEARCH 1305 W 18TH ST SIOUX FALLS, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	528,559.
SANFORD WORLD CLINICS 1305 W 18TH ST SIOUX FALLS, SD 57105	N/A	PC	PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)	59,605.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SAPIR ACADEMIC COLLEGE POST HOF ASHKELON 7915600 GEVIM, ISRAEL	N/A	PC	PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING	303,000.
SAVE A LAB RESCUE 165 ELLERY AVE MIDDLETOWN, RI 02842	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S S-200 SEATTLE, WA 98145-5005	N/A	PC	EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)	609,141.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT	989,083.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER	2,500,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	2,500,000.
SHARE TRUST INC. 310 DEDHAM ST DOVER, MA 02030	N/A	PC	BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION	1,540,658.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	200,000.
SIMULATION IN MOTION MONTANA, INC. 2021 11TH AVE, SUITE 1 HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SIMULATION IN MOTION MONTANA, INC. 2021 11TH AVE, SUITE 1 HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	SCALING THE HEALTHY FUTURE FOR ALL MODEL	1,246,508.
SOCIAL SCIENCE RESEARCH COUNCIL ONE PIERREPONT PLAZA, 15TH FLOOR BROOKLYN, NY 11201	N/A	PC	DATA2GO.NYC REVAMP AND DATA CLINIC	336,025.
SOCIETY FOR MUCOSAL IMMUNOLOGY INC N83 W13410 LEON ROAD MENOMONEE FALLS, WI 53051	N/A	PC	21ST INTERNATIONAL CONGRESS OF MUCOSAL IMMUNOLOGY (ICMI 2024)	15,000.
SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES 151 ESSEX STREET HAVERHILL, MA 01832	N/A	PC	GENERAL OPERATING SUPPORT	50,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SOLIDARIDAD NETWORK FOUNDATION LIMITED 163 KUDU ROAD LUSAKA, ZAMBIA	N/A	PC	HOOVES FOR SUSTAINABILITY (H4S)	468,562.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER	10,791.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	818,171.
SOUTHWEST HEALTHCARE CORPORATION 802 SECOND STREET NW BOWMAN, ND 58623	N/A	PC	NORTH DAKOTA ULTRASOUND INITIATIVE	225,517.
ST ALOISIUS HOSPITAL INC 325 BREWSTER STREET EAST HARVEY, ND 58341	N/A	PC	SMP HEALTH - ST. ALOISIUS ULTRASOUND PROJECT	256,572.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	3,293,350.
ST LUKE'S HOSPITAL 702 1ST ST. SW CROSBY, ND 58730	N/A	PC	ST. LUKE'S MEDICAL CENTER ULTRASOUND INITIATIVE	74,770.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ST. ALEXIUS MEDICAL CENTER 900 EAST BROADWAY AVE BISMARCK, ND 58501	N/A	PC	CHI ST. ALEXIUS HEALTH ULTRASOUND INITIATIVE	3,799,563.
ST. ANDREW'S HOSPITAL 316 OHMER STREET BOTTINEAU, ND 58318	N/A	PC	ST. ANDREW'S HOSPITAL ULTRASOUND INITIATIVE	74,293.
ST. JOSEPHS HOSPITAL AND HEALTH CENTER 2500 FAIRWAY ST. DICKINSON, ND 58601	N/A	PC	CHI ST. ALEXIUS HEALTH DICKINSON ULTRASOUND INITIATIVE	632,439.
ST. MARK'S HOSPITAL FOUNDATION ACTON LANE LONDON, UNITED KINGDOM	N/A	PC	SUPPORT FOR THE ONGOING DEVELOPMENT OF THE TOPCLASS PERIANAL CD CONSORTIUM	254,998.
ST. MARK'S HOSPITAL FOUNDATION ACTON LANE LONDON, UNITED KINGDOM	N/A	PC	GLOBAL PERIANAL CROHN'S DISEASE PRIORITY SETTING PARTNERSHIP	24,288.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM	124,981.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	298,224.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS 901 S. STEWART ST., SUITE 5005 CARSON CITY, NV 89701	N/A	PC	VALLEY OF FIRE VISITOR CENTER	3,500,000.
STATE UNIVERSITY OF IOWA FOUNDATION ONE WEST PARK ROAD IOWA CITY, IA 52242	N/A	PC	SIMULATION IN MOTION-IOWA ENDOWMENT	100,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227, SUITE A AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO DIABETES CARE	1,000,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60 AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	1,200,977.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	SAFECARE A BUSINESS MODEL FOR HEALTHCARE QUALITY	686,565.
STICHTING THE OCEAN CLEANUP BATAVIERENSTRAAT 15 ROTTERDAM, NETHERLANDS	N/A	PC	DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS	5,000,000.
STIFTELSEN FOR UTBILDNING (IOIBD) LINKPING UNIVERSITY HOSPITAL, FLOOR 14 OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SUPPORTIVE HOUSING NETWORK OF NEW YORK INC 247 W 37TH ST NEW YORK CITY, NY 10018	N/A	PC	TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS	450,000.
SUSTAINABLE COASTLINES HAWAII 3160 WAIALAE AVE HONOLULU, HI 96816	N/A	PC	SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT	299,213.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	1,917,417.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	650,000.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	2,567,417.
T1D EXCHANGE, INC 101 FEDERAL STREET, SUITE 440 BOSTON, MA 02110	N/A	PC	EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY	633,709.
TAMPERE UNIVERSITY FOUNDATION SR KALEVANTIE 4, 33100 TAMPERE, FINLAND	N/A	PC	ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK	227,066.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TECHNISCHE UNIVERSITAET MUENCHEN ARCISSTRABE 21 MUNCHEN, GERMANY	N/A	GOV	COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES	151,947.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMANN ST 6 TEL AVIV, ISRAEL	N/A	GOV	IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS	268,340.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMANN ST 6 TEL AVIV, ISRAEL	N/A	GOV	CONSTRUCTION OF THE SHELTERED -5 FLOOR OF THE NORTH TOWER	4,879,510.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.	2,600,000.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	1,517,781.
THE ASSOCIATION FOR THE BETTERMENT OF ESHKOL REGION RESIDENTS ESHKOL REGIONAL COUNCIL KIBBUTZ MAGEN, ISRAEL	N/A	PC	BE'ERI AGRICULTURAL EQUIPMENT	2,203,283.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV 2012100 HALUTZ RAMAT HANEGEV, ISRAEL	N/A	PC	RAMAT HANEGEV SENIOR CITIZEN CENTER	2,241,803.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV 2012100 HALUTZ RAMAT HANEGEV, ISRAEL	N/A	PC	RAMAT HANEGEV CENTRAL AUDITORIUM	843,988.
THE BINYAMIN FUND INC 445 CENTRAL AVENUE CEDARHURST, NY 11516	N/A	PC	EMERGENCY GENERATORS FOR COMMUNITIES IN THE BINYAMIN REGIONAL COUNCIL	350,000.
THE BIONICS INSTITUTE OF AUSTRALIA 384-388 ALBERT STREET EAST MELBOURNE, AUSTRALIA	N/A	PC	PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE	1,779,261.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	971,014.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	3,497,605.
THE CENTER FOR EFFECTIVE PHILANTHROPY, INC. 675 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	GENERAL OPERATING SUPPORT FOR 2024	54,780.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?	808,734.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	NEW INSIGHTS INTO CROHN'S DISEASE FROM STUDYING NAKED MOLE RATS	1,510,641.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	300,000.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY	368,500.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	GENETIC PROTECTION BY HLA-DQ6 IN T1D	235,681.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES	1,321,210.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	THE MILESTONE INITIATIVE EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA	236,313.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE	387,615.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	869,476.
THE COMMUNICATIONS NETWORK 1717 NORTH NAPER BLVD NAPERVILLE, IL 60563	N/A	PC	GENERAL OPERATING SUPPORT FOR 2025-27 MEMBERSHIP	30,000.
THE END FUND, INC. 2 PARK AVENUE NEW YORK, NY 10016	N/A	PC	TACKLING TRACHOMA SURGERY DISPARITIES	2,117,400.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	137,417.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD	127,077.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE	394,365.
THE HOLE IN THE WALL GANG FUND, INC. 555 LONG WHARF DRIVE NEW HAVEN, CT 06511	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES	555,480.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION	248,621.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	156,358.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,032,574.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	BAYIT PROJECT, COMMUNAL MULTI-FAMILY SHELTERS AT THE SHOSHANA ABSORPTION CENTER IN KIRYAT GAT	750,000.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	THE SECURITY FUND SECURING AND SAFEGUARDING JEWISH COMMUNITIES WORLDWIDE	1,500,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	NURSING SIMULATION CENTER UPGRADES	751,269.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	FASTERCURES LEADERSLINK PROGRAM EXPANSION	250,000.
THE NATURE CONSERVANCY 4245 NORTH FAIRFAX DRIVE, SUITE 100 ARLINGTON, VA 22203	N/A	PC	FUTURE FOREST NYC PHASE III	347,804.
THE QUEENS MEDICAL CENTER 1301 PUNCHBOWL ST HONOLULU, HI 96813	N/A	PC	THE QUEENS MEDICAL CENTER & CLARENCE T.C. CHING ECMO PROGRAM EXCELLENCE AND VIABILITY APPRAISAL	1,635,796.
THE QUEENS MEDICAL CENTER 1301 PUNCHBOWL ST HONOLULU, HI 96813	N/A	PC	THE QUEEN'S MEDICAL CENTER - WEST OAHU CANCER CENTER EXPANSION	5,000,000.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION INTEGRATION OF PHYSIOLOGY WITH GENETICS	115,896.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	1,108,867.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES 10889 WILSHIRE BLVD, SUITE 700 LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	439,378.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES 10889 WILSHIRE BLVD, SUITE 700 LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D	128,649.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,091,471.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)	269,368.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA BARBARA UC SANTA BARBARA SANTA BARBARA, CA 93106	N/A	PC	EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES	1,027,327.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EPITHELIAL MITOCHONDRIAL DYSFUNCTION AND EXTRACELLULAR VESICLES IN CROHNS DISEASE FIBROSTENOSIS.	457,178.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	269,500.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	315,557.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES	291,029.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	686,820.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	SEEDS PATHWAY SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY	598,309.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES	150,914.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL	300,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	124,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES	501,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	200,584.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN IMPLEMENTATION AND EVALUATION	332,512.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	935,698.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	513,331.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS 2024	500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV. 845 SHERBROOKE STREET WEST MONTREAL, CANADA	N/A	PC	DATA GOVERNANCE RESOURCE	190,336.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH 2 KATZIR RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	756,699.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH 2 KATZIR RAMAT GAN, ISRAEL	N/A	PC	THE UTILITY OF HAND-HELD ULTRASOUND DEVICES TO DETECT BOWEL WALL INFLAMMATORY ACTIVITY IN CROHN'S DISEASE	118,210.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	482,110.
THE STATE UNIVERSITY COLLEGE AT ONEONTA FOUNDATION CORPORATION, INC. 108 RAVINE PARKWAY ONEONTA, NY 13820	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS	266,667.
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ YOUTH SUICIDE PREVENTION PROJECT	2,081,072.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THE HEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOME NEW YORKERS	146,689.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	413,263.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	429,646.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	200,000.
THE UNIVERSITY OF ADELAIDE NORTH TERRACE ADELAIDE, AUSTRALIA	N/A	PC	PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN	55,260.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND	333,042.
THE UNIVERSITY OF EDINBURGH SOUTH BRIDGE EDINBURGH, UNITED KINGDOM	N/A	PC	BUILDING A CROSS-DISCIPLINE SCIENTIFIC APPROACH TOWARDS UNDERSTANDING CROHNS DISEASE - LEVERAGING UK HELMSLEY STUDIES	47,977.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF EDINBURGH SOUTH BRIDGE EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)	682,311.
THE UNIVERSITY OF EDINBURGH SOUTH BRIDGE EDINBURGH, UNITED KINGDOM	N/A	PC	HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE	209,222.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	PC	GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY	69,271.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	35,866.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE	3,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	300,000.
TIOGA MEDICAL CENTER P.O. BOX 159 TIOGA, ND 58852	N/A	PC	TIOGA MEDICAL CENTER ULTRASOUND INITIATIVE	326,201.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TOWNER COUNTY MEDICAL CENTER, INC. 7448 US 281 CANDO, ND 58324	N/A	PC	TOWNER COUNTY MEDICAL CENTER ULTRASOUND INITIATIVE	241,563.
TRICKLE UP PROGRAM, INC. 31 WEST 34TH STREET NEW YORK, NY 10001	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
TRINITY HEALTH 407 3RD STREET MINOT, ND 58701	N/A	PC	TRINITY HEALTH ULTRASOUND INITIATIVE	3,020,087.
TRUSTEES AND FRIENDS OF AGRICULTURAL RESEARCH AT THE VOLCANI CENTER HA MACABIM 68, P.O. BOX 15159 RISHON LEZION, ISRAEL	N/A	PC	PROTECTING FARMERS AND AGRICULTURAL WORKERS ACROSS NORTHERN ISRAEL	962,990.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, ID 47401-3654	N/A	GOV	TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES	58,372.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, ID 47401-3654	N/A	GOV	THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)	160,875.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA, PA 19104-6205	N/A	PC	ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS	407,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TZAFON MEDICAL CENTER DOV HOZ 0 TIBERIAS, ISRAEL	N/A	GOV	SECURING TZAFON MEDICAL CENTER'S ELECTRICAL CONNECTION TO ISRAEL'S POWER GRID	895,000.
TZAFON MEDICAL CENTER DOV HOZ 0 TIBERIAS, ISRAEL	N/A	GOV	SHELTERED HOSPITALIZATION AREA	340,000.
UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT.	18,000.
UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC 130 EAST 59TH STREET NEW YORK, NY 10022	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	869,232.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	LONGITUDINAL STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN AND ADOLESCENTS WITH NEW-ONSET TYPE 1 DIABETES	62,567.
UNIVERSITE DE GENEVE RUE MICHEL SERVET 1 GENEVE, SWITZERLAND	N/A	GOV	PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES	1,112,238.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	STUDYING THE SELECTIVE B CELL SENSITIVITY TO A HOMOZYGOUS PD-L1 MUTATION IN NEONATAL DIABETES	213,278.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING	213,602.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	419,662.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	118,038.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	866,199.
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA 1800 W CHARLESTON BLVD LAS VEGAS, NV 89102	N/A	GOV	DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	387,094.
UNIVERSITY OF BIRMINGHAM CHANCELLORS COURT BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES AN EXPERIMENTAL MEDICINE STUDY	152,801.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF BRISTOL TYNDALL AVENUE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	431,779.
UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE, SUITE 500 CINCINNATI, OH 45221	N/A	GOV	STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE	416,500.
UNIVERSITY OF DUNDEE NETHERGATE DUNDEE, UNITED KINGDOM	N/A	PC	HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA	133,804.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	ADVANCING B-CELL SPECIFIC THERAPY BY IDENTIFYING B-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS	55,571.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2 FROM OBSERVATION TO MECHANISM	206,160.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES	95,777.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	247,813.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC) A NATIONAL NEEDS ASSESSMENT	548,565.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES	36,272.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES	27,771.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	213,106.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	UNRAVELING THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.	367,104.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE THE BIOPIC STUDY	176,239.
UNIVERSITY OF IOWA 112 NORTH CAPITOL STREET IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	199,968.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF IOWA 112 NORTH CAPITOL STREET IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	714,411.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DIETA ANTI-INFLAMATORIA A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	473,409.
UNIVERSITY OF MELBOURNE 161 BARRY STREET CARLTON , AUSTRALIA	N/A	PC	USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D	371,201.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	247,023.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES	149,796.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS	1,038,654.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	837,846.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH DAKOTA 1301 N COLUMBIA RD, SUITE E105 GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	46,976.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, ID 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	705,510.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, ID 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	483,726.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, ID 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	188,155.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	274,391.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE	237,102.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 2304 WHITIS AVE AUSTIN, TX 78712-1111	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 2304 WHITIS AVE AUSTIN, TX 78712-1111	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	198,646.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN DENDRITIC CELLS	290,806.
UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION 580 MASSIE ROAD CHARLOTTESVILLE, VA 22903	N/A	PC	GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND	75,000.
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE, WA 98195-9472	N/A	GOV	PATHOGENIC ACTION OF AUTOANTIBODIES ON ISLET FUNCTION AND VIABILITY IN TYPE 1 DIABETES	385,000.
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE, WA 98195-9472	N/A	GOV	DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4	387,576.
UPPSALA UNIVERSITY HOSPITAL AKADEMISKA SJUKHUSET UPPSALA, SWEDEN	N/A	PC	IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION	1,139,284.
URBAN PATHWAYS, INC. 575 EIGHTH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY	364,886.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	275,000.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	330,000.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	121,999.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	163,405.
VANDERBILT UNIVERSITY 110 21ST AVENUE SOUTH NASHVILLE, TN 37203-2417	N/A	PC	NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING	275,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	1,913,552.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	1,260,384.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	1,865,381.
VILLAGES OF HOPE AFRICA SOCIETY 2450 MILLTOWER COURT MISSISSAUGA, CANADA	N/A	PC	INFRASTRUCTURE IMPROVEMENTS AND EXPANSION	151,152.
VIVLI, INC. 101 MIDDLESEX TURNPIKE, SUITE 6 BURLINGTON, MA 01803-4914	N/A	PC	DATA SHARING PLATFORM FOR T1-DEXI DATASETS	74,348.
WARREN MEMORIAL HOSPITAL 905 2ND ST. FRIEND, NE 68359	N/A	GOV	TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM	11,027.
WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE SAINT LOUIS, MO 63130	N/A	PC	RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING	330,000.
WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE SAINT LOUIS, MO 63130	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A T1D ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	1,271,885.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE SAINT LOUIS, MO 63130	N/A	PC	CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE	488,300.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING NUMA IN NORTHERN GHANA	1,478,953.
WEST RIVER HEALTH SERVICES FOUNDATION 1000 HIGHWAY 12 HETTINGER, ND 58639	N/A	SOIII FI	NORTH DAKOTA US REVITALIZATION PROJECT	68,591.
WILCOX HEALTH FOUNDATION 3-3420 KUHIO HIGHWAY LIHUE, HI 96766	N/A	PC	WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	3,944,163.
WILDLIFE CONSERVATION SOCIETY 2300 SOUTHERN BOULEVARD BRONX, NY 10460	N/A	PC	GENERAL OPERATING SUPPORT FOR ELEPHANTS	10,000.
WISHEK HOSPITAL CLINIC ASSOCIATION 1007 4TH AVE SOUTH WISHEK, ND 58495	N/A	PC	SOUTH CENTRAL HEALTH ULTRASOUND INITIATIVE	83,657.
WNET FOR THE WLIW-21 PUBLIC BROADCASTING 825 EIGHTH AVENUE NEW YORK, NY 10019-7435	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA , SWITZERLAND	N/A	PC	STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS	3,126,083.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA , SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	3,129,504.
WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE PO BOX 481 DOUGLAS, WY 82633	N/A	PC	WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM	798,469.
YALE UNIVERSITY P.O. BOX 208327 NEW HAVEN, CT 06520-8327	N/A	PC	TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE	599,035.
YALE UNIVERSITY P.O. BOX 208327 NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	413,016.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER	1,978,286.
YOUNG MEN'S CHRISTIAN ASSOCIATION OF RYE, NY 21 LOCUST AVE RYE, NY 10580	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND 120 BROADWAY NEW YORK, NY 10271	N/A	SOI	GENERAL OPERATING SUPPORT	10,000.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2024-2026	200,000.
ZAKA - SEARCH AND RESCUE 234 JAFFA STREET JERUSALEM, ISRAEL	N/A	PC	EMERGENCY AND DISASTER PREPAREDNESS IN ISRAEL	350,000.
ZIV MEDICAL CENTER, ZEFAT DERECH HARAMBAM 1 ZEFAT, ISRAEL	N/A	GOV	NEW NEUROSURGERY DEPARTMENT	2,100,000.
ZIV MEDICAL CENTER, ZEFAT DERECH HARAMBAM 1 ZEFAT, ISRAEL	N/A	GOV	NEW THORACIC SURGERY UNIT	1,325,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX, NY 10461-1975	N/A	PC	ENHANCING THE COMMUNITY HEALTH WORKER (CHW) MODEL TO PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D	171,150.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE	749,412.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE	55,930.
AMERICAN CAMPING ASSOCIATION, INC. 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2024-2027	60,221.
AMERICAN CAMPING ASSOCIATION, INC. 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2024-2027	65,258.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2025-2027 TYPE 1 DIABETES CAMP INITIATIVE	480,260.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2025-2027 TYPE 1 DIABETES CAMP INITIATIVE	480,260.
Total from continuation sheets				481,504,359.

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	TRAINING AND MENTORSHIP PROGRAMS	805,382.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	HEARTCORPS AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE	850,098.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA	1,563,575.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH	4,816,553.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA	1,546,123.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE SOUTH DAKOTA	1,592,190.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE SOUTH DAKOTA	1,836,354.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE HAWAII	2,220,899.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION LIFELINE STROKE HAWAII	1,988,020.
AMSTERDAM UMC RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE OMICROHN	1,476,985.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	1,542,882.
ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE, BOX 205 CHICAGO, IL 60611	N/A	PC	IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D	1,245,216.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	2,750,000.
ANTHOS HOME INC 238 SEELEY ST BROOKLYN, NY 11218	N/A	PC	LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS	750,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)	421,681.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION & MAINTENANCE	928,645.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION & MAINTENANCE	640,509.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	587,221.
ASSOCIATION SANTE DIABETE 5 RUE FEDERICO GARCIA LORCA GRENOBLE, FRANCE	N/A	PC	STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS	325,558.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. 55 VICTORIA PARADE FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.	315,421.
BALLAD RESEARCH INSTITUTE 3525 JOHN HOPKINS COURT SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN	243,390.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON, TX 77030	N/A	PC	PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE	282,140.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D	288,200.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS	350,194.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS	348,874.
BEN-GURION UNIVERSITY OF THE NEGEV BEN-GURION BLVD. 1 BEER SHEVA, ISRAEL	N/A	PC	CONSTRUCTION OF THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING	10,542,857.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE THE OPTIMIZE TRIAL	797,851.
BEYOND TYPE 1 400 CONCAR DRIVE, OFFICE 03-155 SAN MATEO, CA 94402	N/A	PC	CAPACITY BUILDING SUPPORT	645,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	EXPANDING ECMO SERVICES AT BILLINGS CLINIC	485,826.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC TRANSFER CENTER	880,233.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59101	N/A	PC	BILLINGS CLINIC TRANSFER CENTER	348,798.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW, #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES	584,923.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D	1,069,498.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE	775,549.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE	591,775.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR	1,333,066.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR	1,360,687.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	1,006,687.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABDOCS NATIONAL K12 SUPPLEMENT	395,280.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL PLACE BOSTON, MA 02118	N/A	PC	SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D	257,191.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL PLACE BOSTON, MA 02118	N/A	PC	SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D	257,191.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL PLACE BOSTON, MA 02118	N/A	PC	SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D	257,191.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION 505 EIGHTH AVENUE, 5TH FLOOR NEW YORK, NY 10018	N/A	PC	PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING	585,924.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE	133,334.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JOINING FORCES BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES	500,000.
BREAKTHROUGH T1D 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	157,366.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA	2,359,636.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	THE UK IBD BIORESOURCE TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE	657,605.
CARDIFF UNIVERSITY 30-36 NEWPORT RD WALES, UNITED KINGDOM	N/A	PC	T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	525,638.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CARDIFF UNIVERSITY 30-36 NEWPORT RD WALES, UNITED KINGDOM	N/A	PC	T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	525,638.
CARDIFF UNIVERSITY 30-36 NEWPORT RD WALES, UNITED KINGDOM	N/A	PC	T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D	262,543.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE	1,273,764.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	EXPANDING COMMUNITY RECOVERY AND RESILIENCE	1,073,759.
CENTER FOR HEALTH CARE STRATEGIES, INC. 300 AMERICAN METRO BOULEVARD, SUITE 125 HAMILTON, NJ 08619	N/A	PC	CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN	626,707.
CENTER FOR URBAN COMMUNITY SERVICES, INC. 198 EAST 121ST STREET NEW YORK, NY 10035	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
CENTER FOR URBAN COMMUNITY SERVICES, INC. 198 EAST 121ST STREET NEW YORK, NY 10035	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE	93,443.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	515,981.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA	202,677.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.	607,072.
CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.	625,660.
CHI HEALTH FOUNDATION 12809 WEST DODGE ROAD OMAHA, NE 68154	N/A	PC	ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY	229,460.
CHILDREN'S HOSPITAL CORPORATION PO BOX 414413 BOSTON, MA 02241-4413	N/A	PC	ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,332,312.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION PO BOX 414413 BOSTON, MA 02241-4413	N/A	PC	ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,378,160.
CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BOULEVARD LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1 EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	531,630.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)	560,242.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)	733,121.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	1,016,595.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL	407,932.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D	121,207.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CITY FUTURES, INC. 80 8TH AVE NEW YORK, NY 10011	N/A	PC	NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE	75,000.
CITY FUTURES, INC. 80 8TH AVE NEW YORK, NY 10011	N/A	PC	NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE	75,000.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	CATALYST SUSTAINABILITY THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN PARKS	139,790.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	STRENGTHENING NYCS URBAN FOREST PLAN PUBLIC PARK LANDS	188,595.
CITY PARKS FOUNDATION, INC. 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN FUND	500,000.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)	2,901,095.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)	3,215,685.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION	1,166,919.
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	492,300.
CONVERGENT IMPACT INC 3223 ARAPAHOE AVE BOULDER, CO 80303	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH	1,212,300.
COREWELL HEALTH 100 MICHIGAN ST NE GRAND RAPIDS, MI 49503	N/A	PC	EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS	5,885,473.
CORK UNIVERSITY FOUNDATION WESTERN ROAD CORK, IRELAND	N/A	PC	ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS	663,503.
CORK UNIVERSITY FOUNDATION WESTERN ROAD CORK, IRELAND	N/A	PC	ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS	941,943.
CORNELL UNIVERSITY FOR THE JOAN & SANFORD I. WEILL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE	202,620.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CORPORATION FOR SUPPORTIVE HOUSING 55 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	800,000.
CORPORATION FOR SUPPORTIVE HOUSING 55 BROADWAY NEW YORK CITY, NY 10006	N/A	PC	HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING	500,000.
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT	34,000.
COZAD HOSPITAL DISTRICT NO. 2 300 EAST 12TH STREET COZAD, NE 69130	N/A	GOV	TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM	17,570.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE	1,622,595.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE	739,745.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE	626,728.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS	375,484.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	IMPLEMENTATION OF A LOWER GI DIAGNOSTIC PATHWAY IN PRIMARY HEALTHCARE AND DEVELOPMENT AND DISSEMINATION OF A LOWER GI PATIENT TOOLKIT	170,782.
CROHN'S COLITIS CURE 100 HARRIS STREET PYRMONT NSW, AUSTRALIA	N/A	PC	ENHANCING INFLAMMATORY BOWEL DISEASE CARE CONSUMER-CENTRIC PORTAL FOR BETTER COMMUNICATION & REDUCED NAVIGATION STRESS	991,768.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	268,958.
DEUTSCHE WELTHUNGERHILFE E.V. FRIEDRICH-EBERT-STRABE 1 BONN BAD GODESBERG, GERMANY	N/A	PC	HOLISTICALLY ADDRESSING AGROBUSINESS	892,391.
DEUTSCHE WELTHUNGERHILFE E.V. FRIEDRICH-EBERT-STRAE 1 BONN BAD GODESBERG, GERMANY	N/A	PC	HOLISTICALLY ADDRESSING AGROBUSINESS	1,079,659.
DIABETES AUSTRALIA 19-23 MOORE STREET, GROUND FLOOR TURNER, AUSTRALIA	N/A	PC	IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH GEOGRAPHIC EXPANSION AND COUNTRY DATA-DRIVEN INITIATIVES.	2,443,661.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DUKE UNIVERSITY 2200 WEST MAIN STREET, SUITE 1000 DURHAM, NC 27705	N/A	PC	NOVEL ASSAYS FOR PROGLUCAGON PEPTIDES TO UNDERSTAND ALPHA CELL FUNCTION IN HEALTH AND DIABETES	275,096.
EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA, GA 30322-4250	N/A	PC	CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION	283,099.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	MINGA MISSION HOSPITAL DEVELOPMENT	2,112,745.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	MINGA MISSION HOSPITAL DEVELOPMENT	1,089,542.
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS	1,000,000.
FJC 225 WEST 39TH STREET NEW YORK, NY 10018	N/A	PC	NYC FUND TO END YOUTH & FAMILY HOMELESSNESS, A PROJECT OF FJC.	300,000.
FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST) 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	FIRST SENIOR MENTOR PROGRAM	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GALILEE MEDICAL CENTER BEN ZVI BLVD. POB 21 NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF ONE FLOOR OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER	750,000.
GATES PHILANTHROPY PARTNERS PO BOX 60555 CITY OF INDUSTRY, CA 91716	N/A	PC	POLIO ERADICATION FUND SUPPORT	1,000,000.
GENETIC ALLIANCE, INC. 25904 WOODFIELD ROAD DAMASCUS, MD 20872	N/A	PC	IHOPE GENETIC HEALTH	250,000.
GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS CAMBRIDGE, UNITED KINGDOM	N/A	PC	SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE	143,892.
GEOSCIENCE AUSTRALIA 101 JERRABOMBERRA AVE SYMONSTON, AUSTRALIA	N/A	GOV	DIGITAL EARTH AFRICA - SUSTAINABLE UPTAKE AND IMPACT	2,737,545.
GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS 1310 L. STREET NW WASHINGTON, DC 20005	N/A	PC	GENERAL OPERATING SUPPORT	18,920.
HAWAI'I HEALTH SYSTEMS CORP KAUA'I REGION FOR VETERANS MEMORIAL HOSP 4643 WAIMEA CANYON DRIVE WAIMEA, HI 96796	N/A	GOV	MEDICAL SIMULATION AT KAUA'I VETERANS MEMORIAL HOSPITAL	250,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HEALING HANDS OF JOY 4747 HEDGEMORE DR CHARLOTTE, NC 28209	N/A	PC	ELIMINATION OF OBSTETRIC FISTULA	335,000.
HEALING HANDS OF JOY 4747 HEDGEMORE DR CHARLOTTE, NC 28209	N/A	PC	ELIMINATION OF OBSTETRIC FISTULA	165,000.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	2,482,836.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,716,830.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	3,716,830.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	5,172,033.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS	5,172,032.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,550,379.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,550,379.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,353,865.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,353,865.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,821,858.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	1,821,858.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)	526,471.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,829,040.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,829,040.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,755,302.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,755,301.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,917,762.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	5,917,761.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,393,010.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	4,393,009.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	3,565,907.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	3,465,906.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,665,293.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)	1,665,293.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL	4,328,576.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION 2025-2029	1,299,716.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION 2025-2029	1,382,183.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION 2025-2029	912,527.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION 2025-2029	1,272,469.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	1,176,451.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	EUROPEAN PRE-T1D REGISTRY	37,585.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) INGOLSTDTER LANDSTRAE 1 NEUHERBERG, GERMANY	N/A	PC	GPPAD BIOSAMPLE RFP	912,618.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET, NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KFF HEALTH NEWS RURAL HEALTH DESK	1,566,728.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET, NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KFF HEALTH NEWS RURAL HEALTH DESK	1,612,177.
HERLEV OG GENTOFTE HOSPITAL HERLEV RINGVEJ 75, OPG.115 HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	140,000.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS	1,183,489.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS	1,213,318.
HIGH QUALITY MEDICAL EDUCATION 4117 PENFIELD CT. S AFTON, MN 55001	N/A	PC	POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS	1,705,225.
HILLEL THE FOUNDATION FOR JEWISH CAMPUS LIFE 180 S. GARNER STREET STATE COLLEGE, PA 16804	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
HOLON INSTITUTE OF TECHNOLOGY - HIT (R.A.) 52 GOLOMB ST HOLON, ISRAEL	N/A	PC	MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)	2,725,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HOLON INSTITUTE OF TECHNOLOGY - HIT 52 GOLOMB ST HOLON, ISRAEL	N/A	PC	MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)	2,043,650.
HUMBOLDT COUNTY MEMORIAL HOSPITAL 1000 N. 15TH ST. HUMBOLDT, IA 50548	N/A	GOV	TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL	15,775.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD	580,306.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD	597,244.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]	531,966.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]	520,141.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE REFLECTION STUDY PREDICTING OUTCOMES FOLLOWING ILEOCECAL RESECTION IN CROHNS DISEASE.	535,412.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE REFLECTION STUDY PREDICTING OUTCOMES FOLLOWING ILEOCECAL RESECTION IN CROHNS DISEASE.	1,367,190.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	EARLY LIFE EXPOSOME BIOMARKERS AND CROHN'S DISEASE RISK THE EARLY-CD PROJECT	663,610.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE	1,232,170.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE	809,899.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE PREDICT AND PREVENT	587,152.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	DEVELOPMENT OF NOVEL LRRK2 INHIBITORS TO TREAT CROHNS DISEASE	583,880.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL	17,875.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
IMPROVECARENOW, INC. 4 CARMICHAEL ST, UNIT 111 ESSEX JUNCTION, VT 05452	N/A	PC	IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK	872,406.
IMPROVECARENOW, INC. 4 CARMICHAEL ST, UNIT 111 ESSEX JUNCTION, VT 05452	N/A	PC	IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK	771,948.
INNODIA HERESTRAAT 49 LEUVEN, BELGIUM	N/A	PC	INNODIA NONPROFIT LAUNCH	426,278.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	85,150.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	108,058.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	77,919.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	116,852.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	160,613.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION	278,787.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION	186,090.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
INSTITUTE FOR COMMUNITY LIVING, INC. 125 BROAD STREET NEW YORK CITY, NY 10004	N/A	PC	PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT	749,790.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY II	215,700.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY II	50,000.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY II	100,000.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY II	165,700.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET, #130 GAINESVILLE, FL 32608	N/A	PC	STRENGTHENING ORGANIZATIONAL CAPACITY II	265,700.
INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC 75 STATE STREET BOSTON, MA 02109	N/A	PC	SEED FUNDING SUPPORT	971,684.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)	296,500.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)	688,466.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA	1,550,680.
INT'L BANK FOR RECONSTRUCTION & DEV AND INT'L DEVELOPMENT ASSOC. 1818 H STREET, NW WASHINGTON, DC 20433	N/A	PC	HEALTH SYSTEM TRANSFORMATION AND RESILIENCE MULTI-DONOR TRUST FUND - NONCOMMUNICABLE DISEASE PARTNERSHIP GENERAL OPERATING SUPPORT	2,500,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	TRIAL EVALUATING THE EFFECT OF INHALED TECHNOSPHERE INSULIN VERSUS RAPID ACTING ANALOGUE INSULIN ON EXERCISE-INDUCED HYPOGLYCEMIA IN ADULTS WITH T1D	191,816.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING	273,882.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	309,895.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	299,921.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY	531,921.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)	1,256,044.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)	1,223,066.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)	1,108,482.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)	1,131,140.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)	805,385.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE LARGE ADULT STUDY	159,838.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA	448,818.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JERUSALEM FOUNDATION, INC. 420 LEXINGTON AVENUE NEW YORK, NY 10170	N/A	PC	BUILDING A NEW HOME FOR TSAD KADIMA	500,000.
JEWISH BOARD OF FAMILY & CHILDREN'S SERVICES, INC. 463 7TH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
JEWISH BOARD OF FAMILY & CHILDREN'S SERVICES, INC. 463 7TH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS	571,287.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	287,280.
KAISER FOUNDATION HEALTH PLAN OF GEORGIA, INC. 1375 PEACHTREE STREET NE ATLANTA, GA 30309	N/A	PC	EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL	213,776.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	TARGETING CHRONIC INFLAMMATION AND TISSUE REMODELLING IN CROHN'S DISEASE WITH ENGINEERED T CELLS	389,044.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE THE OATS STUDY	490,041.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	199,460.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY	205,983.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	FAT AS A VILLAIN IN CROHN'S DISEASE.	1,344,948.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	1,555,353.
KATHOLIEKE UNIVERSITEIT TE LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	EDENT1FI	944,656.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	T CELL RECEPTOR SEQUENCING IN TYPE 1 DIABETES - BIOMARKER DISCOVERY AND TECHNOLOGY DEVELOPMENT	115,097.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA	307,779.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.	325,389.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS	260,566.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS	218,298.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	805,337.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)	579,408.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	1,069,889.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	1,079,926.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	1,147,254.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	1,296,483.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	1,325,562.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	369,984.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III	778,535.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN FEODOR-LYNEN-STRAE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	949,869.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT MNCHEN FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE	907,027.
KYLER CARES FOUNDATION 8070 CROWDER BOULEVARD, SUITE B NEW ORLEANS, LA 70126	N/A	PC	CAPACITY BUILDING SUPPORT	495,000.
KYLER CARES FOUNDATION 8070 CROWDER BOULEVARD, SUITE B NEW ORLEANS, LA 70126	N/A	PC	CAPACITY BUILDING SUPPORT	251,700.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, TX 77477	N/A	PC	SCALING INTEGRATED WASH SERVICES	2,432,337.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP	8,560,477.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP	9,684,661.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL	1,445,272.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL	767,141.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	U.S. PREVENTIVE TYPE 1 DIABETES COALITION	469,406.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	U.S. PREVENTIVE TYPE 1 DIABETES COALITION	429,475.
MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	U.S. PREVENTIVE TYPE 1 DIABETES COALITION	320,341.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE	123,922.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE	65,218.
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE	781,613.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE	734,202.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	MILITARY SCIENCES MEDICAL TRAINING 2024-2026	249,920.
MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON, SD 29425	N/A	GOV	ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES	384,392.
MICHIGAN STATE UNIVERSITY 426 AUDITORIUM ROAD, ROOM 2 EAST LANSING, MI 48824-2601	N/A	PC	A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH TYPE 1 DIABETES	896,270.
MILLE LACS HEALTH SYSTEM 200 ELM STREET NORTH ONAMIA, MN 56359	N/A	PC	TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM	6,809.
MINNESOTA RURAL HEALTH ASSOCIATION 27011 460TH AVE HENNING, MN 56551	N/A	PC	SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA	378,700.
MINNESOTA STATE COLLEGES AND UNIVERSITIES 30 E. 7TH STREET ST. PAUL, MN 55101	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA	205,285.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MONTANA PEDIATRICS 259 W. FRONT STREET MISSOULA, MT 59802	N/A	NC	CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D	536,186.
NATIONAL ACADEMY OF SCIENCES 500 5TH STREET NW WASHINGTON, DC 20001	N/A	PC	STRENGTHENING MINORITY SERVING INSTITUTIONS	150,000.
NATIONAL ASSOCIATION OF SCHOOL NURSES INC 1100 WAYNE AVE. SILVER SPRING, MD 20910	N/A	PC	PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT	1,110,787.
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	STRENGTHENING NYC'S URBAN FOREST PLAN NATURAL AREAS	206,868.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	2023-2025 PARTNERSHIP	1,759,350.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4126 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA FIRST RESPONDER AED PROJECT	60,670.
NEW VENTURE FUND 1828 L STREET, NW, SUITE 300-A WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2025-2028)	1,894,037.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW VENTURE FUND 1828 L STREET, NW, SUITE 300-A WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2025-2028)	1,842,898.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 50 WATER STREET NEW YORK, NY 10004	N/A	PC	PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS	800,000.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 50 WATER STREET NEW YORK, NY 10004	N/A	PC	PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS	800,000.
NEW YORK RESTORATION PROJECT 254 WEST 31ST STREET NEW YORK, NY 10001	N/A	PC	NYC URBAN REFORESTATION & EXPANSION	306,464.
NEW YORK RESTORATION PROJECT 254 WEST 31ST STREET NEW YORK, NY 10001	N/A	PC	NYC URBAN REFORESTATION & EXPANSION	250,000.
NEW YORK UNIVERSITY 665 BROADWAY, SUITE 801 NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	100,307.
NEW YORK UNIVERSITY 665 BROADWAY, SUITE 801 NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	40,419.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK UNIVERSITY 665 BROADWAY, SUITE 801 NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS	55,372.
NEW YORK UNIVERSITY 665 BROADWAY, SUITE 801 NEW YORK, NY 10012	N/A	PC	TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH	1,360,453.
NORTH DAKOTA STATE UNIVERSITY 1301 12TH AVENUE N FARGO, ND 58102	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA	1,295,711.
NORTH DAKOTA STATE UNIVERSITY 1301 12TH AVENUE N FARGO, ND 58102	N/A	GOV	EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA	494,155.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,139,629.
OAKLAND UNIVERSITY 2200 NORTH SQUIRREL ROAD ROCHESTER, MI 48309	N/A	GOV	A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)	1,019,181.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND, OR 97239-3098	N/A	GOV	AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT	1,783,316.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	T1D COMMUNITY FUND STAGE II	1,535,971.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	T1D COMMUNITY FUND STAGE II	1,444,887.
PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT, INC. 905 KALANIANAOLE HWY KAILUA, HI 96734	N/A	PC	PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING	268,067.
PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT, INC. 905 KALANIANAOLE HWY KAILUA, HI 96734	N/A	PC	PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING	225,393.
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DRIVE SAN FRANCISCO, CA 94129	N/A	PC	UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.	358,140.
PERKINS COUNTY HOSPITAL DISTRICT 900 LINCOLN AVE GRANT, NE 69140	N/A	GOV	TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES	14,706.
PROJECT CONCERN ZAMBIA LIMITED PLOT 37/1P LUSAKA, ZAMBIA	N/A	PC	EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS	1,590,680.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION	400,371.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION	34,097.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CD.	746,990.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA	190,186.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES	1,119,929.
REACHANOTHER FOUNDATION 1900 NE 3RD ST, STE #106-307 BEND, OR 97701	N/A	PC	TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES	122,978.
REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	232,662.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	CONTINUING DEVELOPMENT OF OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES	269,189.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)	502,750.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.	1,454,586.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.	585,172.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	THERAPEUTIC USE OF PEPTIDEMHC MABS FOR T1D	220,565.
REGENTS OF THE UNIVERSITY OF MINNESOTA 200 OAK STREET SE MINNEAPOLIS, MN 55455-2070	N/A	GOV	THERAPEUTIC USE OF PEPTIDEMHC MABS FOR T1D	166,880.
REGION HOVEDSTADEN KONGENS VAENGE 2 HILLEROD, DENMARK	N/A	GOV	CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?	113,358.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
RENOWN HEALTH FOUNDATION 1155 MILL ST RENO, NV 89502	N/A	PC	RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA	243,019.
RESEARCH TRIANGLE INSTITUTE 3040 EAST CORNWALLIS ROAD DURHAM, NC 27709-2194	N/A	PC	USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS A STATEWIDE IMPLEMENTATION STUDY	826,376.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING SUSTAINABLE SAFE WATER ACCESS	1,932,000.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING SUSTAINABLE SAFE WATER ACCESS	998,000.
SANFORD RESEARCH 1305 W 18TH ST SIOUX FALLS, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	583,363.
SANFORD RESEARCH 1305 W 18TH ST SIOUX FALLS, SD 57104-0569	N/A	PC	PLEDGE PHASE 3	1,093,143.
SANFORD WORLD CLINICS 1305 W 18TH ST SIOUX FALLS, SD 57105	N/A	PC	PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)	112,523.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SANFORD WORLD CLINICS 1305 W 18TH ST SIOUX FALLS, SD 57105	N/A	PC	PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)	145,752.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S S-200 SEATTLE, WA 98145-5005	N/A	PC	EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)	616,923.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER	1,500,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER	2,000,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	2,500,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	DEVELOPMENT OF THE HELMSLEY SURGICAL WING	3,500,000.
SHARE TRUST INC. 310 DEDHAM ST DOVER, MA 02030	N/A	PC	BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION	1,540,658.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK, 1ST FLOOR NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	170,000.
SIMULATION IN MOTION MONTANA, INC. 2021 11TH AVE, SUITE 1 HELENA, MT 59601	N/A	PC	SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY	100,000.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	SCALING THE HEALTHY FUTURE FOR ALL MODEL	1,144,205.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	SCALING THE HEALTHY FUTURE FOR ALL MODEL	626,684.
SOLIDARIDAD NETWORK FOUNDATION LIMITED 163 KUDU ROAD LUSAKA, ZAMBIA	N/A	PC	HOOVES FOR SUSTAINABILITY (H4S)	273,384.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	4,790,316.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	HOPE CENTER FOR WOMEN AND CHILDREN	1,908,524.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ST. MARK'S HOSPITAL FOUNDATION ACTON LANE LONDON, UNITED KINGDOM	N/A	PC	PERIANAL CROHNS DISEASE (PCD) EDUCATIONAL MEETING AND TOPCLASS CONSORTIUM MEMBER CONFERENCE	164,712.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT	172,840.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT	87,671.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOI	DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM	101,195.
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH 9 PRINCES ST MELBOURNE, AUSTRALIA	N/A	PC	WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?	255,857.
STATE UNIVERSITY OF IOWA FOUNDATION ONE WEST PARK ROAD IOWA CITY, IA 52242	N/A	PC	SIMULATION IN MOTION-IOWA ENDOWMENT	135,000.
STATE UNIVERSITY OF IOWA FOUNDATION ONE WEST PARK ROAD IOWA CITY, IA 52242	N/A	PC	SIMULATION IN MOTION-IOWA ENDOWMENT	135,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STATE UNIVERSITY OF IOWA FOUNDATION ONE WEST PARK ROAD IOWA CITY, IA 52242	N/A	PC	SIMULATION IN MOTION-IOWA ENDOWMENT	130,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227, SUITE A AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO DIABETES CARE	1,000,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227, SUITE A AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO DIABETES CARE	1,000,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	1,300,026.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV	998,988.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	SAFECARE A BUSINESS MODEL FOR HEALTHCARE QUALITY	538,692.
STICHTING THE OCEAN CLEANUP BATAVIERENSTRAAT 15 ROTTERDAM, NETHERLANDS	N/A	PC	DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS	5,000,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STIFTELSEN FOR UTBILDNING (IOIBD) LINKPING UNIVERSITY HOSPITAL, FLOOR 14 OREBRO, SWEDEN	N/A	PC	THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD	132,000.
SUPPORTIVE HOUSING NETWORK OF NEW YORK INC 247 W 37TH ST NEW YORK CITY, NY 10018	N/A	PC	TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS	251,200.
SUSTAINABLE COASTLINES HAWAII 3160 WAIALAE AVE HONOLULU, HI 96816	N/A	PC	SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT	274,787.
SUSTAINABLE COASTLINES HAWAII 3160 WAIALAE AVE HONOLULU, HI 96816	N/A	PC	SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT	176,000.
TAMPERE UNIVERSITY FOUNDATION SR KALEVANTIE 4, 33100 TAMPERE, FINLAND	N/A	PC	ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK	419,684.
TAMPERE UNIVERSITY FOUNDATION SR KALEVANTIE 4, 33100 TAMPERE, FINLAND	N/A	PC	ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK	283,718.
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMANN ST 6 TEL AVIV, ISRAEL	N/A	GOV	CONSTRUCTION OF THE SHELTERED -5 FLOOR OF THE NORTH TOWER	5,120,490.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL WEIZMANN ST 6 TEL AVIV, ISRAEL	N/A	GOV	GENETICS INSTITUTE AND GENOMICS CENTER	2,538,786.
TEL-AVIV UNIVERSITY P.O. 39040 TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	6,828,500.
TEL-AVIV UNIVERSITY P.O. 39040 TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	1,524,350.
TEL-AVIV UNIVERSITY P.O. 39040 TEL AVIV, ISRAEL	N/A	PC	HELMSLEY MEDICAL SIMULATION CENTER	1,324,350.
THE ACADEMIC COLLEGE AT TEL-HAI MOBILE POST 12210 UPPER GALILEE, ISRAEL	N/A	PC	THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH	3,225,321.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV 2012100 HALUTZ RAMAT HANEGEV, ISRAEL	N/A	PC	RAMAT HANEGEV SENIOR CITIZEN CENTER	699,190.
THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV 2012100 HALUTZ RAMAT HANEGEV, ISRAEL	N/A	PC	RAMAT HANEGEV CENTRAL AUDITORIUM	1,109,829.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BIONICS INSTITUTE OF AUSTRALIA 384-388 ALBERT STREET EAST MELBOURNE, AUSTRALIA	N/A	PC	PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE	932,181.
THE BIONICS INSTITUTE OF AUSTRALIA 384-388 ALBERT STREET EAST MELBOURNE, AUSTRALIA	N/A	PC	PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE	477,568.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS	1,129,976.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	3,499,051.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	3,477,159.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE	718,215.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)	353,223.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?	726,752.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	NEW INSIGHTS INTO CROHN'S DISEASE FROM STUDYING NAKED MOLE RATS	347,219.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?	851,645.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE TRINITY LANE CAMBRIDGE, UNITED KINGDOM	N/A	PC	DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?	820,911.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY	371,800.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE	342,955.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	719,051.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE END FUND, INC. 2 PARK AVENUE NEW YORK, NY 10016	N/A	PC	TACKLING TRACHOMA SURGERY DISPARITIES	2,124,880.
THE END FUND, INC. 2 PARK AVENUE NEW YORK, NY 10016	N/A	PC	TACKLING TRACHOMA SURGERY DISPARITIES	2,132,360.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE	430,190.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE	424,253.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION	250,415.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	340,788.
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION	234,854.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE EXHIBITION RD LONDON, UNITED KINGDOM	N/A	PC	UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE	1,081,289.
THE LANIADO KIRIAT SANZ HOSPITAL DIVREI KHAYIM ST 16 NATANIYA, ISRAEL	N/A	PC	NEW MATERNITY FLOOR C	1,350,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. (CC) YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES	200,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD. (CC) YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES	200,000.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D	620,649.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN	471,131.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE LA JOLLA, CA 92093	N/A	PC	THE DRUGGABLE GPCROME IN CROHNS DISEASE	1,092,733.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS	458,242.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS	217,916.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA BARBARA 552 UNIVERSITY ROAD SANTA BARBARA, CA 93106	N/A	PC	EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES	1,116,996.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EPITHELIAL MITOCHONDRIAL DYSFUNCTION AND EXTRACELLULAR VESICLES IN CROHNS DISEASE FIBROSTENOSIS.	431,482.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	1,840,786.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY	996,486.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	807,989.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)	706,939.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES	226,229.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES	239,819.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES	459,401.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES	329,695.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES	501,000.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	1,036,513.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)	552,433.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	1,215,803.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE	319,937.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS 2024	499,998.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER 13001 E 17TH PLACE AURORA, CO 80045-2571	N/A	PC	ASK THE EXPERTS 2024	499,995.
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV. 845 SHERBROOKE STREET WEST MONTREAL, CANADA	N/A	PC	DATA GOVERNANCE RESOURCE	185,694.
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV. 845 SHERBROOKE STREET WEST MONTREAL, CANADA	N/A	PC	DATA GOVERNANCE RESOURCE	182,394.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA, CA 92037	N/A	PC	GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD	1,836,022.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	993,626.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) 2 KATZIR RAMAT GAN, ISRAEL	N/A	PC	ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)	188,118.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) 2 KATZIR RAMAT GAN, ISRAEL	N/A	PC	THE UTILITY OF HAND-HELD ULTRASOUND DEVICES TO DETECT BOWEL WALL INFLAMMATORY ACTIVITY IN CROHN'S DISEASE	84,659.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	514,210.
THE SONIA NABETA FOUNDATION, INC. 4705 5TH STREET, UNIT 405 LONG ISLAND CITY, NY 11101	N/A	PC	WORLD OF WARRIORS	578,470.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS	266,666.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ YOUTH SUICIDE PREVENTION PROJECT	1,536,740.
THE TREVOR PROJECT, INC. PO BOX 69232 WEST HOLLYWOOD, CA 90069	N/A	PC	LGBTQ YOUTH SUICIDE PREVENTION PROJECT	1,282,735.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	SUPPORT FOR T1D TRANSITION PROGRAMS	150,000.
THE UNIVERSITY OF ADELAIDE NORTH TERRACE ADELAIDE, AUSTRALIA	N/A	PC	PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN	43,631.
THE UNIVERSITY OF EDINBURGH SOUTH BRIDGE EDINBURGH, UNITED KINGDOM	N/A	PC	REPURPOSING POSITIVE ALLOSTERIC MODULATORS OF GLUTAMATE RECEPTORS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES A PILOT CLINICAL STUDY	646,292.
THE UNIVERSITY OF EDINBURGH SOUTH BRIDGE EDINBURGH, UNITED KINGDOM	N/A	PC	REPURPOSING POSITIVE ALLOSTERIC MODULATORS OF GLUTAMATE RECEPTORS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES A PILOT CLINICAL STUDY	426,524.
THE UNIVERSITY OF MANCHESTER OXFORD RD MANCHESTER, UNITED KINGDOM	N/A	PC	A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION	692,839.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE	3,000,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	1,302,462.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, ID 47401-3654	N/A	GOV	THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)	452,575.
TRUSTEES OF INDIANA UNIVERSITY 509 EAST 3RD STREET BLOOMINGTON, ID 47401-3654	N/A	GOV	THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)	475,212.
UNIVERSIT DEGLI STUDI DI MILANO VIA FESTA DEL PERDONO 7 MILAN, ITALY	N/A	GOV	UNRAVELING THE ROLE OF CD45RACCR7 CD4 T CELLS IN THE PATHOGENESIS OF TYPE 1 DIABETES	321,749.
UNIVERSITA DEGLI STUDI DI MILANO VIA FESTA DEL PERDONO 7 MILAN, ITALY	N/A	GOV	UNRAVELING THE ROLE OF CD45RACCR7 CD4 T CELLS IN THE PATHOGENESIS OF TYPE 1 DIABETES	213,050.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM	304,033.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM	152,546.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	STUDYING THE SELECTIVEB CELL SENSITIVITY TO A HOMOZYGOUS PD-L1 MUTATION IN NEONATAL DIABETES	217,239.
UNIVERSITY HOSPITALS HEALTH SYSTEM, INC. 11100 EUCLID AVENUE CLEVELAND, OH 44106	N/A	PC	TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS	677,700.
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA 1800 W CHARLESTON BLVD LAS VEGAS, NV 89102	N/A	GOV	DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	84,783.
UNIVERSITY OF BIRMINGHAM CHANCELLORS COURT BIRMINGHAM, UNITED KINGDOM	N/A	PC	CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES	479,888.
UNIVERSITY OF BRISTOL TYNDALL AVENUE BRISTOL, UNITED KINGDOM	N/A	PC	TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY	358,900.
UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE, SUITE 500 CINCINNATI, OH 45221	N/A	GOV	STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE	429,700.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	ADVANCINGB-CELL SPECIFIC THERAPY BY IDENTIFYINGB-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS	70,533.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2 FROM OBSERVATION TO MECHANISM	465,868.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES	692,073.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES	189,671.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	260,351.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	B CELL SIGNATURES IN TYPE 1 DIABETES	40,825.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC) A NATIONAL NEEDS ASSESSMENT	208,595.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	586,219.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION	435,671.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.	425,075.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.	1,968,566.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.	426,282.
UNIVERSITY OF HAWAII 2444 DOLE STREET HONOLULU, HI 96822	N/A	GOV	IMPROVING HEALTH ACROSS RURAL HAWAII THROUGH RESEARCH AND POLICY	193,410.
UNIVERSITY OF HAWAII 2444 DOLE STREET HONOLULU, HI 96822	N/A	GOV	IMPROVING HEALTH ACROSS RURAL HAWAII THROUGH RESEARCH AND POLICY	190,434.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF IOWA 112 NORTH CAPITOL STREET IOWA CITY, IA 52442	N/A	GOV	SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION	204,566.
UNIVERSITY OF MELBOURNE 161 BARRY STREET VICTORIA, AUSTRALIA	N/A	PC	USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D	524,787.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES	282,000.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD-LIKE DISEASE OF THE POUCH	336,550.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD-LIKE DISEASE OF THE POUCH	71,233.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS	1,058,738.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	GOV	DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR	1,306,168.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH DAKOTA 1301 N COLUMBIA RD, SUITE E105 GRAND FORKS, ND 58202	N/A	GOV	SIMULATION IN MOTION (SIM) CONSORTIUM	54,673.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING	135,549.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL)	307,891.
UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN 2304 WHITIS AVE AUSTIN, TX 78712-1111	N/A	GOV	INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN	200,927.
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE, WA 98195-9472	N/A	GOV	PATHOGENIC ACTION OF AUTOANTIBODIES ON ISLET FUNCTION AND VIABILITY IN TYPE 1 DIABETES	385,000.
UNIVERSITY OF WESTERN ONTARIO 339 WINDERMERE RD. LONDON, CANADA	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	756,873.
UNIVERSITY OF WESTERN ONTARIO 339 WINDERMERE RD. LONDON, CANADA	N/A	PC	ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM	606,448.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF WYOMING FOUNDATION 222 S 22ND ST LARAMIE, WY 82070	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN WYOMING	458,857.
UNIVERSITY OF WYOMING FOUNDATION 222 S 22ND ST LARAMIE, WY 82070	N/A	PC	ULTRASOUND TRAINING INITIATIVE IN WYOMING	458,857.
UPPSALA UNIVERSITY HOSPITAL AKADEMISKA SJUKHUSET UPPSALA, SWEDEN	N/A	PC	IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION	360,374.
URBAN PATHWAYS, INC. 575 EIGHTH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
URBAN PATHWAYS, INC. 575 EIGHTH AVE NEW YORK, NY 10018	N/A	PC	COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE	100,000.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY	149,050.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA	104,599.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	232,525.
VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE, SUITE 970 NASHVILLE, TN 37203	N/A	PC	ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES	182,168.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	318,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	1,242,777.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	2,000,000.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES	4,275,632.
WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE SAINT LOUIS, MO 63130	N/A	PC	PRECLINICAL DEVELOPMENT TO ADVANCE A T1D ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D	1,319,373.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING NUMA IN NORTHERN GHANA	2,294,479.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING NUMA IN NORTHERN GHANA	2,647,448.
WEIZMANN INSTITUTE OF SCIENCE POB 26 REHOVOT, ISRAEL	N/A	PC	QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS	1,397,538.
WESTCHESTER JEWISH CENTER 175 ROCKLAND AVE MAMARONECK, NY 10543	N/A	PC	GENERAL OPERATING SUPPORT	7,500.
WILCOX HEALTH FOUNDATION 3-3420 KUHIO HIGHWAY LIHUE, HI 96766	N/A	PC	WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	6,273,000.
WILCOX HEALTH FOUNDATION 3-3420 KUHIO HIGHWAY LIHUE, HI 96766	N/A	PC	WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	409,000.
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA , SWITZERLAND	N/A	PC	STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS	3,010,445.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WORLD HEALTH ORGANIZATION AVENUE APPIA 20 GENEVA , SWITZERLAND	N/A	PC	STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT	3,130,872.
WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE PO BOX 481 DOUGLAS, WY 82633	N/A	PC	WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM	851,113.
WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE PO BOX 481 DOUGLAS, WY 82633	N/A	PC	WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM	746,408.
YALE UNIVERSITY P.O. BOX 208327 NEW HAVEN, CT 06520-8327	N/A	PC	TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE	605,522.
YEHUDA ABARBANEL GOVERNMENT HOSPITAL 15 KEREN KAYEMET ST. BAT YAM, ISRAEL	N/A	GOV	MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS	454,960.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET, #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2024-2026	200,000.
Total from continuation sheets				

Part XIV Supplementary Information

3a Grants and Contributions Paid During the Year Continuation of Purpose of Grant or Contribution

NAME OF RECIPIENT - ACUMEN AMERICA, LLC

SUPPLEMENTAL SUPPORT TO ADDRESS SOCIAL DETERMINANTS OF HEALTH FOR

PEOPLE WITH INSULIN REQUIRING DIABETES

Part XIV Supplementary Information

3b Grants and Contributions Approved for Future Payment Continuation of Purpose of Grant or Contribution

NAME OF RECIPIENT - ACADEMISCH ZIEKENHUIS LEIDEN

SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC

CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)

NAME OF RECIPIENT - ACADEMISCH ZIEKENHUIS LEIDEN

SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC

CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)

Form **2220**

Department of the Treasury
Internal Revenue Service

Underpayment of Estimated Tax by Corporations

Attach to the corporation's tax return. FORM 990-PF

Go to www.irs.gov/Form2220 for instructions and the latest information.

OMB No. 1545-0123

2024

Name THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST

Employer identification number 13-7184401

Note: Generally, the corporation is not required to file Form 2220 (see Part II below for exceptions) because the IRS will figure any penalty owed and bill the corporation. However, the corporation may still use Form 2220 to figure the penalty. If so, enter the amount from page 2, line 38, on the estimated tax penalty line of the corporation's income tax return, but **do not** attach Form 2220.

Part I Required Annual Payment

1	Total tax (see instructions)		1	4,897,298.
2a	Personal holding company tax (Schedule PH (Form 1120), line 26) included on line 1	2a		
b	Look-back interest included on line 1 under section 460(b)(2) for completed long-term contracts or section 167(g) for depreciation under the income forecast method	2b		
c	Credit for federal tax paid on fuels (see instructions)	2c		
d	**Total.** Add lines 2a through 2c		2d	
3	Subtract line 2d from line 1. If the result is less than $500, **do not** complete or file this form. The corporation does not owe the penalty		3	4,897,298.
4	Enter the tax shown on the corporation's 2023 income tax return. See instructions. **Caution:** If the tax is zero or the tax year was for less than 12 months, skip this line and enter the amount from line 3 on line 5		4	3,123,302.
5	**Required annual payment.** Enter the **smaller** of line 3 or line 4. If the corporation is required to skip line 4, enter the amount from line 3		5	3,123,302.

Part II Reasons for Filing - Check the boxes below that apply. If any boxes are checked, the corporation **must** file Form 2220 even if it does not owe a penalty. See instructions.

6 ☐ The corporation is using the adjusted seasonal installment method.

7 ☒ The corporation is using the annualized income installment method.

8 ☒ The corporation is a "large corporation" figuring its first required installment based on the prior year's tax.

Part III Figuring the Underpayment

		(a)	(b)	(c)	(d)
9	**Installment due dates.** Enter in columns (a) through (d) the 15th day of the 4th (**Form 990-PF filers:** Use 5th month), 6th, 9th, and 12th months of the corporation's tax year	08/15/24	09/15/24	12/15/24	03/15/25
10	**Required installments.** If the box on line 6 and/or line 7 above is checked, enter the amounts from Sch A, line 38. If the box on line 8 (but not 6 or 7) is checked, see instructions for the amounts to enter. If none of these boxes are checked, enter 25% (0.25) of line 5 above in each column	780,826.	1,637,300.	1,254,849.	1,224,324.
11	Estimated tax paid or credited for each period. For column (a) only, enter the amount from line 11 on line 15. See instructions	6,400,234.			1,500,000.
	Complete lines 12 through 18 of one column before going to the next column.				
12	Enter amount, if any, from line 18 of the preceding column		5,619,408.	3,982,108.	2,727,259.
13	Add lines 11 and 12		5,619,408.	3,982,108.	4,227,259.
14	Add amounts on lines 16 and 17 of the preceding column				
15	Subtract line 14 from line 13. If zero or less, enter -0-	6,400,234.	5,619,408.	3,982,108.	4,227,259.
16	If the amount on line 15 is zero, subtract line 13 from line 14. Otherwise, enter -0-		0.	0.	
17	**Underpayment.** If line 15 is less than or equal to line 10, subtract line 15 from line 10. Then go to line 12 of the next column. Otherwise, go to line 18				
18	**Overpayment.** If line 10 is less than line 15, subtract line 10 from line 15. Then go to line 12 of the next column	5,619,408.	3,982,108.	2,727,259.	

Go to Part IV on page 2 to figure the penalty. Do not go to Part IV if there are no entries on line 17 - no penalty is owed.

Part IV Figuring the Penalty

		(a)	(b)	(c)	(d)
19 Enter the date of payment or the 15th day of the 4th month after the close of the tax year, whichever is earlier. **(C corporations with tax years ending June 30 and S corporations:** Use 3rd month instead of 4th month. **Form 990-PF and Form 990-T filers:** Use 5th month instead of 4th month.) See instructions	19				
20 Number of days from due date of installment on line 9 to the date shown on line 19	20				
21 Number of days on line 20 after 4/15/2024 and before 7/1/2024	21				
22 Underpayment on line 17 x Number of days on line 21 / 366 x 8% (0.08)	22	$	$	$	$
23 Number of days on line 20 after 6/30/2024 and before 10/1/2024	23				
24 Underpayment on line 17 x Number of days on line 23 / 366 x 8% (0.08)	24	$	$	$	$
25 Number of days on line 20 after 9/30/2024 and before 1/1/2025	25				
26 Underpayment on line 17 x Number of days on line 25 / 366 x 8% (0.08)	26	$	$	$	$
27 Number of days on line 20 after 12/31/2024 and before 4/1/2025	27				
28 Underpayment on line 17 x Number of days on line 27 / 365 x 7% (0.07)	28	$	$	$	$
29 Number of days on line 20 after 3/31/2025 and before 7/1/2025	29				
30 Underpayment on line 17 x Number of days on line 29 / 365 x *%	30	$	$	$	$
31 Number of days on line 20 after 6/30/2025 and before 10/1/2025	31				
32 Underpayment on line 17 x Number of days on line 31 / 365 x *%	32	$	$	$	$
33 Number of days on line 20 after 9/30/2025 and before 1/1/2026	33				
34 Underpayment on line 17 x Number of days on line 33 / 365 x *%	34	$	$	$	$
35 Number of days on line 20 after 12/31/2025 and before 3/16/2026	35				
36 Underpayment on line 17 x Number of days on line 35 / 365 x *%	36	$	$	$	$
37 Add lines 22, 24, 26, 28, 30, 32, 34, and 36	37	$	$	$	$

38 Penalty. Add columns (a) through (d) of line 37. Enter the total here and on Form 1120, line 34; or the comparable line for other income tax returns ..... **38** $ 0.

* Use the penalty interest rate for each calendar quarter, which the IRS will determine during the first month in the preceding quarter. These rates are published quarterly in an IRS News Release and in a revenue ruling in the Internal Revenue Bulletin. To obtain this information on the Internet, access the IRS website at **www.irs.gov**. You can also call 800-829-4933 to get interest rate information.

Schedule A Adjusted Seasonal Installment Method and Annualized Income Installment Method

See instructions.

Form 1120-S filers: *For lines 1, 2, 3, and 21, "taxable income" refers to excess net passive income or the amount on which tax is imposed under section 1374(a), whichever applies.*

Part I Adjusted Seasonal Installment Method

Caution: Use this method only if the base period percentage for any 6 consecutive months is at least 70%. See instructions.

		(a)	(b)	(c)	(d)
1 Enter taxable income for the following periods.		First 3 months	First 5 months	First 8 months	First 11 months
a Tax year beginning in 2021	1a				
b Tax year beginning in 2022	1b				
c Tax year beginning in 2023	1c				
2 Enter taxable income for each period for the tax year beginning in 2024. See the instructions for the treatment of extraordinary items	2				
3 Enter taxable income for the following periods.		First 4 months	First 6 months	First 9 months	Entire year
a Tax year beginning in 2021	3a				
b Tax year beginning in 2022	3b				
c Tax year beginning in 2023	3c				
4 Divide the amount in each column on line 1a by the amount in column (d) on line 3a	4				
5 Divide the amount in each column on line 1b by the amount in column (d) on line 3b	5				
6 Divide the amount in each column on line 1c by the amount in column (d) on line 3c	6				
7 Add lines 4 through 6	7				
8 Divide line 7 by 3.0	8				
9a Divide line 2 by line 8	9a				
b Extraordinary items (see instructions)	9b				
c Add lines 9a and 9b	9c				
10 Figure the tax on the amt on ln 9c using the instr for Form 1120, Sch J, line 1, or comparable line of corp's return	10				
11a Divide the amount in columns (a) through (c) on line 3a by the amount in column (d) on line 3a	11a				
b Divide the amount in columns (a) through (c) on line 3b by the amount in column (d) on line 3b	11b				
c Divide the amount in columns (a) through (c) on line 3c by the amount in column (d) on line 3c	11c				
12 Add lines 11a through 11c	12				
13 Divide line 12 by 3.0	13				
14 Multiply the amount in columns (a) through (c) of line 10 by columns (a) through (c) of line 13. In column (d), enter the amount from line 10, column (d)	14				
15 Enter any alternative minimum tax for each payment period. See instructions	15				
16 Enter any other taxes for each payment period. See instr.	16				
17 Add lines 14 through 16	17				
18 For each period, enter the same type of credits as allowed on Form 2220, lines 1 and 2c. See instructions	18				
19 Total tax after credits. Subtract line 18 from line 17. If zero or less, enter -0-	19				

Part II ** Annualized Income Installment Method

		(a)	(b)	(c)	(d)
20 Annualization periods (see instructions)	20	First 2 months	First 3 months	First 6 months	First 9 months
21 Enter taxable income for each annualization period. See instructions for the treatment of extraordinary items	21	46,388,736.	86,982,928.	270,935,641.	416,604,069.
22 Annualization amounts (see instructions)	22	6.000000	4.000000	2.000000	1.333330
23a Annualized taxable income. Multiply line 21 by line 22	23a	278,332,416.	347,931,712.	541,871,282.	555,470,703.
b Extraordinary items (see instructions)	23b				
c Add lines 23a and 23b	23c	278,332,416.	347,931,712.	541,871,282.	555,470,703.
24 Figure the tax on the amount on line 23c using the instructions for Form 1120, Schedule J, line 1, or comparable line of corporation's return	24	3,868,821.	4,836,251.	7,532,011.	7,721,043.
25 Enter any alternative minimum tax for each payment period. See instructions	25				
26 Enter any other taxes for each payment period. See instr.	26				
27 Total tax. Add lines 24 through 26	27	3,868,821.	4,836,251.	7,532,011.	7,721,043.
28 For each period, enter the same type of credits as allowed on Form 2220, lines 1 and 2c. See instructions	28				
29 Total tax after credits. Subtract line 28 from line 27. If zero or less, enter -0-	29	3,868,821.	4,836,251.	7,532,011.	7,721,043.
30 Applicable percentage	30	25%	50%	75%	100%
31 Multiply line 29 by line 30	31	967,205.	2,418,126.	5,649,008.	7,721,043.

Part III Required Installments

Note: Complete lines 32 through 38 of one column before completing the next column.		1st installment	2nd installment	3rd installment	4th installment
32 If only Part I or Part II is completed, enter the amount in each column from line 19 or line 31. If both parts are completed, enter the **smaller** of the amounts in each column from line 19 or line 31	32	967,205.	2,418,126.	5,649,008.	7,721,043.
33 Add the amounts in all preceding columns of line 38. See instructions	33		780,826.	2,418,126.	3,672,975.
34 **Adjusted seasonal or annualized income installments.** Subtract line 33 from line 32. If zero or less, enter -0-	34	967,205.	1,637,300.	3,230,882.	4,048,068.
35 Enter 25% (0.25) of line 5 on page 1 of Form 2220 in each column. **Note:** "Large corporations," see the instructions for line 10 for the amounts to enter	35	780,826.	1,667,824.	1,224,325.	1,224,324.
36 Subtract line 38 of the preceding column from line 37 of the preceding column	36			30,524.	
37 Add lines 35 and 36	37	780,826.	1,667,824.	1,254,849.	1,224,324.
38 **Required installments.** Enter the **smaller** of line 34 or line 37 here and on page 1 of Form 2220, line 10. See instructions	38	780,826.	1,637,300.	1,254,849.	1,224,324.

Form **2220** (2024)

** ANNUALIZED INCOME INSTALLMENT METHOD USING STANDARD OPTION

FORM 990-PF INTEREST ON SAVINGS AND TEMPORARY CASH INVESTMENTS STATEMENT 1

SOURCE	(A) REVENUE PER BOOKS	(B) NET INVESTMENT INCOME	(C) ADJUSTED NET INCOME
INTEREST FROM SAVINGS	3,068,246.	3,068,246.	
INTEREST ON BARZILAI MEDICAL CENTER GRANT REFUND	55,000.	55,000.	
IRS REFUND INTEREST	43.	43.	
TOTAL TO PART I, LINE 3	3,123,289.	3,123,289.	

FORM 990-PF DIVIDENDS AND INTEREST FROM SECURITIES STATEMENT 2

SOURCE	GROSS AMOUNT	CAPITAL GAINS DIVIDENDS	(A) REVENUE PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME
DIVIDENDS AND INTEREST FROM SECURITIES	69,499,667.	0.	69,499,667.	141,050,038.	
TO PART I, LINE 4	69,499,667.	0.	69,499,667.	141,050,038.	

FORM 990-PF OTHER INCOME STATEMENT 3

DESCRIPTION	(A) REVENUE PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME
FX TRANSACTION NET LOSS - TAX	0.	-429,874.	
CLASS ACTION PROCEEDS, NET	19,132.	19,132.	
OTHER PARTNERSHIP INCOME	25,329,605.	22,439,795.	
SECTION 951(A) INCOME INCLUSION	0.	2,447,781.	
OTHER INVESTMENT INCOME	42.	42.	
GRANT RECOVERIES	7,276,276.	0.	
OTHER NON-TAXABLE INCOME	27,454.	0.	
FEDERAL EXCISE TAX BENEFIT	3,842,567.	0.	
FX TRANSACTION NET LOSS - BOOK	-496,216.	0.	
TOTAL TO FORM 990-PF, PART I, LINE 11	35,998,860.	24,476,876.	

FORM 990-PF LEGAL FEES STATEMENT 4

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
LEGAL FEES - INVESTMENTS	184,836.	184,836.		0.
LEGAL FEES - PROGRAMS	252,018.	0.		310,816.
LEGAL FEES - GENERAL ADMINISTRATIVE	118,389.	0.		123,435.
TO FM 990-PF, PG 1, LN 16A	555,243.	184,836.		434,251.

FORM 990-PF ACCOUNTING FEES STATEMENT 5

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AUDIT AND TAX PREPARATION	224,069.	0.		151,031.
BOOKKEEPING	33,406.	6,023.		31,269.
OTHER ACCOUNTING SERVICES	46,450.	0.		46,450.
TO FORM 990-PF, PG 1, LN 16B	303,925.	6,023.		228,750.

FORM 990-PF OTHER PROFESSIONAL FEES STATEMENT 6

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
GRANTS MANAGEMENT CONSULTING	122,100.	0.		151,588.
HUMAN RESOURCE CONSULTING	79,696.	7,000.		75,696.
INFORMATION TECHNOLOGY CONSULTING	406,409.	40,896.		348,594.
INVESTMENT ADVISORY	513,656.	513,656.		0.
INVESTMENT MANAGEMENT	14,260,530.	14,260,530.		0.
MANAGEMENT CONSULTING	70,936.	0.		110,936.
PROGRAM CONSULTING	1,182,556.	0.		1,375,891.
PUBLIC RELATIONS	321,574.	0.		385,730.
RECRUITMENT	127,045.	25,306.		90,073.
TO FORM 990-PF, PG 1, LN 16C	17,084,502.	14,847,388.		2,538,508.

FORM 990-PF TAXES STATEMENT 7

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
STATE UBI AND OTHER TAXES	823,811.	0.		0.
FOREIGN TAXES WITHHELD	478,700.	3,875,590.		0.
TO FORM 990-PF, PG 1, LN 18	1,302,511.	3,875,590.		0.

FORM 990-PF OTHER EXPENSES STATEMENT 8

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST-MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AMERICAN DEPOSITARY RECEIPT FEE	10,820.	10,820.		0.
CONSULTING REIMBURSEMENTS	34,621.	126.		42,173.
CUSTODY, BANK, & PERFORMANCE REPORTING FEES	731,527.	731,477.		50.
STATE FILING FEES AND PENALTIES	163.	0.		0.
INFORMATION TECHNOLOGY/COMPUTERS	1,676,118.	254,043.		1,559,119.
INSURANCE	415,037.	39,955.		374,123.
OFFICE EXPENSES	1,000,781.	466,522.		513,810.
PORTFOLIO DEDUCTIONS	12,723,578.	54,775,206.		0.
TO FORM 990-PF, PG 1, LN 23	16,592,645.	56,278,149.		2,489,275.

FORM 990-PF OTHER DECREASES IN NET ASSETS OR FUND BALANCES STATEMENT 9

DESCRIPTION	AMOUNT
UNREALIZED LOSS ON INVESTMENTS	152,784,093.
UNREALIZED LOSS ON PROGRAM RELATED INVESTMENTS	178,498.
PROVISION FOR CREDIT LOSSES - RELATED TO PROGRAM RELATED INVESTMENTS	8,876,050.
TOTAL TO FORM 990-PF, PART III, LINE 5	161,838,641.

FORM 990-PF CORPORATE STOCK STATEMENT 10

DESCRIPTION	BOOK VALUE	FAIR MARKET VALUE
WASTE CONNECTIONS INC, 31,189 SHRS	6,087,781.	6,087,781.
ASML HOLDING NV, 6,798 SHRS	4,504,559.	4,504,559.
ALPHABET INC, 49,324 SHRS	7,705,889.	7,705,889.
AMAZON.COM INC, 56,745 SHRS	10,796,304.	10,796,304.
ANSYS INC, 17,725 SHRS	5,611,026.	5,611,026.
ATLASSIAN CORP, 10,030 SHRS	2,128,466.	2,128,466.
BIO-TECHNE CORP, 77,353 SHRS	4,535,206.	4,535,206.
BOOZ ALLEN HAMILTON HOLDING CO, 24,977 SHRS	2,612,095.	2,612,095.
CBRE GROUP INC, 41,905 SHRS	5,480,336.	5,480,336.
CADENCE DESIGN SYSTEMS INC, 19,189 SHRS	4,880,338.	4,880,338.
COPART INC, 51,249 SHRS	2,900,181.	2,900,181.
COSTAR GROUP INC, 56,648 SHRS	4,488,221.	4,488,221.
DANAHER CORP, 28,442 SHRS	5,830,610.	5,830,610.
ECOLAB INC, 15,801 SHRS	4,005,870.	4,005,870.
FASTENAL CO, 26,379 SHRS	2,045,691.	2,045,691.
GUIDEWIRE SOFTWARE INC, 21,690 SHRS	4,063,838.	4,063,838.
HEICO CORP, 39,020 SHRS	8,232,049.	8,232,049.
INTUIT INC, 7,419 SHRS	4,555,192.	4,555,192.
INTUITIVE SURGICAL INC, 8,518 SHRS	4,218,710.	4,218,710.
KINSALE CAPITAL GROUP INC, 7,556 SHRS	3,677,581.	3,677,581.
MANHATTAN ASSOCIATES INC, 18,581 SHRS	3,215,256.	3,215,256.
MASTERCARD INC, 18,961 SHRS	10,392,903.	10,392,903.
MICROSOFT CORP, 20,472 SHRS	7,684,984.	7,684,984.
MONOLITHIC POWER SYSTEMS INC, 7,694 SHRS	4,462,366.	4,462,366.
MOODY'S CORP, 12,092 SHRS	5,631,123.	5,631,123.
MOTOROLA SOLUTIONS INC, 5,167 SHRS	2,262,164.	2,262,164.
OLD DOMINION FREIGHT LINE INC, 34,487 SHRS	5,705,874.	5,705,874.
S&P GLOBAL INC, 12,553 SHRS	6,378,179.	6,378,179.
SERVICENOW INC, 4,067 SHRS	3,237,901.	3,237,901.
SHERWIN-WILLIAMS CO/THE, 15,113 SHRS	5,277,308.	5,277,308.
THERMO FISHER SCIENTIFIC INC, 10,030 SHRS	4,990,928.	4,990,928.
TRANSDIGM GROUP INC, 5,495 SHRS	7,601,179.	7,601,179.
TYLER TECHNOLOGIES INC, 3,847 SHRS	2,236,607.	2,236,607.
UBER TECHNOLOGIES INC, 82,728 SHRS	6,027,562.	6,027,562.
VEEVA SYSTEMS INC, 26,243 SHRS	6,078,666.	6,078,666.
VERALTO CORP, 56,194 SHRS	5,476,105.	5,476,105.
VISA INC, 32,563 SHRS	11,412,029.	11,412,029.
VULCAN MATERIALS CO, 24,319 SHRS	5,673,623.	5,673,623.

WEST PHARMACEUTICAL SERVICES I, 18,135 SHRS	4,060,064.	4,060,064.
ZOETIS INC, 29,428 SHRS	4,845,320.	4,845,320.
SCHLUMBERGER LTD, 74,480 SHRS	3,113,264.	3,113,264.
FRESENIUS MEDICAL CARE AG, 141,319 SHRS	3,518,843.	3,518,843.
ALLEGION PLC, 20,244 SHRS	2,641,032.	2,641,032.
SONY GROUP CORP, 230,530 SHRS	5,853,157.	5,853,157.
KONINKLIJKE PHILIPS NV, 176,944 SHRS	4,494,378.	4,494,378.
SMITH & NEPHEW PLC, 89,859 SHRS	2,549,300.	2,549,300.
UNILEVER PLC, 81,279 SHRS	4,840,164.	4,840,164.
ALPHABET INC, 31,362 SHRS	4,849,820.	4,849,820.
ARAMARK, 175,247 SHRS	6,049,526.	6,049,526.
AVERY DENNISON CORP, 29,869 SHRS	5,315,786.	5,315,786.
BERKSHIRE HATHAWAY INC, 15,142 SHRS	8,064,326.	8,064,326.
BLACKROCK INC, 2,036 SHRS	1,927,033.	1,927,033.
BOOKING HOLDINGS INC, 1,484 SHRS	6,836,654.	6,836,654.
CDW CORP/DE, 16,609 SHRS	2,661,758.	2,661,758.
CSX CORP, 147,478 SHRS	4,340,278.	4,340,278.
CARLISLE COS INC, 6,663 SHRS	2,268,752.	2,268,752.
CARMAX INC, 62,091 SHRS	4,838,131.	4,838,131.
CARRIER GLOBAL CORP, 86,144 SHRS	5,461,530.	5,461,530.
DOLLAR TREE INC, 31,754 SHRS	2,383,773.	2,383,773.
FERGUSON ENTERPRISES INC, 36,995 SHRS	5,927,709.	5,927,709.
MASCO CORP, 72,819 SHRS	5,063,833.	5,063,833.
MICROCHIP TECHNOLOGY INC, 61,499 SHRS	2,977,167.	2,977,167.
O'REILLY AUTOMOTIVE INC, 2,722 SHRS	3,899,483.	3,899,483.
PROGRESSIVE CORP/THE, 19,411 SHRS	5,493,507.	5,493,507.
QUEST DIAGNOSTICS INC, 29,141 SHRS	4,930,657.	4,930,657.
CHARLES SCHWAB CORP/THE, 106,941 SHRS	8,371,341.	8,371,341.
SYSCO CORP, 57,302 SHRS	4,299,942.	4,299,942.
UNITEDHEALTH GROUP INC, 11,037 SHRS	5,780,629.	5,780,629.
RB GLOBAL INC, 72,772 SHRS	7,299,032.	7,299,032.
VIVENDI SE, 890,005 SHRS	2,650,534.	2,650,534.
AON PLC, 18,887 SHRS	7,537,613.	7,537,613.
NINTENDO CO LTD, 168,200 SHRS	11,371,553.	11,371,553.
SHISEIDO CO LTD, 416,100 SHRS	7,846,743.	7,846,743.
NOVARTIS AG, 125,364 SHRS	13,863,367.	13,863,367.
NESTLE SA, 32,891 SHRS	3,321,257.	3,321,257.
CIE FINANCIERE RICHEMONT SA, 47,477 SHRS	8,207,524.	8,207,524.
UNILEVER PLC, 214,237 SHRS	12,737,291.	12,737,291.
RENTOKIL INITIAL PLC, 1865,670 SHRS	8,370,603.	8,370,603.
RECKITT BENCKISER GROUP PLC, 177,062 SHRS	11,952,787.	11,952,787.
INFORMA PLC, 1003,213 SHRS	9,962,939.	9,962,939.
HALEON PLC, 2295,109 SHRS	11,591,918.	11,591,918.
GSK PLC, 744,353 SHRS	14,046,511.	14,046,511.
RENTOKIL INITIAL PLC, 7,123 SHRS	163,117.	163,117.
BRISTOL-MYERS SQUIBB CO, 233,005 SHRS	14,210,975.	14,210,975.
CORTEVA INC, 215,129 SHRS	13,538,068.	13,538,068.
EBAY INC, 150,383 SHRS	10,185,441.	10,185,441.
ELECTRONIC ARTS INC, 56,582 SHRS	8,177,231.	8,177,231.
FOX CORP, 152,390 SHRS	8,625,274.	8,625,274.
FOX CORP, 68,592 SHRS	3,615,484.	3,615,484.
INTERCONTINENTAL EXCHANGE INC, 81,240 SHRS	14,013,900.	14,013,900.
JOHNSON & JOHNSON, 73,505 SHRS	12,190,069.	12,190,069.
ESTEE LAUDER COS INC/THE, 102,083 SHRS	6,737,478.	6,737,478.
LIVE NATION ENTERTAINMENT INC, 73,216 SHRS	9,560,545.	9,560,545.
NEWS CORP, 347,717 SHRS	9,464,857.	9,464,857.
NEWS CORP, 124,376 SHRS	3,777,299.	3,777,299.
ORACLE CORP, 55,200 SHRS	7,717,512.	7,717,512.

SOLVENTUM CORP, 61,649 SHRS	4,687,790.	4,687,790.
TKO GROUP HOLDINGS INC, 39,558 SHRS	6,044,858.	6,044,858.
TRANSUNION, 27,518 SHRS	2,283,719.	2,283,719.
WARNER MUSIC GROUP CORP, 110,454 SHRS	3,462,733.	3,462,733.
ZILLOW GROUP INC, 26,341 SHRS	1,761,159.	1,761,159.
ZILLOW GROUP INC, 135,353 SHRS	9,279,802.	9,279,802.
QANTAS AIRWAYS LTD, 39,302 SHRS	221,644.	221,644.
NORTHERN STAR RESOURCES LTD, 58,974 SHRS	673,254.	673,254.
ERSTE GROUP BANK AG, 422 SHRS	29,046.	29,046.
AGNICO EAGLE MINES LIMITED, 7,865 SHRS	851,994.	851,994.
BARRICK GOLD CORP, 68,600 SHRS	1,331,724.	1,331,724.
ENBRIDGE INC, 500 SHRS	22,126.	22,126.
LOBLAW COMPANIES LTD, 600 SHRS	84,069.	84,069.
PAN AMERICAN SILVER CORP, 18,700 SHRS	482,945.	482,945.
WESTON (GEORGE) LTD, 400 SHRS	68,183.	68,183.
KINROSS GOLD CORP, 62,545 SHRS	787,869.	787,869.
TMX GROUP LTD, 800 SHRS	29,204.	29,204.
WHEATON PRECIOUS METALS CORP, 2,600 SHRS	201,731.	201,731.
WSP GLOBAL INC, 3,200 SHRS	542,972.	542,972.
IA FINANCIAL CORP INC, 4,800 SHRS	455,771.	455,771.
SHOPIFY INC, 8,200 SHRS	779,976.	779,976.
SEA LTD, 8,755 SHRS	1,142,440.	1,142,440.
GRAB HOLDINGS LTD, 6,774 SHRS	30,686.	30,686.
YANGZIJIANG SHIPBUILDING HOLDI, 131,300 SHRS	231,516.	231,516.
NOVO NORDISK A/S, 22,888 SHRS	1,556,863.	1,556,863.
WARTSILA OYJ ABP, 25,517 SHRS	451,903.	451,903.
NOKIA OYJ, 141,686 SHRS	740,758.	740,758.
ORION OYJ, 5,521 SHRS	327,173.	327,173.
THALES SA, 179 SHRS	47,488.	47,488.
HANNOVER RUECK SE, 1,465 SHRS	434,711.	434,711.
RHEINMETALL AG, 1,704 SHRS	2,427,832.	2,427,832.
DEUTSCHE TELEKOM AG, 77,111 SHRS	2,850,365.	2,850,365.
RATIONAL AG, 259 SHRS	214,025.	214,025.
MTU AERO ENGINES AG, 744 SHRS	257,415.	257,415.
TALANX AG, 3,275 SHRS	342,091.	342,091.
COMMERZBANK AG, 1,955 SHRS	44,284.	44,284.
LEG IMMOBILIEN SE, 892 SHRS	63,073.	63,073.
VONOVIA SE, 1,865 SHRS	50,284.	50,284.
SIEMENS ENERGY AG, 849 SHRS	49,376.	49,376.
DAIMLER TRUCK HOLDING AG, 16,684 SHRS	668,979.	668,979.
BOC HONG KONG HOLDINGS LTD, 187,500 SHRS	756,719.	756,719.
AIA GROUP LTD, 137,200 SHRS	1,033,369.	1,033,369.
CRH PLC, 1,524 SHRS	134,066.	134,066.
EATON CORP PLC, 4,142 SHRS	1,125,920.	1,125,920.
FLUTTER ENTERTAINMENT PLC, 741 SHRS	164,169.	164,169.
SEAGATE TECHNOLOGY HOLDINGS PL, 10,692 SHRS	908,285.	908,285.
TRANE TECHNOLOGIES PLC, 1,808 SHRS	609,151.	609,151.
BANK HAPOALIM BM, 40,669 SHRS	546,480.	546,480.
BANK LEUMI LE-ISRAEL BM, 39,827 SHRS	532,387.	532,387.
ISRAEL DISCOUNT BANK LTD, 24,965 SHRS	172,286.	172,286.
MIZRAHI TEFAHOT BANK LTD, 7,869 SHRS	351,544.	351,544.
WIX.COM LTD, 212 SHRS	34,637.	34,637.
FERRARI NV, 1,278 SHRS	541,430.	541,430.
FINECOBANK BANCA FINECO SPA, 27,842 SHRS	547,213.	547,213.
BANCO BPM SPA, 59,401 SHRS	599,686.	599,686.
UNICREDIT SPA, 38,704 SHRS	2,154,369.	2,154,369.
ANA HOLDINGS INC, 8,100 SHRS	149,471.	149,471.
ASAHI KASEI CORP, 4,800 SHRS	33,607.	33,607.

ASICS CORP, 5,600 SHRS	117,775.	117,775.
TREND MICRO INC/JAPAN, 4,900 SHRS	328,163.	328,163.
DAIFUKU CO LTD, 16,500 SHRS	401,852.	401,852.
DAITO TRUST CONSTRUCTION CO LT, 2,900 SHRS	297,001.	297,001.
OTSUKA CORP, 11,200 SHRS	242,365.	242,365.
HITACHI LTD, 12,800 SHRS	295,990.	295,990.
SUMITOMO MITSUI TRUST GROUP IN, 19,800 SHRS	492,550.	492,550.
KOMATSU LTD, 18,500 SHRS	532,707.	532,707.
KONAMI GROUP CORP, 5,100 SHRS	599,559.	599,559.
LASERTEC CORP, 200 SHRS	16,959.	16,959.
TOKIO MARINE HOLDINGS INC, 23,900 SHRS	916,747.	916,747.
SUMITOMO MITSUI FINANCIAL GROU, 12,100 SHRS	307,072.	307,072.
NOMURA HOLDINGS INC, 12,700 SHRS	77,131.	77,131.
NIPPON YUSEN KK, 22,400 SHRS	737,130.	737,130.
OBAYASHI CORP, 15,300 SHRS	202,991.	202,991.
ONO PHARMACEUTICAL CO LTD, 1,700 SHRS	18,218.	18,218.
ORIX CORP, 50,100 SHRS	1,033,225.	1,033,225.
T&D HOLDINGS INC, 25,000 SHRS	530,627.	530,627.
SUZUKI MOTOR CORP, 2,500 SHRS	30,259.	30,259.
TOKYO ELECTRON LTD, 2,600 SHRS	349,646.	349,646.
ASTELLAS PHARMA INC, 40,900 SHRS	395,626.	395,626.
DAIICHI SANKYO CO LTD, 14,100 SHRS	331,049.	331,049.
BANDAI NAMCO HOLDINGS INC, 15,500 SHRS	518,671.	518,671.
MS&AD INSURANCE GROUP HOLDINGS, 21,800 SHRS	470,142.	470,142.
ENEOS HOLDINGS INC, 139,600 SHRS	730,300.	730,300.
JAPAN AIRLINES CO LTD, 7,300 SHRS	124,799.	124,799.
CONCORDIA FINANCIAL GROUP LTD, 3,800 SHRS	24,934.	24,934.
ASR NEDERLAND NV, 1,730 SHRS	99,006.	99,006.
NN GROUP NV, 1,956 SHRS	108,348.	108,348.
TELENOR ASA, 4,749 SHRS	67,845.	67,845.
KONGSBERG GRUPPEN ASA, 994 SHRS	144,835.	144,835.
NORSK HYDRO ASA, 2,941 SHRS	16,840.	16,840.
DNB BANK ASA, 35,370 SHRS	924,989.	924,989.
CARNIVAL CORP, 25,323 SHRS	494,558.	494,558.
INPOST SA, 9,235 SHRS	134,671.	134,671.
SINGAPORE TECHNOLOGIES ENGINEE, 37,800 SHRS	190,955.	190,955.
DBS GROUP HOLDINGS LTD, 900 SHRS	31,116.	31,116.
SINGAPORE EXCHANGE LTD, 22,100 SHRS	219,833.	219,833.
UNITED OVERSEAS BANK LTD, 8,600 SHRS	243,713.	243,713.
OVERSEA-CHINESE BANKING CORP L, 2,100 SHRS	27,029.	27,029.
SINGAPORE TECHNOLOGIES ENGINEE, 41,400 SHRS	211,140.	211,140.
BANCO BILBAO VIZCAYA ARGENTARI, 76,025 SHRS	1,030,223.	1,030,223.
BANCO SANTANDER SA, 17,990 SHRS	120,406.	120,406.
CAIXABANK SA, 142,302 SHRS	1,102,749.	1,102,749.
TELEFONAKTIEBOLAGET LM ERICSSO, 80,203 SHRS	620,220.	620,220.
TELIA CO AB, 12,362 SHRS	44,660.	44,660.
SKANSKA AB, 17,265 SHRS	379,672.	379,672.
ALFA LAVAL AB, 1,801 SHRS	76,898.	76,898.
SWEDISH ORPHAN BIOVITRUM AB, 2,110 SHRS	60,369.	60,369.
VOLVO AB, 1,649 SHRS	48,132.	48,132.
ADDTECH AB, 1,192 SHRS	34,745.	34,745.
SVENSKA HANDELSBANKEN AB, 2,458 SHRS	27,687.	27,687.
ZURICH INSURANCE GROUP AG, 576 SHRS	400,384.	400,384.
NOVARTIS AG, 4,910 SHRS	542,972.	542,972.
ABB LTD, 2,738 SHRS	139,941.	139,941.
SWISS RE AG, 1,365 SHRS	231,421.	231,421.
UBS GROUP AG, 10,996 SHRS	333,950.	333,950.
GARMIN LTD, 2,544 SHRS	552,379.	552,379.

BAE SYSTEMS PLC, 61,871 SHRS	1,245,417.	1,245,417.
HSBC HOLDINGS PLC, 23,693 SHRS	267,254.	267,254.
MARKS & SPENCER GROUP PLC, 6,830 SHRS	31,340.	31,340.
ROLLS-ROYCE HOLDINGS PLC, 17,822 SHRS	172,298.	172,298.
ROYALTY PHARMA PLC, 19,160 SHRS	596,451.	596,451.
AT&T INC, 13,220 SHRS	373,862.	373,862.
ABBVIE INC, 13,736 SHRS	2,877,967.	2,877,967.
AECOM, 6,271 SHRS	581,510.	581,510.
ALLSTATE CORP/THE, 5,185 SHRS	1,073,658.	1,073,658.
ALNYLAM PHARMACEUTICALS INC, 966 SHRS	260,839.	260,839.
ALPHABET INC, 2,536 SHRS	396,199.	396,199.
ALPHABET INC, 2,865 SHRS	443,044.	443,044.
ALTRIA GROUP INC, 24,639 SHRS	1,478,833.	1,478,833.
AMAZON.COM INC, 5,724 SHRS	1,089,048.	1,089,048.
AMERICAN EXPRESS CO, 4,573 SHRS	1,230,366.	1,230,366.
AMPHENOL CORP, 23,232 SHRS	1,523,787.	1,523,787.
ANALOG DEVICES INC, 499 SHRS	100,633.	100,633.
APPLE INC, 10,715 SHRS	2,380,123.	2,380,123.
APPLOVIN CORP, 499 SHRS	132,220.	132,220.
ARISTA NETWORKS INC, 4,852 SHRS	375,933.	375,933.
ATLASSIAN CORP, 4,639 SHRS	984,442.	984,442.
BLACKSTONE INC, 3,414 SHRS	477,209.	477,209.
BOOZ ALLEN HAMILTON HOLDING CO, 5,994 SHRS	626,853.	626,853.
BRISTOL-MYERS SQUIBB CO, 4,448 SHRS	271,284.	271,284.
BROADCOM INC, 12,323 SHRS	2,063,240.	2,063,240.
BROWN & BROWN INC, 2,698 SHRS	335,631.	335,631.
CAPITAL ONE FINANCIAL CORP, 6,720 SHRS	1,204,896.	1,204,896.
CHARTER COMMUNICATIONS INC, 312 SHRS	114,981.	114,981.
CHENIERE ENERGY INC, 7,420 SHRS	1,716,988.	1,716,988.
CISCO SYSTEMS INC, 20,303 SHRS	1,252,898.	1,252,898.
CITIGROUP INC, 3,588 SHRS	254,712.	254,712.
COMCAST CORP, 22,716 SHRS	838,220.	838,220.
CORNING INC, 19,794 SHRS	906,169.	906,169.
DELTA AIR LINES INC, 8,235 SHRS	359,046.	359,046.
DOCUSIGN INC, 991 SHRS	80,667.	80,667.
DOORDASH INC, 2,967 SHRS	542,279.	542,279.
EDISON INTERNATIONAL, 11,710 SHRS	689,953.	689,953.
EMCOR GROUP INC, 1,356 SHRS	501,218.	501,218.
EQUITABLE HOLDINGS INC, 13,677 SHRS	712,435.	712,435.
EXPEDIA GROUP INC, 5,973 SHRS	1,004,061.	1,004,061.
META PLATFORMS INC, 942 SHRS	542,931.	542,931.
F5 INC, 2,709 SHRS	721,325.	721,325.
FORTINET INC, 14,669 SHRS	1,412,038.	1,412,038.
FREEPORT-MCMORAN INC, 40,617 SHRS	1,537,760.	1,537,760.
GE AEROSPACE, 1,294 SHRS	258,994.	258,994.
GILEAD SCIENCES INC, 22,495 SHRS	2,520,565.	2,520,565.
HCA HEALTHCARE INC, 200 SHRS	69,110.	69,110.
HOWMET AEROSPACE INC, 16,398 SHRS	2,127,313.	2,127,313.
INCYTE CORP, 4,902 SHRS	296,816.	296,816.
JOHNSON & JOHNSON, 16,144 SHRS	2,677,321.	2,677,321.
KLA CORP, 738 SHRS	501,692.	501,692.
LAM RESEARCH CORP, 6,198 SHRS	450,595.	450,595.
ELI LILLY & CO, 103 SHRS	85,069.	85,069.
LOCKHEED MARTIN CORP, 239 SHRS	106,764.	106,764.
LULULEMON ATHLETICA INC, 2,632 SHRS	745,014.	745,014.
MERCADOLIBRE INC, 11 SHRS	21,460.	21,460.
MERCK & CO INC, 2,899 SHRS	260,214.	260,214.
MICROSOFT CORP, 1,966 SHRS	738,017.	738,017.

MOLINA HEALTHCARE INC, 1,621 SHRS	533,941.	533,941.
MOODY'S CORP, 417 SHRS	194,193.	194,193.
MOTOROLA SOLUTIONS INC, 1,206 SHRS	527,999.	527,999.
NRG ENERGY INC, 9,467 SHRS	903,720.	903,720.
NETFLIX INC, 1,827 SHRS	1,703,732.	1,703,732.
NORTHROP GRUMMAN CORP, 55 SHRS	28,161.	28,161.
NVIDIA CORP, 42,681 SHRS	4,625,767.	4,625,767.
PALANTIR TECHNOLOGIES INC, 3,345 SHRS	282,318.	282,318.
PARKER-HANNIFIN CORP, 479 SHRS	291,160.	291,160.
PFIZER INC, 38,902 SHRS	985,777.	985,777.
PHILIP MORRIS INTERNATIONAL IN, 12,570 SHRS	1,995,236.	1,995,236.
PROGRESSIVE CORP/THE, 1,302 SHRS	368,479.	368,479.
RAYMOND JAMES FINANCIAL INC, 3,722 SHRS	517,023.	517,023.
RTX CORP, 2,778 SHRS	367,974.	367,974.
RESMED INC, 259 SHRS	57,977.	57,977.
CHARLES SCHWAB CORP/THE, 26,230 SHRS	2,053,284.	2,053,284.
SIMON PROPERTY GROUP INC, 12,119 SHRS	2,012,724.	2,012,724.
SNAP INC, 6,292 SHRS	54,803.	54,803.
SNOWFLAKE INC, 351 SHRS	51,302.	51,302.
SYNCHRONY FINANCIAL, 13,535 SHRS	716,543.	716,543.
TARGA RESOURCES CORP, 129 SHRS	25,861.	25,861.
TESLA INC, 3,741 SHRS	969,518.	969,518.
TRADEWEB MARKETS INC, 2,172 SHRS	322,455.	322,455.
TWILIO INC, 3,828 SHRS	374,799.	374,799.
US BANCORP, 44,345 SHRS	1,872,246.	1,872,246.
UNITED THERAPEUTICS CORP, 379 SHRS	116,834.	116,834.
UNIVERSAL HEALTH SERVICES INC, 2,730 SHRS	512,967.	512,967.
VENTAS INC, 1,744 SHRS	119,917.	119,917.
VERIZON COMMUNICATIONS INC, 14,687 SHRS	666,202.	666,202.
VISA INC, 2,611 SHRS	915,051.	915,051.
VISTRA CORP, 2,806 SHRS	329,537.	329,537.
WALMART INC, 1,643 SHRS	144,239.	144,239.
UNITED THERAPEUTICS CORP, 1,256 SHRS	387,187.	387,187.
NETFLIX INC, 895 SHRS	834,614.	834,614.
FORTINET INC, 2,839 SHRS	273,282.	273,282.
META PLATFORMS INC, 1,932 SHRS	1,113,528.	1,113,528.
ARISTA NETWORKS INC, 428 SHRS	33,161.	33,161.
MOTOROLA SOLUTIONS INC, 2,718 SHRS	1,189,968.	1,189,968.
NORTHROP GRUMMAN CORPORATION, 179 SHRS	91,650.	91,650.
LILLY (ELI) & CO COM STK NPV, 311 SHRS	256,858.	256,858.
PROGRESSIVE CORP OHIO COM, 4,151 SHRS	1,174,775.	1,174,775.
AMERICAN EXPRESS CO, 1,046 SHRS	281,426.	281,426.
AMAZON COM INC COM, 8,567 SHRS	1,629,957.	1,629,957.
MERCK & CO INC, 9,163 SHRS	822,471.	822,471.
BRISTOL MYERS SQUIBB CO, 20,387 SHRS	1,243,403.	1,243,403.
APPLE INC, 14,677 SHRS	3,260,202.	3,260,202.
CISCO SYSTEMS INC COM, 17,506 SHRS	1,080,295.	1,080,295.
ALPHABET INC, 8,411 SHRS	1,314,051.	1,314,051.
ALPHABET INC, 9,502 SHRS	1,469,389.	1,469,389.
RESMED INC COM, 857 SHRS	191,839.	191,839.
MICROSOFT CORP COM, 5,848 SHRS	2,195,281.	2,195,281.
WALMART INC, 12,334 SHRS	1,082,802.	1,082,802.
PDD HOLDINGS INC, 12,500 SHRS	1,479,375.	1,479,375.
NU HOLDINGS LTD/CAYMAN ISLANDS, 567,667 SHRS	5,812,910.	5,812,910.
WISE PLC, 168,200 SHRS	2,051,634.	2,051,634.
CONFLUENT INC, 22,315 SHRS	523,064.	523,064.
CROWDSTRIKE HOLDINGS INC, 12,800 SHRS	4,513,024.	4,513,024.
DOXIMITY INC, 6,974 SHRS	404,701.	404,701.

META PLATFORMS INC, 8,000 SHRS	4,610,880.	4,610,880.
FRESHWORKS INC, 18,841 SHRS	265,847.	265,847.
MAPLEBEAR INC, 80,000 SHRS	3,191,200.	3,191,200.
ROBINHOOD MARKETS INC, 50,000 SHRS	2,081,000.	2,081,000.
ROBLOX CORP, 54,000 SHRS	3,147,660.	3,147,660.
SAMSARA INC, 101,250 SHRS	3,880,913.	3,880,913.
SNOWFLAKE INC, 42,316 SHRS	6,184,907.	6,184,907.
TOTAL TO FORM 990-PF, PART II, LINE 10B	797,048,528.	797,048,528.

FORM 990-PF OTHER INVESTMENTS STATEMENT 11

DESCRIPTION	VALUATION METHOD	BOOK VALUE	FAIR MARKET VALUE
JPM US LARGE CAP	FMV	178,600,044.	178,600,044.
SPDR TRUST SERIES I	FMV	184,715,613.	184,715,613.
JPM CORE BOND	FMV	1,024,328,467.	1,024,328,467.
JPM SHORT DURATION BOND	FMV	250,849,044.	250,849,044.
CHATHAM	FMV	113,440,052.	113,440,052.
CHATHAM OFFSHORE	FMV	111,292,568.	111,292,568.
CAMBER	FMV	153,014,742.	153,014,742.
ORBIMED GENESIS FUND	FMV	37,527,977.	37,527,977.
SEQUOIA CAP GLOBAL	FMV	206,953,932.	206,953,932.
ACADIAN FRONTIER	FMV	19.	19.
HIGHCLERE INTL SC	FMV	134,563,864.	134,563,864.
LACM WORLD SMALL CAP	FMV	119,401,516.	119,401,516.
MARATHON GLOBAL	FMV	211,603,977.	211,603,977.
SILCHESTER INTL	FMV	147,151,131.	147,151,131.
BLACKROCK US DEBT	FMV	96,977,617.	96,977,617.
EIG ENERGY FUND XVI	FMV	30,133,391.	30,133,391.
EIG ENERGY XV	FMV	1,002,113.	1,002,113.
EIG ENERGY XVII	FMV	6,505,004.	6,505,004.
FDAF DISLOCATED II	FMV	8,202,611.	8,202,611.
FDAF DISLOCATED III	FMV	25,456,191.	25,456,191.
FDAF DISLOCATED IV	FMV	30,329,915.	30,329,915.
GSO CAPITAL SOLS II	FMV	2,006,596.	2,006,596.
HIG BAYSIDE III	FMV	3,232,157.	3,232,157.
MHR AXIOM	FMV	265,837,155.	265,837,155.
MHR INST PARTNERS IV	FMV	61,299,374.	61,299,374.
NEWMARKET IIFC	FMV	6,973,612.	6,973,612.
ORBIMED ROYALTY II	FMV	334,374.	334,374.
ACCEL GROWTH FUND IV	FMV	16,748,134.	16,748,134.
ACCEL GROWTH II	FMV	9,271,705.	9,271,705.
ACCEL GROWTH III	FMV	11,675,661.	11,675,661.
ACCEL GROWTH V	FMV	27,092,782.	27,092,782.
ACCEL GROWTH VI	FMV	20,568,357.	20,568,357.
ACCEL GROWTH VII	FMV	1,500,000.	1,500,000.
ACCEL INDIA V	FMV	12,493,701.	12,493,701.
ACCEL INDIA VI	FMV	7,439,015.	7,439,015.
ACCEL INDIA VII	FMV	4,788,163.	4,788,163.
ACCEL INDIA VIII	FMV	480,000.	480,000.
ACCEL LEADERS 4	FMV	22,921,263.	22,921,263.
ACCEL LEADERS FUND	FMV	13,524,240.	13,524,240.
ACCEL LEADERS II	FMV	7,276,777.	7,276,777.

ACCEL LEADERS III	FMV	30,532,173.	30,532,173.
ACCEL XI	FMV	5,410,664.	5,410,664.
ACCEL XII	FMV	28,342,318.	28,342,318.
ACCEL XIII	FMV	13,141,628.	13,141,628.
ACCEL XIV	FMV	8,594,510.	8,594,510.
ACCEL XV	FMV	6,585,862.	6,585,862.
ACCEL XVI	FMV	735,234.	735,234.
AH 2024 MULTIPLEXER	FMV	12,737,561.	12,737,561.
AH BIO FUND I	FMV	5,176,647.	5,176,647.
AH BIO FUND II	FMV	14,929,368.	14,929,368.
AH BIO III	FMV	16,462,239.	16,462,239.
AH BIO IV	FMV	7,998,035.	7,998,035.
AH CNK IV	FMV	8,208,321.	8,208,321.
AH CNK SEED I	FMV	4,301,427.	4,301,427.
AH FUND VII	FMV	12,034,065.	12,034,065.
AH FUND VIII	FMV	11,590,228.	11,590,228.
AH III	FMV	49,216,024.	49,216,024.
AH III PARALLEL	FMV	11,126,940.	11,126,940.
AH IV	FMV	30,083,291.	30,083,291.
AH IV PARALLEL	FMV	11,316,856.	11,316,856.
AH LSV FUND II	FMV	19,257,909.	19,257,909.
AH LSV FUND III	FMV	20,045,228.	20,045,228.
AH LSV I	FMV	19,976,431.	19,976,431.
AH V	FMV	44,769,088.	44,769,088.
AH V PARALLEL	FMV	33,862,315.	33,862,315.
AH VI	FMV	24,736,043.	24,736,043.
ANGELENO INV III	FMV	16,937,302.	16,937,302.
ARBORETUM III	FMV	1,524,062.	1,524,062.
ARBORETUM IV	FMV	9,387,239.	9,387,239.
ARBORETUM V	FMV	18,895,979.	18,895,979.
ARBORETUM VI	FMV	6,985,934.	6,985,934.
COLLER VI	FMV	1,828,988.	1,828,988.
COLLER VII	FMV	16,996,428.	16,996,428.
COLLER VIII	FMV	30,024,784.	30,024,784.
CONGRUENT CONTINUITY	FMV	9,287,107.	9,287,107.
CRESTVIEW ELO	FMV	8,183,115.	8,183,115.
CRESTVIEW III	FMV	26,093,392.	26,093,392.
CRESTVIEW IV	FMV	33,243,027.	33,243,027.
EMERGENCE III	FMV	46,017,551.	46,017,551.
EMERGENCE IV	FMV	20,172,577.	20,172,577.
EMERGENCE OPP I	FMV	9,089,321.	9,089,321.
EMERGENCE V	FMV	23,199,567.	23,199,567.
EMERGENCE VI	FMV	17,410,140.	17,410,140.
EPIRIS ELEC CO INV	FMV	11,385,608.	11,385,608.
EPIRIS II	FMV	23,171,624.	23,171,624.
EPIRIS III	FMV	16,328,049.	16,328,049.
FORTISSIMO IV	FMV	19,196,561.	19,196,561.
FORTISSIMO V	FMV	22,493,956.	22,493,956.
FORTISSIMO VI	FMV	9,078,435.	9,078,435.
FRAZIER COINVEST 2	FMV	5,326,646.	5,326,646.
FRAZIER GTH BUYOUT X	FMV	21,632,010.	21,632,010.
FRAZIER IX	FMV	9,082,650.	9,082,650.
FRAZIER OVERAGE	FMV	15,831,875.	15,831,875.
FRAZIER PUBLIC FUND	FMV	22,412,499.	22,412,499.
FRAZIER SUNMD CO INV	FMV	19,746,931.	19,746,931.
FRAZIER X	FMV	12,252,780.	12,252,780.
FRAZIER XI	FMV	11,103,867.	11,103,867.
GAVEA IV	FMV	1,481,298.	1,481,298.

GAVEA V	FMV	4,823,759.	4,823,759.
GENERL ATLANTIC 2013	FMV	56,584,009.	56,584,009.
GENERL ATLANTIC 2018	FMV	81,061,163.	81,061,163.
HIG BRAZIL	FMV	4,561,515.	4,561,515.
HIG BRAZIL LATAM B	FMV	13,830,119.	13,830,119.
HIG BRAZIL LATAM C	FMV	13,830,119.	13,830,119.
HIG CAPITAL V	FMV	6,919,413.	6,919,413.
HIG GROWTH B&E F II	FMV	5,863,861.	5,863,861.
HIG GROWTH III	FMV	9,010,867.	9,010,867.
HIG HEALTHBRIDGE	FMV	12,324,531.	12,324,531.
HIG MID MARKET II	FMV	9,689,585.	9,689,585.
HIG MID MARKET III	FMV	14,609,366.	14,609,366.
HONGSHAN EXP I	FMV	3,085,468.	3,085,468.
HONGSHAN GROWTH III	FMV	95,878,511.	95,878,511.
HONGSHAN GROWTH IV	FMV	25,673,901.	25,673,901.
HONGSHAN GROWTH V	FMV	27,640,078.	27,640,078.
HONGSHAN GROWTH VI	FMV	20,523,846.	20,523,846.
HONGSHAN GROWTH VII	FMV	3,545,914.	3,545,914.
HONGSHAN VTR IV	FMV	9,697,533.	9,697,533.
HONGSHAN VTR IX	FMV	1,322,435.	1,322,435.
HONGSHAN VTR V	FMV	5,824,079.	5,824,079.
HONGSHAN VTR VI	FMV	8,559,963.	8,559,963.
HONGSHAN VTR VII	FMV	4,923,713.	4,923,713.
HONGSHAN VTR VIII	FMV	4,325,586.	4,325,586.
IDG BREYER	FMV	8,885,912.	8,885,912.
IDG CHINA CAP III	FMV	26,363,578.	26,363,578.
IDG CHINA VTR IV	FMV	23,121,637.	23,121,637.
IDG CHINA VTR V	FMV	26,625,184.	26,625,184.
IDG-ACCEL CHINA CAP	FMV	10,968,798.	10,968,798.
IDG-ACCEL CHINA GWTH	FMV	9,016,097.	9,016,097.
IRON POINT IV	FMV	18,434,932.	18,434,932.
JPM PEG SECONDRY III	FMV	4,230,920.	4,230,920.
ORBIMED ASIA III	FMV	60,416,564.	60,416,564.
ORBIMED ASIA IV	FMV	22,143,164.	22,143,164.
ORBIMED ISRAEL	FMV	1,901,085.	1,901,085.
ORBIMED ISRAEL II	FMV	18,373,039.	18,373,039.
ORBIMED PI IX	FMV	12,366,730.	12,366,730.
ORBIMED PI VI	FMV	8,266,524.	8,266,524.
ORBIMED PI VII	FMV	22,037,580.	22,037,580.
ORBIMED PI VIII	FMV	20,222,556.	20,222,556.
ORBMIED ASIA V	FMV	9,096,219.	9,096,219.
PEAK XV GWTH III	FMV	12,330,411.	12,330,411.
PEAK XV GWTH IV	FMV	3,179,607.	3,179,607.
PEAK XV SEA I	FMV	3,021,093.	3,021,093.
PEAK XV V	FMV	11,804,254.	11,804,254.
PEAK XV VI	FMV	12,978,906.	12,978,906.
PEAK XV VIII	FMV	1,240,660.	1,240,660.
PEAK XV VTR VII	FMV	3,398,972.	3,398,972.
PEP IV CORE	FMV	993,669.	993,669.
PEP IV SUPPL	FMV	415,294.	415,294.
PEP VI	FMV	24,448,554.	24,448,554.
PEP VII	FMV	771,788.	771,788.
PIATNGO VTR IX	FMV	1,248,959.	1,248,959.
PITANGO GROWTH	FMV	61,640,072.	61,640,072.
PITANGO GROWTH II	FMV	22,204,708.	22,204,708.
PITANGO HEALTH II	FMV	2,764,419.	2,764,419.
PITANGO HEALTHTECH I	FMV	9,827,519.	9,827,519.
PITANGO SPV	FMV	21,958,799.	21,958,799.

PITANGO VI, LP	FMV	26,100,607.	26,100,607.
PITANGO VTR VII	FMV	26,088,396.	26,088,396.
PITANGO VTR VIII	FMV	16,931,226.	16,931,226.
RIDGEWOOD III	FMV	32,098,781.	32,098,781.
RIDGEWOOD IV	FMV	28,194,204.	28,194,204.
S CAPITAL	FMV	17,281,159.	17,281,159.
S CAPITAL II	FMV	11,018,147.	11,018,147.
S CAPITAL III	FMV	4,253,438.	4,253,438.
SCF LIQUID PORTFOLIO	FMV	48,081,485.	48,081,485.
SEQUOIA GBL GRTH III	FMV	99,769,116.	99,769,116.
SEQUOIA GG 3 CH ANX	FMV	16,460,729.	16,460,729.
SEQUOIA GLB GROWTH	FMV	29,555,443.	29,555,443.
SEQUOIA GLB GRWTH II	FMV	39,595,153.	39,595,153.
SEQUOIA ISRAEL V	FMV	7,530,636.	7,530,636.
SEQUOIA SCOUT III	FMV	2,279,728.	2,279,728.
SEQUOIA SCOUT IV	FMV	1,334,197.	1,334,197.
SEQUOIA US ECO I	FMV	917,754.	917,754.
SEQUOIA US EXP I	FMV	10,005,071.	10,005,071.
SEQUOIA US GROWTH V	FMV	745,209.	745,209.
SEQUOIA US GRTH VIII	FMV	10,900,783.	10,900,783.
SEQUOIA US GRWTH VII	FMV	4,075,351.	4,075,351.
SEQUOIA US GWTH IX	FMV	8,557,960.	8,557,960.
SEQUOIA US GWTH VI	FMV	810,240.	810,240.
SEQUOIA US GWTH X	FMV	5,831,950.	5,831,950.
SEQUOIA US SEED V	FMV	892,249.	892,249.
SEQUOIA US VENT XVI	FMV	12,559,632.	12,559,632.
SEQUOIA US VTR XIV	FMV	2,869,150.	2,869,150.
SEQUOIA US VTR XV	FMV	5,144,966.	5,144,966.
SEQUOIA US VTR XVII	FMV	5,923,830.	5,923,830.
SEQUOIA US VTR XVIII	FMV	1,822,252.	1,822,252.
SQUOIA GG 3 US IN AX	FMV	15,234,847.	15,234,847.
STARWOOD X	FMV	11,001,661.	11,001,661.
STARWOOD XI	FMV	42,603,687.	42,603,687.
STARWOOD XII	FMV	39,678,065.	39,678,065.
QMETCO	FMV	27,754,179.	27,754,179.
WTI VLL IX	FMV	10,474,200.	10,474,200.
WTI VLL VII	FMV	6,649,000.	6,649,000.
WTI VLL VIII	FMV	10,939,495.	10,939,495.
WTI VLL X	FMV	7,561,920.	7,561,920.
YORK CO INVEST 1	FMV	996,336.	996,336.
TOTAL TO FORM 990-PF, PART II, LINE 13		6,125,814,330.	6,125,814,330.

FORM 990-PF DEPRECIATION OF ASSETS NOT HELD FOR INVESTMENT STATEMENT 12

DESCRIPTION	COST OR OTHER BASIS	ACCUMULATED DEPRECIATION	BOOK VALUE
FURNITURE, FIXTURES AND EQUIPMENT	3,154,445.	2,231,333.	923,112.
LEASEHOLD IMPROVEMENTS	7,446,632.	2,514,038.	4,932,594.
WORK IN PROGRESS	1,325.	0.	1,325.
TOTAL TO FM 990-PF, PART II, LN 14	10,602,402.	4,745,371.	5,857,031.

FORM 990-PF OTHER ASSETS STATEMENT 13

DESCRIPTION	BEGINNING OF YR BOOK VALUE	END OF YEAR BOOK VALUE	FAIR MARKET VALUE
ACCRUED INCOME RECEIVABLE	1,416,200.	1,680,919.	1,680,919.
DUE FROM BROKER	25,945,689.	14,137,129.	14,137,129.
RETIREMENT PLAN ASSET	2,162,642.	2,064,360.	2,064,360.
ADVANCES AND OTHER RECEIVABLES	6,037.	7,040.	7,040.
PROGRAM RELATED INVESTMENTS	18,971,538.	24,011,405.	24,011,405.
OPERATING LEASE RIGHT OF USE ASSET	7,359,283.	6,372,839.	6,372,839.
PREPAID FEDERAL EXCISE TAX	0.	786,796.	786,796.
TO FORM 990-PF, PART II, LINE 15	55,861,389.	49,060,488.	49,060,488.

FORM 990-PF OTHER LIABILITIES STATEMENT 14

DESCRIPTION	BOY AMOUNT	EOY AMOUNT
DEFERRED FEDERAL EXCISE TAX	24,836,165.	22,654,960.
RETIREMENT PLAN LIABILITY	2,432,030.	2,948,693.
ACCRUED VACATION	1,168,550.	1,342,903.
GRANT REFUNDS PENDING MODIFICATION	3,852,387.	38,746.
OPERATING LEASE LIABILITIES	8,365,590.	7,261,172.
FEDERAL EXCISE TAX PAYABLE	4,555,771.	0.
ALLOWANCE FOR CREDIT LOSSES	646,935.	6,171,350.
REFUNDABLE DEPOSITS	0.	419.
TOTAL TO FORM 990-PF, PART II, LINE 22	45,857,428.	40,418,243.

FORM 990-PF NAME OF FOREIGN COUNTRY IN WHICH ORGANIZATION HAS FINANCIAL INTEREST STATEMENT 15

NAME OF COUNTRY
AUSTRALIA
AUSTRIA
BELGIUM
CANADA
DENMARK
FINLAND
FRANCE
GERMANY
HONG KONG
INDONESIA
IRELAND
ISRAEL
ITALY
JAPAN
NETHERLANDS
NEW ZEALAND
NORWAY
PORTUGAL
SINGAPORE
KOREA (SOUTH)
SPAIN
SWEDEN
SWITZERLAND
TAIWAN
UNITED KINGDOM

FORM 990-PF TRANSFERS TO CONTROLLED ENTITIES STATEMENT 16
PART VI-A, LINE 11

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
LACM WORLD SMALL CAP EQUITY FUND, L.P.	83-2888004

ADDRESS

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT OF TRANSFER
20,000,000.

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	61-1915057

ADDRESS

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UNITED KINGDOM WC2H 9EA

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT OF TRANSFER
30,000,000.

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
MHR LONGEVITY PARTNERS	98-1471155

ADDRESS

40 WEST 57TH ST. FLOOR 24
NEW YORK, NY 10019

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

	AMOUNT OF TRANSFER
	54,725,000.

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.	98-1142649

ADDRESS

1325 NORTH BEACH STREET, SUITE 201
PHILADELPHIA, PA 19125

DESCRIPTION OF TRANSFER

MANAGEMENT FEES

	AMOUNT OF TRANSFER
	8,659,313.

TOTAL AMOUNT OF TRANSFERS TO CONTROLLED ENTITIES	113,384,313.

FORM 990-PF TRANSFERS FROM CONTROLLED ENTITIES STATEMENT 17
PART VI-A, LINE 11

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
MHR LONGEVITY PARTNERS	98-1471155

ADDRESS

40 WEST 57TH ST. FLOOR 24
NEW YORK, NY 10019

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

	AMOUNT OF TRANSFER
	44,352,086.

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.	98-1142649

ADDRESS

1325 NORTH BEACH STREET, SUITE 201
PHILADELPHIA, PA 19125

DESCRIPTION OF TRANSFER

DISTRIBUTION

	AMOUNT OF TRANSFER
	21,940,820.

TOTAL AMOUNT OF TRANSFERS FROM CONTROLLED ENTITIES	66,292,906.

FORM 990-PF SCHEDULE OF CONTROLLED ENTITIES STATEMENT 18
PART VI-A, LINE 11

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
ESTATE OF LEONA M. HELMSLEY	20-7535047

ADDRESS
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169

EXCESS BUSINESS HOLDING [ ] YES [X] NO

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
HELMSLEY ENTERPRISES, INC.	13-2665914

ADDRESS
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169

EXCESS BUSINESS HOLDING [ ] YES [X] NO

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
LACM WORLD SMALL CAP EQUITY FUND, L.P.	83-2888004

ADDRESS
11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

EXCESS BUSINESS HOLDING [ ] YES [X] NO

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	61-1915057

ADDRESS
ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UNITED KINGDOM WC2H 9EA

EXCESS BUSINESS HOLDING [ ] YES [X] NO

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
MHR LONGEVITY PARTNERS	98-1471155

ADDRESS
40 WEST 57TH ST. FLOOR 24
NEW YORK, NY 10019

EXCESS BUSINESS HOLDING [ ] YES [X] NO

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.	98-1142649

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

1325 NORTH BEACH STREET, SUITE 201
PHILADELPHIA, PA 19125

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
PITANGO SPV	98-1492234

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL

NAME OF CONTROLLED ENTITY	EMPLOYER ID NO
STARTUP HEALTH T1D PRI LP	93-2618051

ADDRESS

EXCESS BUSINESS HOLDING [ ] YES [X] NO

2000 BROADWAY, 18TH FLOOR
NEW YORK, NY 10023

FORM 990-PF PART VII - LIST OF OFFICERS, DIRECTORS TRUSTEES AND FOUNDATION MANAGERS STATEMENT 19

NAME AND ADDRESS	TITLE AND AVRG HRS/WK	COMPEN-SATION	EMPLOYEE BEN PLAN CONTRIB	EXPENSE ACCOUNT
SANDOR FRANKEL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 25.00	150,000.	0.	0.
DAVID PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 35.00	150,000.	0.	0.
WALTER PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 32.00	150,000.	0.	0.
SARAH E. PAUL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF EXECUTIVE OFFICER 40.00	1,030,857.	238,318.	0.
JACQUELINE F. BAUSCH C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	GENERAL COUNSEL 40.00	652,750.	102,800.	0.
JOSHUA W. FENTON C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF INVESTMENT OFFICER 40.00	1,017,577.	237,966.	0.
NICHOLAS J. SCHIAVO C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF FINANCIAL OFFICER 40.00	486,040.	123,033.	0.
TOTALS INCLUDED ON 990-PF, PAGE 6, PART VII		3,637,224.	702,117.	0.

FORM 990-PF EXPENDITURE RESPONSIBILITY STATEMENT STATEMENT 20
PART VI-B, LINE 5D

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

PO BOX 579
CEDAR PARK, TX 78630

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
5,000,000.	02/20/18	5,000,000.

PURPOSE OF GRANT

INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA

DATES OF REPORTS BY GRANTEE

PRIOR+ 1/2020, 2/2021, 1/2022, 1/2023, 1/2024, 2/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

PO BOX 579
CEDAR PARK, TX 78630

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
4,800,000.	12/20/22	2,799,822.

PURPOSE OF GRANT

EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY

DATES OF REPORTS BY GRANTEE

1/2024, 1/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ABVANCE THERAPEUTICS, INC.

GRANTEE'S ADDRESS

38 BENNINGTON COURT
RENO, NV 89511

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
3,920,820.	06/18/24	1,203,212.

PURPOSE OF GRANT

DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON

DATES OF REPORTS BY GRANTEE

10/2024, 3/2025, 4/2025, 7/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AKSTON BIOSCIENCES CORPORATION

GRANTEE'S ADDRESS

100 CUMMINGS CENTER, SUITE 454C
BEVERLY, MA 01915

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
6,194,000.	03/01/17	6,194,000.

PURPOSE OF GRANT

PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY & IMPROVE QUALITY OF LIFE FOR PEOPLE LIVING WITH T1D

DATES OF REPORTS BY GRANTEE

PRIOR+ 3/2024, 6/2024, 9/2024, 10/2024, 3/2025, 5/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ON, CANADA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
1,275,257.	11/05/24	24,517.

PURPOSE OF GRANT

VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE

DATES OF REPORTS BY GRANTEE

1/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ONTARIO, CANADA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
3,390,428.	11/20/18	2,751,742.

PURPOSE OF GRANT

STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM TO IMPROVE CARE OF CD PATIENTS

DATES OF REPORTS BY GRANTEE

PRIOR+ 6/2022, 2/2023, 7/2023, 11/2023, 3/2024, 3/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ONTARIO, CANADA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
894,043.	02/10/22	411,228.

PURPOSE OF GRANT

DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES FOR PATIENTS

DATES OF REPORTS BY GRANTEE

2/2023, 6/2023, 3/2024, 1/2025, 4/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,599,216.	01/22/25	0.

PURPOSE OF GRANT

DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION & MAINTENANCE

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,500,000.	11/20/21	2,500,000.

PURPOSE OF GRANT

EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE

DATES OF REPORTS BY GRANTEE

PRIOR+ 1/2023, 12/2023, 1/2024, 12/2024, 1/2025, 4/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

55 VICTORIA PARADE, LEVEL 2
FITZROY, AUSTRALIA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
3,560,371.	07/23/20	3,560,371.

PURPOSE OF GRANT

FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES

DATES OF REPORTS BY GRANTEE

PRIOR+ 2/2023, 8/2023, 3/2024, 8/2024, 2/2025, 8/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BIORASIS, INC.

GRANTEE'S ADDRESS

1392 STORRS RD U4213, ATL ROOM 106
STORRS, CT 06269

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
3,016,000.	02/06/18	2,676,000.

PURPOSE OF GRANT

EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D

DATES OF REPORTS BY GRANTEE

PRIOR+ 6/2024, 7/2024, 10/2024, 2/2025, 5/2025, 6/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

CAPILLARY BIOMEDICAL, INC.

GRANTEE'S ADDRESS

2 WRIGLEY
IRVINE, CA 92617

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
1,500,000.	09/02/20	1,428,325.

PURPOSE OF GRANT

ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR+ 1/2022, 5/2022, 6/2022, 3/2023, 8/2023, 8/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DIABETOMICS, INC.

GRANTEE'S ADDRESS

2345 NE OVERLOOK DRIVE, SUITE #140
HILLSBORO, OR 97006

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
4,031,900.	01/11/18	4,031,900.

PURPOSE OF GRANT

POINT-OF-CARE RAPID TESTS FOR TID SCREENING AND INTERVENTION

DATES OF REPORTS BY GRANTEE

PRIOR+ 10/2023, 7/2024, 10/2024, 1/2025, 4/2025, 8/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DREAMED DIABETES LTD.

GRANTEE'S ADDRESS

14 KAPLAN ST
PETAH TIKVA, TEL AVIV, ISRAEL

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,850,000.	02/23/23	2,683,341.

PURPOSE OF GRANT

INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES

DATES OF REPORTS BY GRANTEE

5/2023, 10/2024

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

IMMUNOMOLECULAR THERAPEUTICS, INC.

GRANTEE'S ADDRESS

299 WASHINGTON STREET
WOBURN, MA 01801

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
5,450,000.	09/24/24	108,524.

PURPOSE OF GRANT

TARGETED IMMUNOTHERAPY TO TREAT TYPE 1 DIABETES

DATES OF REPORTS BY GRANTEE

12/2024, 1/2025, 2/2025, 6/2025, 8/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, GERMANY

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
1,614,000.	11/08/23	464,198.

PURPOSE OF GRANT

DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION.

DATES OF REPORTS BY GRANTEE

1/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, GERMANY

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
4,752,086.	10/22/20	2,141,708.

PURPOSE OF GRANT

DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.

DATES OF REPORTS BY GRANTEE

PRIOR+ 11/2022, 12/2022, 8/2023, 2/2024, 1/2025, 5/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, GERMANY

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
342,387.	03/23/22	342,384.

PURPOSE OF GRANT

POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES:
INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY FOR CD PATIENTS

DATES OF REPORTS BY GRANTEE

3/2023, 1/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, GERMANY

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
1,556,119.	06/22/23	637,199.

PURPOSE OF GRANT

THE EXTENT STUDY TO IMPROVE THE CARE OF CROHN'S DISEASE.

DATES OF REPORTS BY GRANTEE

5/2024, 8/2024, 1/2025, 8/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

NUDGE BG, INC.

GRANTEE'S ADDRESS

725 OLD FARM ROAD
THOUSAND OAKS, CA 91360

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
1,000,000.	04/08/25	0.

PURPOSE OF GRANT

AUTOMATED INSULIN DELIVERY INTEROPERABILITY FRAMEWORK (AIDIF)

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

PERCUSENSE, INC,

GRANTEE'S ADDRESS

25134 RYE CANYON LOOP
VALENCIA, CA 91355

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,700,000.	09/02/20	1,850,000.

PURPOSE OF GRANT

DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

PRIOR+ 8/2023, 10/2023, 6/2024, 9/2024, 3/2025, 8/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

PHENOTAP, INC.

GRANTEE'S ADDRESS

106 WEST 32ND STREET, 2ND FLOOR
NEW YORK, NY 10001

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
3,000,000.	03/05/25	0.

PURPOSE OF GRANT

DEVELOPMENT OF A BHBOX ENZYME TO ENABLE CONTINUOUS KETONE SENSING

DATES OF REPORTS BY GRANTEE

7/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

STARTUP HEALTH T1D PRI LP

GRANTEE'S ADDRESS

2000 BROADWAY, 18TH FLOOR
NEW YORK, NY 10023

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
5,000,000.	01/30/23	3,151,963.

PURPOSE OF GRANT

CATALYZING SEED AND EARLY-STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS

DATES OF REPORTS BY GRANTEE

PRIOR+ 11/2023, 6/2024, 9/2024, 12/2024, 2/2025, 5/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND
BRISBANE, QUEENSLAND, AUSTRALIA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,493,864.	09/08/21	2,493,864.

PURPOSE OF GRANT

LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES

DATES OF REPORTS BY GRANTEE

1/2023, 3/2024, 2/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE UNIVERSITY OF QUEENSLAND

GRANTEE'S ADDRESS

CUMBRAE STEWART BUILDING #72, THE UNIVERSITY OF QUEENSLAND
BRISBANE, QUEENSLAND, AUSTRALIA

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
226,017.	05/22/23	189,690.

PURPOSE OF GRANT

GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY

DATES OF REPORTS BY GRANTEE

3/2024, 9/2024, 5/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THETIS PHARMACEUTICALS, LLC

GRANTEE'S ADDRESS

54 DANBURY ROAD, SUITE 285
RIDGEFIELD, NJ 06877

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
14,044,660.	02/24/22	5,912,106.

PURPOSE OF GRANT

DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE

DATES OF REPORTS BY GRANTEE

PRIOR+ 4/2024, 6/2024, 7/2024, 12/2024, 4/2025, 6/2025

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

TIXIMED, INC.

GRANTEE'S ADDRESS

1927 FIRST AVENUE NORTH
BIRMINGHAM, AL 35203

GRANT AMOUNT	DATE OF GRANT	AMOUNT EXPENDED
2,650,000.	12/03/24	1,734,080.

PURPOSE OF GRANT

DEVELOPING A DRUG TO PROTECT BETA CELLS DURING TYPE 1 DIABETES DEVELOPMENT

DATES OF REPORTS BY GRANTEE

5/2025, 7/2025

ANY DIVERSION BY GRANTEE

NONE

FORM 990-PF SUMMARY OF DIRECT CHARITABLE ACTIVITIES STATEMENT 21

ACTIVITY ONE

FOR COMMUNICATIONS DESIGNED TO SUPPORT AND AMPLIFY THE CHARITABLE WORK OF OUR GRANTEES, THROUGH STRATEGIC COMMUNICATIONS PLANNING, VIDEO PRODUCTION, AND DESIGN, SPECIFICALLY IN FURTHERANCE OF THE FOUNDATION'S MISSION OF PROMOTING HEALTH AND IMPROVING PEOPLE'S LIVES.

	EXPENSES
TO FORM 990-PF, PART VIII-A, LINE 1	1,390,656.

FORM 990-PF SUMMARY OF DIRECT CHARITABLE ACTIVITIES STATEMENT 22

ACTIVITY THREE

FOR CONVENING OF GRANTEES AND RESEARCHERS, INCLUDING CONFERENCE SPONSORSHIP AND SUPPORT, TO PROMOTE SHARED LEARNING AND THE IDENTIFICATION OF NEW PROJECTS TO FURTHER THE FOUNDATION'S CHARITABLE MISSION.

	EXPENSES
TO FORM 990-PF, PART VIII-A, LINE 3	312,168.

FORM 990-PF OTHER PROGRAM-RELATED INVESTMENTS STATEMENT 23

DESCRIPTION	AMOUNT
ABVANCE THERAPEUTICS, INC. - DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON	1,170,000.

DESCRIPTION	AMOUNT
IMMUNOMOLECULAR THERAPEUTICS, INC. - TARGETED IMMUNOTHERAPY TO TREAT TYPE 1 DIABETES	350,000.

TOTAL TO FORM 990-PF, PART VIII-B, LINE 3	1,520,000.

990-PF INVOLVEMENT WITH NONCHARITABLE ORGANIZATIONS STATEMENT 24
PART XVI, LINE 1, COLUMN (D)

NAME OF NONCHARITABLE EXEMPT ORGANIZATION

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

DESCRIPTION OF TRANSFERS, TRANSACTIONS, AND SHARING ARRANGEMENTS

GRANT IN SUPPORT OF EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE

GENERAL EXPLANATION STATEMENT 25

FORM/LINE IDENTIFIER AND DESCRIPTION/RETURN REFERENCE

FORM 990-PF, PART VI-A, LINE 11: - CONTROLLED ENTITIES

EXPLANATION:

THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:

ESTATE OF LEONA M. HELMSLEY
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 20-7535047

HELMSLEY ENTERPRISES, INC.
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 13-2665914

LACM WORLD SMALL CAP EQUITY FUND, L.P.
11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025
EIN# 83-2888004

MARATHON-LONDON GLOBAL SELECT
ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UK WC2H 9EA
EIN# 61-1915057

MHR LONGEVITY PARTNERS
40 WEST 57TH STREET, FLOOR 24
NEW YORK, NY 10019
EIN# 98-1471155

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.
1325 NORTH BEACH STREET, SUITE 201
PHILADELPHIA, PA 19125
EIN# 98-1142649

PITANGO SPV
BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL
EIN# 98-1492234

STARTUP HEALTH T1D PRI LP
2000 BROADWAY, 18TH FLOOR
NEW YORK, NY 10023
EIN# 93-2618051

GENERAL EXPLANATION — STATEMENT 26

FORM/LINE IDENTIFIER

FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:

EXPLANATION:

ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.